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Recent studies have shown that Sca-1
+
 (stem cell antigen-1) stem/progenitor cells within blood 
vessel walls may contribute to neointima formation, but the mechanism behind their recruitment 
has not been explored. In this work Sca-1
+
 progenitor cells were cultivated from mouse vein 
graft tissue and found to exhibit increased migration when co-cultured with smooth muscle cells 
(SMCs) or when treated with SMC-derived conditioned medium. This migration was associated 
with elevated levels of chemokines, CCL2 (chemokine (C-C motif) ligand 2) and CXCL1 
(chemokine (C-X-C motif) ligand 1), and their corresponding receptors on Sca-1
+
 progenitors, 
CCR2 (chemokine (C-C motif) receptor 2) and CXCR2 (chemokine (C-X-C motif) receptor 2), 
which were also up-regulated following SMC conditioned medium treatment. Knockdown of 
either receptor in Sca-1
+
 progenitors significantly inhibited cell migration. The GTPases Cdc42 
and Rac1 were activated by both CCL2 and CXCL1 stimulation and p38 phosphorylation was 
increased. However, only Rac1 inhibition significantly reduced migration and p38 
phosphorylation. After Sca-1
+
 progenitors labelled with GFP were applied to the adventitial side 
of wire-injured mouse femoral arteries, a large proportion of GFP-Sca-1
+
-cells were observed in 
neointimal lesions, and a marked increase in neointimal lesion formation was seen 1 week post-
operation. Interestingly, Sca-1
+
 progenitor migration from the adventitia to the neointima was 
abrogated and neointima formation diminished in a wire injury model using CCL2
-/-
 mice. 
These findings suggest vascular stem/progenitor cell migration from the adventitia to the 
neointima can be induced by SMC release of chemokines which act via CCR2/Rac1/p38 and 
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1.1 The vascular system and vessel structure 
1.1.1 The classification of vessels 
The blood vessels, which transport blood throughout the whole body, are very important parts 
of the cardiovascular system. There are 5 main types of blood vessels: arteries, arterioles, 
capillaries, venules and veins. Each time the heart beats, blood is pumped into the aorta (large 
artery) which then flows through its branches into progressively smaller arterioles. These 
arterioles then carry blood into every part of the body. Consequently, they connect with 
capillaries that exchange oxygen, carbon dioxide, water and chemicals between blood and 
tissues.  After this stage of its journey, blood returns to smaller venules from capillaries and 





1.1.2 The structure of vessels 
 
Ondine Cleaver & Douglas A Melton, Nature Medicine, 2003 
Figure 1.1 The structure of blood vessel wall. The schema shows the structures of an artery, 
vein and capillary. The large vessels (artery and vein) contain multiple layers of cells and 
extracellular tissues. In contrast, the small vessels (arteriole, venule and capillary) are only 
composed of a layer of endothelial cells with a loose covering of smooth muscle cells and 
pericytes (Cleaver & Melton, 2003). 
As shown in Figure 1.1, diameters of different vessels (from 25mm in the aorta to 8µm in 
capillaries) and their tolerances of circulating blood pressure are different, except in capillaries, 




composed of 3 layers of tissues in the vessel walls. From the inside (lumen side) of the vessel 
wall outwards, they are the tunica intima, tunica media and tunica adventitia.  
The tunica intima is the thinnest layer of the vessel wall, which consists of a single layer of 
endothelial cells (EC) linked by a polysaccharide intercellular matrix and surrounded by the 
internal elastic lamina. Though this layer can be seen clearly under the light microscope when 
viewing large arteries it appears to be thin or incomplete in arterioles, veins and venules. The 
tunica intima forms the only layer of cells in the vessel wall of capillaries indicating the 
necessity of the endothelium throughout the entire vascular system. As endothelium is an 
important barrier to separate circulating blood and other parts of the vessel wall, endothelial 
cells which express markers PECAM-1 (CD31) and VE-Cadherin (CD144) play a crucial role in 
maintaining vascular homeostasis and initiating various responses to vascular injury.  
The outer layer in contact with the tunica intima is the tunica media. This layer is comprised of 
a large number of smooth muscle cells (SMC), and is much thicker in arteries than in veins, due 
to the constriction and dilation functions of arteries, which is necessary to control the blood 
volume supplied to different parts of the body and to maintain blood pressure throughout the 
circulation. The external elastic lamina forms the boundary between the tunica media and tunica 
adventitia and is also much thicker in arteries than in veins for similar reasons. SMCs are 
usually identified by alpha-smooth muscle actin (α-SMA), calponin, myocardin and smooth 
muscle myosin heavy chain (SMMHC) and are the major cell type in the tunica media. In 
physiological conditions, they control vascular tone to regulate blood volume and pressure in 
vessels, while in pathological conditions, they participate in repair of the injured vessel wall.  
The tunica adventitia is the outermost layer of the vessel wall and is mainly composed of 
collagen and elastic fibres which make it the strongest layer of the vessel wall. It can enhance 
the stability of the vessel by anchoring the vessel to nearby tissues and protecting from 
overexpansion of the vessel wall. In large vessels, the vasa vasorum is present in the tunica 
adventitia to supply nutrients to the outer layer of the vessels, while the inner layer of the vessel 




1.2 The pathophysiology of atherosclerosis 
Atherosclerosis is one of the leading causes of mortality and morbidity in the world. It is a 
multifactorial vascular disease influenced by genetic, gendered and environmental factors. It is 
the most common kind of arteriosclerosis and usually gives rise to coronary artery disease, 
carotid artery disease, peripheral arterial diseases and cerebrovascular diseases (e.g. acute 
coronary syndrome (ACS), myocardial infarction or stroke). The main characteristics of 
atherosclerosis are lipid deposition and vessel stiffness, which result in thickening of the vessel 
wall and narrowing of the lumen. As shown in Figure 1.2 the underlying pathophysiology of 
atherosclerosis is initiated by endothelial dysfunction, caused by physical or chemical offence 
such as hypertension, shear stress of disturbed laminar flow in the branch of the vessel, reactive 
oxygen species in the circulation (e.g. smoking), hyperlipidaemia and hyperglycaemia. These 
factors activate endothelial cells to provoke a cascade of inflammatory responses.  
In the initial stages, molecules and lipoproteins (e.g. low density lipoprotein (LDL)) from 
plasma leak into subendothelial areas through the impaired endothelium. At the injured intima 
sites, retained LDL is prone to modification (e.g. oxidisation) into a cytotoxic form (e.g. ox-
LDL) by factors such as reactive oxygen species, myeloperoxidase, lipoxygenases, and/or nitric 
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Figure 1.2 The pathological development of atherosclerosis. Transverse views of 
alterations of the vessel wall and lumen area in atherosclerotic coronary arteries. Initially, the 
fatty streak is formed by the accumulation of macrophage-derived foam cells in the sub-
endothelium area. In the early atheroma, a lipid-rich necrotic core consisting of necrotic foam 
cells and SMCs debris is surrounded by a fibrous cap and infiltrated with inflammatory cells. 
The thickness of the fibrous cap, which is composed of SMCs and extracellular matrix, 
determines the stabilization of lesions. In the late stage, thrombosis formation is related to 





Subsequently, chemokines that are derived either from platelets in the blood or released from 
ox-LDL activated ECs attract inflammatory cells such as monocytes and T lymphocytes to 
migrate into sub-endothelial sites. During this process, ox-LDL also triggers defective 
endothelial cells to express adhesion molecules (e.g. VCAM-1) on their surface, which leads to 
immune cells adhering to the endothelial cells before extravasation into the sub-endothelium 
area.  
The fatty streak, the earliest lesion visible without focal magnification, is the first sign of 
atherosclerosis. It consists of a large number of foam cells (monocyte-derived-macrophages that 
have ingested ox-LDL) and some T lymphocytes. As the disease progresses, foam cells become 
more lipid-laden and undergo death (apoptosis and necrosis), which subsequently results in an 
accumulation of cell debris and necrotic core formation from lipids.  
At the same time, inflammatory cells in the intima secrete chemokines and cytokines that 
stimulate proliferating SMCs to migrate from the media to the intima. At this stage, 
atherosclerosis is established and a fibrous cap is formed from proliferative smooth muscle cells 
and collagen.  This cap makes the lesion relatively stable due to its restriction of the necrotic 
core inside.  
Over time, a continuous accumulation of lipid and production of inflammatory molecules by 
infiltrated inflammatory cells causes the lesion to become unstable. Macrophages will then 
replace SMC in the fibrous cap to create an inflamed cap, which is more susceptible to rupture. 
Once the plaque ruptures, platelets and the clotting cascade response result in thrombotic 





1.3 Treatment of atherosclerosis and complications 
1.3.1 Drug treatments 
Based on the proposed cause of atherosclerosis, different medical treatments are prescribed to 
patients. In cases of hypertension angiotensin-converting enzyme (ACE) inhibitors, β-blockers, 
calcium channel blockers and thiazide diuretics are used to lower the blood pressure by reducing 
the amount of water in the blood and/or dilating the arteries. For hyperlipidaemia, statins are 
commonly used medicines, which lower cholesterol levels in the circulation by inhibiting the 
effects of HMG-CoA reductase, to control the production of cholesterol in the liver. To prevent 
thrombosis, antiplatelet agents, such as aspirin, are used to stop platelets binding to each other 
and forming a clot on the damaged vessel wall.  Alternatively, anticoagulants, such as warfarin, 
are applied to decrease blood coagulation through inhibition of vitamin K epoxide reductase. 
The level of blood glucose also needs to be controlled in cases of diabetes. As atherosclerosis is 
an inflammatory disease, anti-inflammatory drugs are also indispensable in atherosclerosis 
treatment, for example, statins which can block GTPase isoprenylation in ECs, macrophages, 
dendritic cells and T cells, and which also have an effect on both the innate and adaptive 
immunological reactions (Bu, Griffin, & Lichtman, 2011). 
1.3.2 Coronary artery bypass grafting  
In some cases, severe atherosclerosis results in a narrowed or even blocked vessel lumen, which 
will reduce or stop blood flow supplying organs such as the heart or brain, thereby leading to 
myocardial infarction or stroke. To prevent or rectify these risks, surgeries are required to widen 
the lesion area or bypass the site of the blockage. Coronary artery bypass grafting (CABG) is 
carried out by attaching a part of vessel derived from a great saphenous vein or internal 
mammary artery to the coronary artery to bypass the narrowed or blocked area. This new graft 
creates a channel to restore normal blood perfusion to the part of the myocardium previously 




1.3.3 Percutaneous transluminal coronary angioplasty   
In the cardiovascular system, percutaneous coronary intervention (PCI) (Figure 1.3), also 
known as coronary angioplasty, can improve blood flow by widening the narrowed or blocked 
vessel using a balloon and holding the vessel open using a stent. Stents are made of a metal 
mesh and are usually coated with different drugs which can be released into lesion sites 
continuously to prevent the artery from re-narrowing.  
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Figure 1.3 Schematic representation of a percutaneous coronary intervention. The 
catheter, containing a deflated balloon within a closed stent, is inserted into the narrow coronary 
artery. Once the stent reaches the plaque lesion site, the balloon is inflated and the stent is 
expanded to widen the narrowed artery. The catheter with the balloon is withdrawn, leaving the 
stent to support the lumen opening in the artery. The cross-section shows the compressed plaque 
and the stent-widened artery (Panoulas & Colombo, 2014). 
1.3.4 Complications 
1.3.4.1 Post-angioplasty restenosis 
Due to the advantages of a less invasive procedure and a more rapid recovery rate than surgery, 
PCI is the first-line treatment for obstructive coronary artery disease, however, it may not 
always be successful long-term due to complex vascular remodelling processes such as post-
angioplasty restenosis (Holmes et al., 1984; Nobuyoshi et al., 1988; Nobuyoshi et al., 1991). 




increases the risk of morbidity and mortality of the disease. The flow chart in Figure 1.4 
indicates a cascade of mechanisms leading to neointimal hyperplasia.  
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Figure 1.4 A series of cellular and molecular responses in the vascular wall during 
post-angioplasty restenosis. A. Injury, damage to the endothelium and the elastic lamina 
activates the inflammatory response and the SAPK (stress-activated protein kinases) signalling 
pathway, which results in (B) Medial proliferation, activation of SMCs and release of growth 
factors, (C) Intimal hyperplasia, due to localised SMCs proliferation and interaction with 
plasma mitogens. Intimal hyperplasia is also caused by (D) Migration of VSMCs, medial 
SMCs migration to the intimal layer with disruption of the ECM.  
At an early stage (days to weeks) after angioplasty, endothelial injury initiates thrombus 
formation (Virmani, Kolodgie, Farb, & Lafont, 2003), and fibrin and platelet accumulation 
activate an inflammatory response. Specifically, leukocytes infiltrate into the vessel wall across 
the stent site, particularly monocyte-derived macrophages (Gradus-Pizlo et al., 2003). In human 
studies, the staining for a specific macrophage marker (CD68) on sections of patients’ coronary 
arteries showed that macrophage infiltration into the neointima is correlated with neointima 
expansion (Burke, Kolodgie, Farb, Weber, & Virmani, 2002). However, others argue that rather 
than macrophages it is neutrophils that infiltrate into the media and this was seen early after 








process (Welt, Edelman, Simon, & Rogers, 2000). Deposited platelets, monocytes and local 
SMCs can recruit more leukocytes to migrate into the injured site through the release of 
cytokines, growth factors and chemokines. Growth factors such as transforming growth factor 
beta (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor 
(VEGF) can induce EC and SMC proliferation. 
During the late phase (weeks to months), the dominant change in the vessel wall is medial 
SMCs dedifferentiation and subsequent proliferation and migration towards the intima. SMCs 
also release intracellular hyaluronan, proteoglycans and collagens. These factors are major 
components of the neointima (Rollins, 1997) and interact to stabilize the Extracellular matrix 
(ECM). The ECM can then facilitate SMC and inflammatory cell adhesion and migration, and 
thus plays an important role in vessel repair and the remodelling process. The ECM is initially 
comprised from fibrin, fibrinogen, and fibronectin. Following the subsequent digestion of 
hyaluronan, inflammatory cells produce metalloproteinases (MMPs) that break down collagen 
type 1 to promote permanent wound healing (Wight & Potter-Perigo, 2011).  
1.3.4.2 Late stent thrombosis after drug-eluting stent application 
Although the bare metal stent has successfully treated many coronary atherosclerosis patients 
and has effectively prevented acute myocardium infarction, the high incidence of post-
angioplasty restenosis is the main challenge in PCI (Serruys et al., 1994). In the decade since the 
development and application of drug-eluting stents (DES) in PCI, there has been a revolutionary 
improvement in treatment. These DES are coated with drugs that target SMC proliferation, and 
this local delivery of treatments has been widely applied in the clinic, to reduce the occurrence 
of post-angioplasty restenosis and vessel re-narrowing.  
Sirolimus, as an inhibitor of mammalian target of rapamycin (mTOR), can suppress cell 
proliferation by inhibiting multiple regulators of the cell cycle (Marx, Jayaraman, Go, & Marks, 
1995). Sirolimus has anti-proliferative and anti-migratory effects on vascular SMCs through 




Compared with bare metal stents, DESs have remarkable advantages in preventing restenosis, 
but they still have some limitations, for example there is no significant difference in late stent 
thrombosis incidence between bare metal and drug eluting stents (Joner et al., 2006).  
Late stent thrombosis usually occurs at least 1 month after stent implantation and is 
characterised by occlusion of the coronary artery, caused by thrombosis formation in the stent, 
which results in a high rate of myocardial infarction occurrence (Daemen et al., 2007). This 
problem is attributed to the delay in arterial healing after PCI due to fibrin deposition and 
decreased re-endothelialisation (Bavry & Bhatt, 2008; D. W. Park et al., 2006). The possible 
reasons for late thrombosis after stent implantation are variable; one of the reasons is the 
premature termination of anti-platelet therapy (McFadden et al., 2004). Furthermore, others 
have found that the parts of the stent-implanted vessel wall where incompletely healed had 
much higher risk of thrombosis. The morphology of the atherosclerotic lesion may alter the 
proportion of coverage of cells on the stent which depends on the local drug concentration. 
Researchers demonstrated that at vessel sections with reduced evidence of thrombosis there was 
less neointimal formation (Farb, Burke, Kolodgie, & Virmani, 2003; Finn et al., 2007).  
1.3.5 Optimization and further studies 
As described above, DESs have proved a beneficial treatment for coronary atherosclerosis but 
much could still be done to improve their success long-term.  The main factors affecting DES 
performance are the stent backbone, the drug eluted, the polymer and the delivery system 
(Figure 1.5). Improvements may be focused on development of bio-absorbable stents, coating 
stents with drugs, antibodies, peptides, nucleotides or a combination which can induce re-
endothelialisation and promote anti-thrombotic processes, and improve the way of drug delivery, 
for example through control of drug release direction to deliver the drugs to their specific targets 
(e.g. SMC or EC), which would suppress SMC proliferation as well as improve endothelium 
healing. For some coronary artery disease patients with other complications (e.g. diabetes), the 
lesions are more difficult to treat due to multiple risk factors, so a greater range of drugs could 
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Figure 1.5 The important components of drug-eluting stent performance. The schema 
shows the 4 main factors influencing drug-eluting stent performance. These include stent 
backbone, polymer, drug and way of delivery. Each box lists the specific function and 
modifications which are being developed for each element.  
Though PCI is widely applied in the clinic, complications still cause a bad prognosis for the 
disease. In recent years a proposed alternative to surgical intervention put forward is the use of 
regenerative medicine to encourage vessel repair or to develop artificial vessels by application 
of stem/progenitor cells. 
1.3.6 Endovascular intervention for peripheral artery disease 
Besides coronary arteries, atherosclerosis is also formed in carotid arteries (Ku, Giddens, Zarins, 
& Glagov, 1985), cerebral arteries (Sacco, Kargman, Gu, & Zamanillo, 1995), renal arteries 
(Missouris, Buckenham, Cappuccio, & MacGregor, 1994) and peripheral arteries (Heinrich, 
Schulte, Schonfeld, Kohler, & Assmann, 1995) among others. In most cases, peripheral artery 
disease caused by lower extremity atherosclerosis leads to intermittent claudication and critical 
limb ischemia. Bajwa et al. reviewed several current imaging modalities which are being 
applied on patients to assess tissue perfusion of the lower limbs (Bajwa et al., 2014). The 




develop localized inflammatory injury and is a common site for peripheral artery disease 
occurrence and development (Wood et al., 2006). As the progressive lesion develops in the 
superficial femoral artery, chronic total occlusion will completely obstruct the blood supply to 
the lower limb which eventually results in severe ischemic ulcer formation or gangrene  (Jude, 
Oyibo, Chalmers, & Boulton, 2001). 
Similarly to percutaneous coronary intervention, peripheral vascular intervention can be used to 
treat patients with peripheral artery disease. In aortoiliac segments, peripheral vascular 
intervention achieves successful long-term patency, while in femoropopliteal and infrapopliteal 
segments, a high incidence of restenosis is still the major challenge of this technique. Peripheral 
restenosis was found to occur in 5%-70% of patients, depending on lesion localization, 
complexity and procedural factors (Deloose et al., 2014; Schmidt et al., 2010). To improve the 
long-term outcome of patients after self-expanding stent implantation, drug-eluting stents are 
widely applied as clinical treatments. As the first-generation DES, compared with bare metal 
stents in clinical trials, sirolimus-coated stents did not show significant improvement in target 
lesion revascularization and restenosis rates after follow-up at 24 months, which may be due to 
an inflammatory response to the polymer matrix (Duda et al., 2006). Furthermore, the results of 
other trials also reported a high incidence rate of stent fracture in approximately 30% of patients 
(Duda et al., 2005; Duda et al., 2002). Recently, the second-generation of DES was developed 
by coating paclitaxel directly on the stents to abolish the inflammatory effects of the polymer 
matrix. As an alternative, a drug-coated balloon is also applied in the clinic, since it can provide 
anti-proliferative drugs without having to deploy a stent as a permanent inflammatory stimulus 
for neointima formation (Byrne et al., 2013). Ongoing trials should focus on the comparison of 
long-term outcomes of patients with different treatment technologies. The further basic 
investigation is required to thoroughly understand the pathophysiology of post-angioplasty 





1.4 Stem cells 
In the past 30 years, research into stem cells has been identified as a promising area for 
regenerative medicine. Stem cells have the notable potential to self-renew and differentiate into 
many cell types. These abilities are crucial not only during embryo development but also in self-
repair throughout the lifespan of the organism.   
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Figure 1.6 Development of human embryonic and adult stem cells. Human embryonic 
stem cells are derived from the inner cells of a blastocyst which is the divided product of a 
zygote, a fusion of the egg and sperm. These embryonic stem cells are either self-renewing or 
pluripotent. Human adult stem cells reside in different adult tissues and they are also capable of 
self-renewal and multipotent differentiation. Whether differentiated cells are lineage restricted 
to the original organs of their origin or have potential to differentiate into other cell types 




There are two broad categories of stem cells, embryonic stem cells (ESC) and adult stem cells 
(somatic stem cells) (Figure 1.6). ESCs are derived from the inner cell mass of blastocysts and 
are pluripotent and able to generate every kind of cell in the body. Adult stem cells reside in 
specific tissues and are multipotent, only differentiating into specific lineages of cells but 
thought to act as major sources of cells to replenish injured adult tissues. 
Recent research into stem cells is not only limited to drug screening and embryo development 
studies, but also focused on patient-derived cell-based personal therapies and regenerative 
medicines. For example, atherosclerosis is one of the major causes of morbidity and mortality, 
to treat this disease stem cells can potentially be used to repair damaged vessels, to prepare graft 
tissue and to develop cell culture models to increase our understanding of the disease process.  
1.4.1 Embryonic stem cells 
1.4.1.1 Overview of ESCs 
ESCs derived from the inner cell mass of blastocyst stage embryos are pluripotent stem cells 
with self-renewal ability. They have a high proliferative potential and an unlimited capacity to 
differentiate into all cell types (Reubinoff, Pera, Fong, Trounson, & Bongso, 2000; Wong et al., 
2014) (Figure 1.7). In 1981, mouse ESCs were first derived from blastocysts which were 
cultured in a mouse uterus ex vivo to expand the cell number by Martin Evans and Matthew 
Kaufman (Evans & Kaufman, 1981). In 1998, another revolution occurred in this field, when 
the first human ESC was isolated and cultured in vitro by Thomson et al. (Thomson et al., 1998). 
Initially in order to culture ESC in vitro, a layer of feeder cells (mouse embryonic fibroblasts, 
MEF) was needed to provide the leukemia inhibitory factor (LIF), which is indispensable in 
maintaining ESCs in an undifferentiated state (Doetschman, Eistetter, Katz, Schmidt, & Kemler, 
1985; A. G. Smith et al., 1988). More recently it has been discovered that adding purified 
recombinant LIF into the culture medium is enough for mouse ESC to retain their pluripotency 
(Williams et al., 1988). For human ESCs, LIF in isolation does not  have the same effect, 
however, a different factor basic fibroblast growth factor (bFGF) in the culture medium can 




and mouse ESC express transcription factors Nanog, Sox2, and Oct3/4, which play an important 
role in  maintaining cell pluripotency, and which serve as markers to identify the 
undifferentiated state of stem cells. Additionally, these cells express species-specific stem cell 
markers, for example, stage-specific embryonic antigens SSEA-3 and SSEA-4 are expressed on 
human ESCs while mouse ESCs express SSEA-1 (Ginis et al., 2004; Richards, Fong, Chan, 
Wong, & Bongso, 2002). 
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Figure 1.7 Differentiation of ESCs. Embryonic stem cells possess pluripotent differentiation 
potentiality. They can differentiate into all cell types belonging to lineages of the three primary 
germ layers. For example, neurons of the ectoderm, cardiac muscle cells of the mesoderm and 




Many studies have successfully driven ESCs to differentiate into specific cell type lineages, 
such as EC and SMCs in various conditions. More established methods, including treatment of 
ESCs with PDGF-BB when cultivated on collagen-IV coated flasks, will lead to SMC-
differentiation (Xiao, Zeng, Zhang, Hu, & Xu, 2007); while, supplement ESC culture medium 
with VEGF for more than 21 days can induce EC-differentiation (Xiao et al., 2006). As SMCs 
and ECs are essential to cell types in the vascular wall, the ESC-derived SMC and EC will play 
crucial roles in the treatment of cardiovascular diseases. 
1.4.1.2 Research into ESCs in cardiovascular diseases 
In recent years, studies to develop new therapies for cardiovascular diseases have found that 
ESCs can be differentiated into specific lineages of vascular cells in vitro for potential use in 
vascular repair. In a mouse ischemia model, transplantation of ECs derived from human ESCs 
significantly increased neovascularization and blood perfusion in the ischemic hind limb, 
suggesting a promising therapy for new vessel generation in patients (Kane et al., 2010). 
Moreover, some studies have also demonstrated that ESCs have the ability to differentiate into 
SMCs. Within an ESC-derived embryonic body model system, the TGF-β-Smad signalling 
pathway is involved in the differentiation of SMCs, which provides very interesting evidence to 
suggest that different TGF-β signalling pathways may contribute to induction of early (α-SMA) 
(both Smad 2 and Smad 3 dependent) vs. late (SMMHC) (only Smad2 dependent) SMC 
markers (Sinha, Hoofnagle, Kingston, McCanna, & Owens, 2004). In a novel in vitro model, 
human ESC-derived mesenchymal cells (hES-MCs) can also differentiate into SMCs through 
TGF-β induced high level myocardin expression (Guo, Stice, Boyd, & Chen, 2013). 
1.4.1.3 Challenges of ESC research  
Human ESCs have various epigenetic profiles depending on the embryo they were derived from. 
This may lead to variation in their differentiation capacities. In order to remove this chance of 
variability, mouse ESCs are more extensively used, as mice have been bred selectively and have 
very similar genetic backgrounds (Lagarkova, Volchkov, Lyakisheva, Philonenko, & Kiselev, 




undifferentiated ESCs may form teratomas comprising diverse sorts of tissues of all three germ 
layers, which will be a major challenge of ESC-based therapy in patients (Baker, 2009). 
Because of these limitations, researchers are focusing on methods to control ESC differentiation 
and proliferation prior to transplantation into live organisms.  
1.4.2 iPS cells 
1.4.2.1 The generation of iPS cells  
In 2006, Shinya Yamanaka made a revolutionary discovery in the stem cells field. In his study, 
both embryonic and adult mouse fibroblasts were induced into pluripotent stem cells by the 
introduction of Oct4, Sox2, Klf4, and c–Myc genes (Takahashi & Yamanaka, 2006). These are 
known as induced pluripotent stem cells (iPS cells). iPS cells can be obtained by reprograming 
human or animal adult cells and then differentiating them into derivatives which constitute the 
three germ layers (endoderm, mesoderm, ectoderm). Subsequently, other research groups have 
successfully generated iPS cells from various mature mouse and human cell types by applying 
these four factors (Aoi et al., 2008; Hanna et al., 2008; Lowry et al., 2008; I. H. Park et al., 2008; 
Wernig et al., 2007; J. Yu et al., 2007). These iPS cells have similar morphologies and growth 
pattern and possess the ability, along with ESCs, to form teratomas after injection to mice. 
Recently, partially induced cells were prepared in a simpler way: researchers generated these 
partial-iPS (PiPS) cells by transferring four reprogramming factors to human fibroblasts for 
only 4 days. These PiPS cells can differentiate into ECs via SET translocation (myeloid 
leukemia-associated) (SET) similar protein (SETSIP) and VEGF without forming tumours in 
vivo (Margariti et al., 2012).  
 
1.4.2.2 Research into application of iPS cells in cardiovascular diseases 
It was found that when iPS cells are cultured on collagen IV-coated plates and stimulated with 
VEGF, they can differentiate into functional EC through the microRNA-21 and TGF-β2 






 cells, intravenously into mice after femoral artery injury, can effectively enhance re-
endothelialisation and attenuate neointima formation, which suggests iPS may be useful in a 
therapeutic manner for the protection of vessels from post-angioplasty restenosis (Yamamoto et 
al., 2013). Besides differentiation to ECs, other studies show evidence that functional vascular 
SMCs can be derived from iPS cells. Human iPS cells can differentiate into contractile SMCs 
through mesenchymal stem cell (MSC) intermediates, indicating that it may be possible to 
acquire a limitless number of SMC for vascular regenerative medicine from iPS cells (Bajpai, 
Mistriotis, Loh, Daley, & Andreadis, 2012).    
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Figure 1.8 Directed differentiation of iPS cells. The generation of iPS cells is performed by 
transfection of specific factors such as KLF4, SOX2, c-Myc, Nanog, Oct-3/4, LIN-28 into 
mature somatic cells isolated from patients.  These reprogrammed iPS cells have the pluripotent 
potential to differentiate into a variety of specialised cells. These specific lineages of cells 
derived from iPS cells can be widely applied in construction of disease models (a), screening of 
drugs (b) and toxicity tests (c), which are ideal for both basic research into disease mechanisms 
and for preclinical trials for new drugs (Bellin, Marchetto, Gage, & Mummery, 2012) 
 






As shown in Figure 1.8, due to iPS cells infinite self–renewal and pluripotency characteristics 
they are unique models for investigating various processes during embryonic development and 
establishing patient-specific cell and tissue growth for the study of the pathogenesis of diseases. 
Furthermore, as patient-derived iPS can be transplanted back into the same patient from whom 
they were derived, they can be generated to have the exact same genetic background and thus 
can evade immunological rejection and become a promising source for cell therapy with fewer 
ethical concerns (A. G. Smith, 2001; Takahashi et al., 2007).  
 
1.4.3 Adult stem cells 
Adult stem cells have been found in different tissues and organs around the whole body, not 
only in adults but also in infants. They can renew themselves and differentiate into specific 
lineages of cells found in the tissues they are located in. However, unlike ESC, which is known 
to be derived from blastocysts, the origins of some adult stem cells in specific tissues remain 
uncertain.  
There are several cell types which have been identified as adult stem cells. The earliest 
discovery of adult stem cells can be traced back to the 1950s when researchers identified 
hematopoietic stem cells and bone marrow stromal stem cells (Thomas, Lochte, Lu, & Ferrebee, 
1957) . The most mature clinical application of adult hematopoietic stem cells is bone marrow 
transplantation, which has been used for leukemia patients for many decades. A more recent 
discovery was made in the 1990s when scientists discovered stem cells in the adult brain, which 
had always been regarded as non-renewable. These cells are capable of differentiation into 
astrocytes, oligodendrocytes and neurons (Skoff & Knapp, 1991). 
The advantages of adult stem cells are that they should be easier to harvest than ESCs and 
should not need the complex and time-consuming reprogramming of IPSCs. The derivation of 
blood, fat, and bone marrow-derived stem cells is much easier and without ethical complications 




abundance. In addition, as they are acquired from individuals, once they are transplanted back to 
the donor, they will not be rejected by the immune system.   
The specific environment of the body which harbours the adult stem cells is called the “stem 
cell niche”. A specific niche is thought to exist in many tissues and organs, such as bone 
marrow, peripheral blood, skin, heart, brain, blood vessel wall. Usually, adult stem cells are 
maintained in a quiescent state for many years in the niche, but once they receive stimulation 
from adjacent injured tissues, the cells are activated to proliferate, migrate and differentiate to 
participate in a cascade of repair.  
1.4.3.1 Adult stem cells within the vessel wall  
For a long time, adult blood vessels were believed to be quiescent, and not thought to contribute 
to new blood vessel formation. This changed in the 1970s when, based on observations of 
tumour tissue vascularisation, Judah Folkman and colleagues hypothesised that new vessels 
were formed via angiogenesis - a process in which new vessels grow from pre-existing vessels 
(Folkman, 1971). The second tremendous discovery came in 1997 from  Asahara et al., who 
found that CD34
+
 vascular endothelial growth factor receptor-2
+ 
(VEGFR2) endothelial 
progenitor cells (EPCs) circulating in peripheral blood could participate in the formation of new 
vessels at the sites of active angiogenesis (Asahara et al., 1997). Subsequent studies indicated 
the bone marrow as a niche for  EPCs, a source from which they are mobilised into the 
circulation and directed to the place of new vessel formation (Rafii, Lyden, Benezra, Hattori, & 
Heissig, 2002) (Barber & Iruela-Arispe, 2006). However, recent studies indicate that “EPCs” 
described in many published papers, especially early “EPCs” are monocytes/macrophages 
(Rehman, Li, Orschell, & March, 2003; S. J. Zhang et al., 2007). Thus, to date, the nature and 
function of “EPCs” in the circulating blood remain controversial. 
In the last decade, breakthrough experiments in the field of stem cell research have taken place. 
Though there is still some debate, it is widely believed that new vessel formation is in part 
dependent on stem/progenitor cells that reside within the vascular wall (Hu, Davison, et al., 




stem/progenitor cells reside in two main zones within the vessel wall i.e. the subendothelial 
zone and the adventitia (Alessandri et al., 2001; Ergun, Hohn, Kilic, Singer, & Tilki, 2008; 
Ergun, Tilki, Hohn, Gehling, & Kilic, 2007; D. Klein, Hohn, Kleff, Tilki, & Ergun, 2010; 
Pasquinelli et al., 2007; Peault et al., 2007). The subendothelial zone in the microvessel wall 
corresponds
 
to the adventitial zone in medium and large blood vessels. 
As mentioned previously, the adventitia is the outermost layer of a vessel, which is composed of 
connective tissue, collagen fibres, vasa vasorum, fibroblasts and quiescent inflammatory cells. 
The adventitia plays a key role in maintaining vessel wall homeostasis, including retrieval, 
integration, storage, and release of regulators such as nitric oxide (NO) (Gutterman, 1999; 
Scotland, Vallance, & Ahluwalia, 2000). It participates in the growth and repair of the vessel 
and mediates cross-talk between different cell types residing in the vessel wall (Gutterman, 
1999; Haurani & Pagano, 2007; Sartore et al., 2001). In the adventitia of the aortic root, 
immunohistochemistry revealed the presence of progenitor cells that express a panel of 
progenitor cell markers such as Sca-1, c-kit, CD34, FLK-1 (Hu et al., 2004). The adventitia 
niche, the region of adventitia close to the media seems to fulfil the definition of such a niche 
environment and is believed to be a source of progenitors for vasculogenesis (Zengin et al., 
2006) 
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Figure 1.9 Cellular components of the adventitia of vessel wall. The adventitia interacts 
with other layers of the vessel wall (top) and the surrounding tissues in which the vessel is 
located (bottom). Because of their specific loci, adventitial cells can participate in vessel 




As shown in Figure 1.9, Sca-1
+
 adventitial progenitor cells (green) are shown to differentiate 
into SMC-like cells to replace lost or damaged SMCs in the media (upward solid arrows). 
Furthermore, these Sca-1
+
 progenitors can also respond to injury or disease of surrounding 
tissues and participate in repair of damaged tissues (downward solid arrows). Dashed arrows 
indicate the theoretical direction of cell movement, either of SMCs in the media or of 
neighbouring tissue cells in the adventitia (Majesky, Dong, Hoglund, Mahoney, & Daum, 2011). 
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Figure 1.10 Subsets of vessel wall stem cells and their differentiation capacities. Many 
studies have identified different populations of progenitor cells in the vascular adventitia using a 
variety of markers. These cells show a variety of differentiation capacities (D. Klein et al., 
2011).  
As shown in Figure 1.10, CD34
+
 cells are found in the vasculogenic zone, which potentially 




















 cells that differentiate into vascular SMCs. Additionally, 
vessel wall resident mesenchymal stem cells have also been identified within the native 
adventitial niche and can similarly differentiate into SMCs. Furthermore, adventitial Sca-1
+ 
cells 
that reside within the vasculogenic zone from embryonic development to adulthood have the 












1.4.3.2 Vascular Wall Mesenchymal Stem/Stromal Cells 
Mesenchymal stem cells (MSCs) are heterogeneous multipotent stem cells, which can 
differentiate into a variety of cells such as osteoblasts, adipocytes, chondrocytes and myocytes 
and play an important role in the development of organs and tissues derived from the 
mesenchyme (Abedin, Tintut, & Demer, 2004). Besides the bone marrow, which is the best-
known storage site for MSCs, the vascular adventitia niche is suggested to be the reservoir for 
MSCs existence in nearly all organs (da Silva Meirelles, Caplan, & Nardi, 2008).  Traditionally, 
MSCs were identified if cells showed the ability of plastic adherence in standard culture 
conditions and possessed fibroblast-like morphology. Recently, immuno-selection of specific 
markers to verify MSCs is more widely used. In 2006, the ISCT (international society for cell 





















(Dominici et al., 2006). 
However, several studies have found that CD34, which is supposed to be a negative marker of 
MSCs according to the ISCT, can be expressed on uncultured bone marrow MSCs (Lin, Ning, 
Lin, & Lue, 2012) (Zimmerlin, Donnenberg, Rubin, & Donnenberg, 2013). Some groups have 
also reported CD34
+
 MSCs to be present on the vascular adventitia. In a study from 




cells isolated from human saphenous vein are found to express 
pericyte/mesenchymal antigens with Sox2 and to be endowed with clonogenic and multilineage 
differentiation capacities. In both in vitro and in vivo studies, they demonstrated that these cells 
interacted with the endothelial cell network and participated in angiogenesis (Campagnolo et al., 




cells of three different human vessel walls: artery, vein 
and small vessels in adipose were compared with adipose-derived stem/progenitor cells. 
Although they displayed fibroblast-like morphologies, those cells exhibited different 
differentiation potentials, such as arterial stromal cells undergoing osteogenic processes and 
venous and small vessel stromal cells promoting angiogenesis (S. Yang et al., 2013). 
Furthermore, Klein et al. recently demonstrated a population of CD44
+
 vascular wall 
multipotent stem cells residing in the adventitial vasculogenic zone of human internal thoracic 




As MSCs in the adventitia expressing a variety of surface markers have been reported by many 
different groups, it is unclear how many unique MSC populations exist and how many overlap 
with cell populations defined by other groups. 
 
1.4.3.3 Pericytes 
Pericytes were first described as contractile cells surrounding the endothelial cells of capillaries 
and venules by Rouget in 1873, however, description of their identifying features is still 
controversial (Armulik, Genove, & Betsholtz, 2011) . The controversy exists due to the absence 
of a single specific marker which can distinguish them from other perivascular cells, such as 
SMCs or MSCs.  Currently, several validated markers are involved in the definition of pericytes 
including PDGFR-β, NG2, CD13, α-SMA, and desmin (Armulik et al., 2011).  Pericytes and 
microvascular ECs are  thought to interact by direct contact or through paracrine molecular 
signalling and are separated by a basement membrane on their interface  (Bergers & Song, 2005) 
(Fakhrejahani & Toi, 2012). They have been suggested to control blood flow and permeability 
through regulating vessel tone and maintenance of  vascular homeostasis, playing an important 
role in angiogenesis (Gerhardt & Betsholtz, 2003). After de-endothelialisation of venous 
coronary bypass grafts, sub-endothelial pericytes in the venous intima are exposed to tissue 
factors in the blood stream, which induced their proliferation.  An overabundance of these cells 
is implicated in plaque instability (Juchem et al., 2010). In addition, both in vitro and in vivo, 
pericytes have been demonstrated to contribute to vascular calcification by differentiating into 
adipocytes, chondrocytes or osteoblasts (Doherty et al., 1998; Johnson, Leopold, & Loscalzo, 
2006).  
Many similarities have been found between pericytes and MSCs. Besides the fact that they 
reside in the same compartment of the vessel, pericytes also express some MSC markers, such 
as CD44, CD73, CD90, CD105, and CD146 (Covas et al., 2008) (Dellavalle et al., 2007). Under 
in vitro culture conditions, pericytes have MSC-like properties, for instance: clonal proliferation 




adipocytes, osteoblasts, chondrocytes and smooth muscle cells, depending upon their specific 
tissue origin (Crisan et al., 2008; Farrington-Rock et al., 2004; Feng, Mantesso, De Bari, 
Nishiyama, & Sharpe, 2011). MSCs and pericytes appear to function similarly, both have been 
shown to promote angiogenesis and repair ischemic tissue (C. W. Chen et al., 2013) (Katare et 
al., 2011).  
However, an increasing number of reports find differences in phenotype and genotype between 
MSCs and microvascular pericytes. The prevalent view of their distinction is that though both of 
them are CD31
-








(Zimmerlin et al., 
2010) (Suga et al., 2009). In addition, not all cells defined as pericytes express MSC markers 
and possess multilineage differentiation capacity (Braun et al., 2013; Zimmerlin et al., 2013).
 
To address this controversy further, the evidence is required to determine whether pericytes and 
MSCs are just two different cell types residing in close proximity within the adventitia or 
whether one is the precursor of the other. 
1.4.3.4 Sca-1+ vascular progenitor cells 









in the adventitia of aortic roots of ApoE
−/−
 mice. Stimulated by PDGF-
BB in vitro, these Sca-1
+




 cells carrying the SMC-
LacZ gene were seeded on the adventitia side of vein graft in ApoE
−/−
 mice, after 2-4 weeks, the 
β-gal
+
 cells can be found in the neointima, which indicates these Sca-1
+
 cells can migrate from 
adventitia to the neointima and differentiate into SMC in vivo (Hu et al., 2004). Subsequently, 
Passman et al. reported a sonic hedgehog (Shh) signalling domain restricted to the adventitia of 
the artery wall which is in close proximity to Sca-1
+
 progenitor cells. In Shh
−/− 
mice, the number 
of Sca-1
+
 cells in the aortic root is dramatically reduced. Similarly to the data showed by Hu, the 
Sca-1
+






. They also found that in 
vivo, these Sca1
+
 cells did not express SMC markers, but expressed transcription factors (e.g. 
serum response factor, myocardin family member) which are related to SMC differentiation. 
These Sca-1
+




progenitor properties in vivo. These data suggest Shh signalling is important to maintain Sca-1
+
 
function as smooth muscle cell progenitors (Passman et al., 2008).  Chen et al. reported a 
population of Sca-1
+
 cells, localised to the vasa vasorum in the adventitia of vein grafts, which 
possesses a differentiation potential to SMCs, adipocytes, osteoblasts or chondrocytes in vitro. 
In a bioreactor system, these Sca-1
+
 migrate into the decellularized vessel in response to 
CXCL12 circulating in the system (Y. Chen et al., 2013). Furthermore, Wong et al. 
demonstrated that sirolimus, a commonly used drug in DES, can induce Sca-1
+
 progenitor cells 
isolated from the adventitia of vein graft to migrate and differentiate into SMCs. The authors 
thus suggest a plausible mechanistic cause of restenosis following the application of sirolimus-






1.5 Cellular contributions to post-angioplasty restenosis 
Post-angioplasty restenosis is a long process, occurring due to  a cascade of cellular responses to 
mechanical injury of the vessel wall (Figure 1.11), including endothelial denudation, thrombosis 
caused by platelets and fibrinogens, leukocyte-mediated inflammation, vessel wall cell 
migration and proliferation and ECM deposition in the neointima (Chaabane, Otsuka, Virmani, 
& Bochaton-Piallat, 2013). 
 
Frederick G.P. Welt et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 2002 
Figure 1.11 Schematic of the progress of post-angioplasty restenosis. A. Pre-stent 
atherosclerotic plaque in the artery. B. Endothelial cell impairment and platelet/fibrinogen 
deposition immediately after stent implantation. C. Leukocyte recruitment and cytokine release. 
D. Leukocyte infiltration into the subendothelium and SMCs proliferation and migration. E. 
Continuous SMC proliferation and macrophage recruitment contribute to neointima formation. 
F. More ECM replaces cells in the neointima, which results in stent-derived restenosis over a 




1.5.1 Endothelial cells 
1.5.1.1 Endothelial cell injury  
Vascular endothelium, as a crude restrictive barrier of the vessel wall, can protect vascular wall 
cells from inflammation; however, once ECs are impaired, they will become the initial sensors 
of a complex cascade of events, such as endothelial denudation, platelet activation, 
inflammatory cytokine and growth factor release and further neointima formation (Tesfamariam, 
2008). The activation of ECs includes type I (transient response) and type II (more sustained 
response). Type I activation is rapid and mediated by ligands (e.g. histamine) binding to GPCRs 
(G protein-coupled receptors) directly, without protein synthesis, while type II activation is 
stimulated by TNF-α or IL-1 and keeps ECs in a persistently activated form, with production of 
adhesion molecules and cytokines (Pober & Sessa, 2007).  
In vivo, disruption to shear stress is the major risk factor that activates the endothelium and 
induces cell migration, proliferation and apoptosis, as well as an increase in endothelium 
permeability, leukocyte and monocyte adhesion and cytokine release (Hahn & Schwartz, 2009). 
As mentioned above, GPCRs are involved in shear stress-induced EC activation. When a G 
protein is activated by a GPCR, both of the GTP-bound Gαq/11 and released β and γ subunits 
can activate PLCβ. Furthermore, β, γ also have the abilities to activate Ras (5-10min), ERK1/2 
and JNK within 30min (Gudi et al., 2003), these signalling pathways then control the synthesis 
of new proteins such as  E-selectin and VCAM-1 and MCP-1 release from ECs is increased 
(Chien, 2007).  In another study, βγ units of activated heterotrimeric G proteins were also 
identified as activators of a new guanine nucleotide exchange factor (GEF), p114RhoGEF, 
which in turn activates RhoA and Rac1, but not Cdc42 (Niu, Profirovic, Pan, Vaiskunaite, & 
Voyno-Yasenetskaya, 2003).  
Post-angioplasty, ECs are injured and activated by the implanted stent, which recruits 
leukocytes and induces their adhesion by increasing expression of P-selectin, ICAM-1, VCAM-
1, TNF-α and other inflammatory cytokines (e.g. IL-6, IL-8).  Injured ECs are also associated 




(Koppara et al., 2015). Subsequently, platelets adhere to adhesion proteins (e.g. vWF, collagen 
and fibrinogen) to promote platelet aggregation sub-endothelium and further thrombosis 
formation (Tesfamariam, 2008). Furthermore, injured ECs also cause dysfunction in the 
maintenance of vascular homeostasis and vasomotor tone.  These dysfunctional ECs have 
reduced eNOS (endothelial nitric oxide synthase) activity but induce oxidative stress and 
increase reactive oxygen species, which further impairs ECs and continuously induces 
inflammatory signalling (Cai, 2005). The impaired ECs also have diminished NO (nitric oxide) 
activity, which together with decreased eNOS activity results in endothelium-modulated 
vasodilation. Another major factor inhibiting endothelial repair after stent implantation is the 
side effects of the drugs coating the stents. For example, sirolimus, which has been 
demonstrated to induce PAI-1 and inhibit tPA expression, also induced apoptosis and 
thrombosis, attributed to re-endothelialisation delay (Q. Ma et al., 2012; Muldowney et al., 
2007). Sirolimus, as a lipophilic drug can easily be taken up by ECs, which induces NADPH 
oxidase-triggered superoxide production and aggravates oxidative stress in EC (Jabs et al., 
2008). In terms of shear stress, the local blood flow is also disturbed by the implanted stent, and 
turbulent shear stress due to disturbed flow promotes the expression of pro-thrombotic and pro-
adhesion molecules, such as vWF, ICAM-1and VCAM-1, which also inhibit re-
endothelialisation and thrombosis (Jimenez & Davies, 2009). 
 
1.5.1.2 Endothelium repair 
Re-endothelialisation is a self-repair process after an injury to maintain the protective role of 
endothelium in the vessel wall, which includes proliferation and migration of adjacent intact 
endothelial cells, resident vascular stem cells and recruited stem cells from the bone marrow. 
Resident vascular-derived endothelial cells have been proven to contribute to re-
endothelialisation much more effectively in response to damaging stimulation than stem cells 









 are described as progenitors with the ability to differentiate into ECs, to 
participate in blood vessel formation and progression of atherosclerosis (Hu & Xu, 2011; Hu et 




 adventitia cells can interact with ECs and promote 
capillary-like structure formation and stabilisation (Campagnolo et al., 2010). When adventitial 
cells were injected into a hind limb ischemia mouse model, a significant pro-angiogenic effect 
(a full blood flow recovery) was observed as early as 7 days after injection. This indicates that 
adventitial cells have therapeutic potential in angiogenesis/vasculogenesis (Campagnolo et al., 
2010). Transplantation of adventitial cells can repair infarcted hearts through angiogenesis 
(Katare et al., 2011). Taken together, these recent data demonstrate that adventitial progenitor 
cells have the ability to repair ECs in ischemic tissue.  
In response to injury or atherosclerotic plaques, resident stem or progenitor cells will have 
different structural and functional behaviours (Gutterman, 1999). In atherosclerosis, adventitial 
inflammation and angiogenesis are widespread. In particular, advanced plaques are vulnerable 
to rupture and thrombosis formation. In normal conditions, progenitor cells are involved in 
maintaining homeostasis of the physiological vasculature. On the other hand, progenitor cells 
may also supply cells that contribute to neointimal lesion formation and atherosclerosis.  
It is widely accepted that the proliferation of SMCs significantly contributes to neointima 
formation. However, the debate over the origin of SMCs still persists. It is believed that the 
media and adjacent undamaged cells, such as mature ECs and SMCs can migrate into the intima 
to replace dead ECs (Ross, Glomset, & Harker, 1977). In addition, bone marrow-derived 
progenitors have also been postulated as another main source of SMCs (Saiura, Sata, Hirata, 
Nagai, & Makuuchi, 2001; Sata, 2003). Subsequently, experimental mouse models in which 
genes are over-expressed, deleted, or mutated have demonstrated that SMCs and ECs in 
atherosclerotic plaques are derived from local resident progenitor cells in the vessel wall rather 
than bone marrow-derived progenitor cells (Xu, 2004). In porcine coronary arteries and canine 
and rat carotid arteries, the increase in adventitial cell proliferation and migration in response to 




1999; Oparil et al., 1999; Scott et al., 1996; Shi et al., 1996). Transplanting cells to the 
adventitia of the injured artery and monitoring movement of these cells gives direct evidence for 
the ability of adventitial cell migration (Stenmark et al., 2013). Furthermore, Sca-1
+
 progenitor 
cells in the adventitia may be stimulated by injury to adopt a SMC-like phenotype before 
migration through the media and intima to form the neointima.   
1.5.2 Leukocytes recruitment 
Following angioplasty, platelets, leukocytes and monocytes are recruited by injured endothelial 
cells at the beginning of the inflammatory response (Furman et al., 1998; Ott, Neumann, Gawaz, 
Schmitt, & Schomig, 1996) (Figure 1.12). In both atherosclerosis and post-angioplasty 
neointima lesions, leukocytes and platelets have all been shown to co-localise in ischemic and 
reperfusion areas (Libby & Simon, 2001). Activated platelets interact with their recruited 
leukocytes through a cascade of adhesion involving P-selectin and β2 integrin Mac-1 
(CD11b/CD18) (Diacovo, Roth, Buccola, Bainton, & Springer, 1996; Evangelista et al., 1996). 
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Figure 1.12 The cascade of leukocyte recruitment and transendothelial migration. 
Post-angioplasty, the injured endothelial cells express a variety of adhesion receptors (shown in 
each panel as adhesion molecules for each step of leukocyte movement) at the initial stage of 
inflammatory response. These adhesion molecules mediate multiple steps of leukocytes 
movement including capture, rolling, slow rolling, arrest, crawling and trans-endothelial 
migration which leads to their recruitment and extravasation from the circulation into the 






1.5.2.1 T cell infiltration 
Recently, an abundance of studies has revealed that atherosclerosis is regulated by a series of 
immune responses. In these processes, immune cells play crucial roles in regulating 
atherosclerosis initiation and progression. Interestingly, either an increased or decreased number 
of lymphocytes is a documented risk for accelerating atherosclerosis (Dworacka et al., 2007; 
Nunez et al., 2011), which indicates that different lymphocyte subsets are acting in diverse ways 
during the progression of atherosclerosis. In the early stages of atherosclerosis, regulatory T 
cells can clear out injured cells and oxidized LDL from the vessel wall to prevent further 
inflammatory responses. Regulatory T cells increased markedly between 4-6 weeks and kept 
this high level until 12 weeks in ApoE
-/-
 mice fed a high-cholesterol diet. In contrast T helper 2 
cells are  recruited into the vessel wall between 4-10 weeks but after 10 weeks regulatory T cells 
decreased distinctly (Veillard, Steffens, Burger, Pelli, & Mach, 2004). As the disease progresses, 
T helper 1 cells play a dominant role against self-antigens, which exacerbate inflammation in 
the progression of atherosclerosis.  
Similarly to the pathophysiology of original atherosclerosis, post-angioplasty restenosis is also 
attributed to a cascade of inflammatory events. A clinical investigation found that T 
lymphocytes were activated with an expression of the soluble interleukin-2 receptor in stable 
angina pectoris patients, but after coronary angioplasty, these cells developed a silent 
immunological status (Blum, Sclarovsky, & Shohat, 1995). In contrast, another study reported 
that there were significantly more T lymphocytes in restenotic lesions of patients with unstable 
angina (Piek et al., 2000). A further clinical study reported that in each stage of restenosis after 




 T lymphocytes (Grewe, 
Deneke, Machraoui, Barmeyer, & Muller, 2000). Neutrophils are observed at an early stage of 
restenosis, whereas lymphocytes and macrophages exist both in the early (3-7 days) and late (>6 





were found to be significantly increased in the circulation (Navarro-Lopez et al., 2003). In a 




increased neointimal formation and percentage of restenosis (Kornowski et al., 1998). Thus, the 
presence of T lymphocytes as immune cells in the in-stent neointima during both acute and 
chronic inflammation after PTCA indicates that there is a local immune response in post-
angioplasty restenosis.  
1.5.2.2 Monocyte/Macrophage recruitment 
Increased macrophage infiltration is found in coronary plaques with restenosis, which 
implicates macrophages as a major indicator of restenosis after PCI (Moreno et al., 1996). At 
the sites of stent restenosis, there are abundant macrophages accumulating in the neointima 
(Komatsu, Ueda, Naruko, Kojima, & Becker, 1998). A possible mechanism suggested for 
restenosis relates to activation of monocytes and neutrophils in the circulation and adherence to 
thrombin-activated platelets after PCI (Mickelson, Lakkis, Villarreal-Levy, Hughes, & Smith, 
1996).  
In the early stages after vessel injury, monocyte recruitment is mediated by adherent platelet-
derived adhesive substrates, such as selectins, integrins, and adhesion molecules (C. Weber, 
2003). For example, the absence of platelet P-selectin on ApoE
-/-
 mice significantly inhibits 
macrophage infiltration and neointima formation after wire injury of the carotid artery (C. 
Weber, 2003). Besides the above, chemokines are also known to play a central role in monocyte 
recruitment in atherosclerosis. CCL2, as a potent monocyte chemoattractant, was found to be 
expressed on injured vessels within 24 hours of mechanical injury (Furukawa et al., 1999; 
Taubman et al., 1992). A clinical investigation reported that after PTCA patients with restenosis 
had significantly higher levels of CCL2 in their plasma, which correlated with elevated 
monocyte accumulation (Cipollone et al., 2001). This finding is also supported by various 
animal experimental models. In hypercholesterolemic rabbits, CCL2-mediated monocyte 
recruitment and neointimal hyperplasia were significantly diminished after anti-CCL2 gene 
therapy (Mori et al., 2002).  Furthermore, the CCL2-CCR2 axis also contributed to monocyte 
accumulation and activation mediated neointima formation after perivascular cuff placement in 




induced arrest of monocytes on adherent platelets, and this effect was abolished by pre-
treatment with CCL2 antibody in an ex vivo perfusion of injured carotid arteries model. 
Moreover, deficiency of CCR2 also reduced macrophage accumulation in the neointima 
(Schober et al., 2004). These findings imply that CCL2 plays an important role in rapidly 
arresting monocytes to the denudated endothelium. In contrast, CXCL1 was immobilized on 
endothelial cells which enabled ECs to convert monocytes from a rolling phenotype to firmly 
adherent to the TNF-α activated endothelium, under physiological flow conditions (K. S. Weber, 
von Hundelshausen, Clark-Lewis, Weber, & Weber, 1999).  
Beyond the early stage of monocyte infiltration, extended monocyte recruitment is induced by 
NF-кB and IкB-α released from SMCs and ECs in the neointima (Landry, Couper, Bryant, & 
Lindner, 1997; Lindner & Collins, 1996). Similar studies reported migration of macrophages 
into the neointima was significantly attenuated by inhibition of NF-кB activation, using decoy 
oligodeoxynucleotides (Yamasaki et al., 2003; Yoshimura et al., 2001). P-selectin expressed on 
neointimal SMCs of an injured carotid artery in ApoE
-/-
 mice, mediated monocyte adhesion to 
SMCs in the neointima (Zeiffer et al., 2004). Chemokine CCL5 was detected on the luminal 
surface of neointima lesions 4 weeks after wire injury in ApoE
-/-
 mice and triggered circulating 
monocyte adherence to inflamed endothelium resistant to shear stress (Schober et al., 2002; von 
Hundelshausen et al., 2001).  
In brief, many studies have established the role of monocyte and monocyte-derived macrophage 
infiltration in neointima, both in acute and chronic stages after vascular injury (Colombo & 
Sangiorgi, 2004; Fukuda et al., 2004). These monocytes/macrophages not only participate in 
neointimal hyperplasia but also activate injured endothelial cells and SMCs through the release 
of chemokines, cytokines and other growth factors (Libby, Schwartz, Brogi, Tanaka, & Clinton, 




1.5.3 Smooth muscle cells (SMCs) 
1.5.3.1 SMC phenotype transition after vascular injury 
After vascular injury and under the regulation of micro-environmental molecules, such as 
injured ECs, adherent platelets and recruited inflammatory cells, SMCs partially switch from a 
contractile to a synthetic phenotype and subsequently participate in neointima formation 
(Owens, Kumar, & Wamhoff, 2004) (Figure 1.13). Some of the growth factors and cytokines 
they produce are well characterised, such as TGF-β and PDGF-BB.  TGF-β is one of the most 
potent growth factors that can induce contractile phenotypes in SMCs, and thus their functional 
differentiation (Tang et al., 2010) (S. Chen & Lechleider, 2004) (Masszi et al., 2003).  
Meanwhile, TGF-β inhibits SMC proliferation through regulating the cell cycle in late G1 phase 
(Reddy & Howe, 1993; Seay et al., 2005). PDGF-BB is shown to stimulate SMC proliferation 
and migration in both human and porcine SMCs (Hao et al., 2002; Madi et al., 2009). 
Furthermore, co-culture of ECs isolated from the porcine coronary artery with SMCs can induce 
proliferation of the latter and change their morphology from spindle- to rhomboid-shaped (Hao 
et al., 2002). Since coronary artery ECs are more heterogeneous in shape, these EC are 
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Figure 1.13 Smooth muscle cell phenotypic transition after stent implantation. Schema 
shows the process of SMCs dedifferentiation from a contractile to a synthetic phenotype. A 
series of cellular responses after stent implantation initiates the activation of smooth muscle cell 
migration, proliferation, and phenotypic transition. From contractile to synthetic phenotype 
transition, the contractile markers in SMCs (blue) are decreased, while the synthetic markers in 
SMCs (red) are increased. In ECM, elastin is replaced by decorin. A group of MMP members is 
expressed in synthetic SMCs. The growth factors participating in this process are also shown 
here.  
1.5.3.2 SMCs contribution to neointima formation 
SMCs proliferation and migration play essential roles in post-angioplasty restenosis. In a rat 
carotid artery injury model, PDGF has been found to significantly induce SMCs migration 
towards neointima but did not affect proliferation. In contrast, bFGF markedly induced SMCs 





As part of the acute injury response, cells located around the stent start to proliferate, which 
prevents the stent from exposure to the flowing blood (Uchida et al., 2010),.  This exposure is 
necessary for vessel healing after stenting. However, in the late stages of injury, excessive 
proliferation of SMCs will cause intimal hyperplasia. Thus, these dedifferentiated and 
proliferative SMCs play an important role in the development of restenosis post angioplasty 
(Rzucidlo, Martin, & Powell, 2007). 
SMC migration is another major cause of neointimal hyperplasia and involves the degradation 
of ECM, FAK activation and reorganisation of cytoskeletal related protein in SMCs. Studies 
show that high plasminogen activator activity correlates with SMC migration in rats (Bochaton-
Piallat, Gabbiani, & Pepper, 1998), while in pigs, high urokinase activity is more important 
(Hao et al., 2002). Inhibition of FAK activity also attenuates SMC migration (Taylor et al., 
2001). Reorganization of the cytoskeleton allows actin-based SMC movement by supplying a 
scaffold to generate force (Z. Wang & Newman, 2003).  
1.5.4 Extracellular matrix degradation facilitates vascular cells 
migration 
Extracellular matrix (ECM) is a mixture of molecules released from vessel wall cells which 
supports the vascular structure, mediates multicellular communication and maintains normal 
vessel function. The ECM exists in each layer of the vessel wall and has a diverse composition 
depending upon its origin. In the intima, a thin layer of subendothelial ECM is composed of 
proteoglycans and hyaluronan; in the media, ECM surrounding SMCs comprises elastic 
elements, collagen and proteoglycans; in the adventitia, fibrillary collagen is the main 
component of ECM.  
Under pathological conditions, ECM also plays an important role in cell migration which 
contributes to both atherosclerotic and neointimal lesions post angioplasty. After vascular injury, 
ECM is degraded by matrix metalloproteinases (MMPs) at the margin and core of the lesions, 
which may contribute to lesion rupture (Nikkari et al., 1996). These MMPs have been shown to 




SMC migration in response to balloon injury in rat carotid arteries (Bendeck, Irvin, & Reidy, 
1996). Overexpression of either tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) or 
TIMP-2 in SMCs significantly reduced migration in both migration assays in vitro and to a 
lesser extent in balloon-injured rat carotid artery intimal hyperplasia in vivo (Cheng et al., 1998; 
Forough et al., 1996). Overexpression of MMP9 in SMCs induced their migration and invasion 
in vitro and migration in an arterial matrix in vivo, which changed vascular remodelling (Mason 
et al., 1999). Similarly, SMCs isolated from MMP8
-/-
 mice exhibited lower migration in vitro 
compared with SMCs from WT mice (Xiao et al., 2014).  
In addition, proteoglycans are involved in vascular cell migration (Wight, Kinsella, & 
Qwarnstrom, 1992). Hyaluronan (HA) and the HA-binding proteoglycan versican were found to 
be enriched in the pericellular matrix around SMCs, which facilitates SMCs migration by 
inhibition of cell adhesion (Evanko, Angello, & Wight, 1999). Furthermore, administering  HA 
also diminishes monocyte influx and migration to the balloon injured carotid artery in 
rabbits(Ferns, Konneh, Rutherford, Woolaghan, & Anggard, 1995). Collagen type VIII 
contributes to neointimal lesion development due to induction of SMC migration and 
attachment (Hou, Mulholland, Gronska, & Bendeck, 2000). A soluble non-collagenous (NC1) 
domain of collagen type IV has also been demonstrated to regulate endothelial cells migration 
and adhesion, which may inhibit angiogenesis (Petitclerc et al., 2000). 
1.5.5 Vascular progenitor cells contribute to neointima formation 
SMCs are well established as the main source of cells contributing to restenosis. In recent years, 
many studies have demonstrated that a group of adventitia vascular progenitor cells participates 
in lesion formation. Some studies report that inflammatory cytokines or growth factors play a 
chemotactic role in progenitor cell migration. Endothelial cell-derived PDGF-B induced 
migration and proliferation of vascular progenitor cells with expression of PDGFRβ (Hellstrom, 
Kalen, Lindahl, Abramsson, & Betsholtz, 1999). An ex vivo model showed that progenitor cells 
isolated from vein graft could migrate into decellularized vessels in response to SDF-1 via 




ability of these vascular progenitor cells was significantly enhanced by Sirolimus via CXCR4 
activation, which elucidated a new mechanism behind Sirolimus-eluting stent-induced 
restenosis (Wong et al., 2013). Furthermore, metalloproteinsase-8 expressed on stem/progenitor 
cells facilitated their migration and subsequent contribution to atherosclerosis via the 
MMP8/ADAM10/E-cadherin signalling pathway (Xiao et al., 2013). EC-derived microparticles 
and non-microparticle secreted factors can induce perivascular mesenchymal stem cell 
proliferation and migration by activating NF-кB signalling (Lozito & Tuan, 2014).  However, 
the exact mechanism of vascular progenitor cells migration and subsequent neointima formation 





1.6 Molecular mechanisms mediate restenosis 
Atherosclerosis and post-angioplasty neointima formation complicates progression of vascular 
disease, which contains three major stages: 1) endothelial cells activation and inflammatory cell 
infiltration to the sub-endothelial cell layer; 2) lesion development including neointima 
formation, collagen accumulation and core necrosis; 3) thrombosis.  In each stage, the complex 
interactions between different cell types and molecules are transmitted through numerous 
signalling pathways at different times in different cell types. In this redundant signalling 
network, similar pathways may take different effects in another cell type and overlapping of 
different pathways may take over the same function. These redundant mechanisms are a product 
of evolution, which guarantees that critical biological functions can proceed without failure due 
to some deficiency in some stage of the signalling (Hopkins, 2013).  This may bring difficulties 
for researchers wishing to explore the signalling mechanisms behind particular cell activities. 
1.6.1 Inflammatory cytokines 
In the adventitia, progenitor cells may communicate with SMCs and ECs via soluble factors 
produced in the media and the intima and carried by the transmural fluid. This communication 
is driven by steep pressure gradients from the lumen to the adventitia (Alberding, Baldwin, 
Barton, & Wiley, 2005; Zerwes & Risau, 1987). In injured vessels, cytokines are produced by 
neutrophils, activated macrophages and SMCs in response to initial mechanical injury or acute 
thrombosis, in either an autocrine or paracrine manner, to maintain cells during the process of 
restenosis (Donners, Daemen, Cleutjens, & Heeneman, 2003). Accumulating data indicate that 
cytokines produced in inflammatory conditions can be categorised into two groups: pro-
inflammatory cytokines, such as IL-1, IL-8, TNF-α, IFN-γ; anti-inflammatory cytokines, such 
as IL-4, IL-10, TGF-β. Cytokines of both groups can stimulate the mobilisation of vessel wall 
cells. For example, TNF-α exacerbates vein graft neointima formation by an induction role in 
SMC and EC proliferation and migration (L. Zhang, Peppel, Brian, Chien, & Freedman, 2004). 
IL-8 is reported to increase EC proliferation and migration in the regulation of angiogenesis (A. 




cytokine, has both pro- and anti- inflammatory effects. One study showed that TGF-β enhanced 
neointima formation through induction of SMC proliferation (J. D. Smith et al., 1999). However, 
another research group reported that TGF-β-increased collagen deposition in the adventitia was 
the main reason behind constrictive remodelling in angioplasty restenosis (Kingston et al., 
2001). IL-10 is also reported to have significantly reduced SMCs proliferation and migration 
which exerts a protective effect from restenosis in balloon-injured rat aorta (Mazighi et al., 
2004). Previous studies have shown that when adventitial inflammation occurs in injured 
vessels, a panel of cytokines such as TNF-α，TGF-β, granulocyte colony stimulating factor are 
produced (Michel et al., 2007; Mitchell & Libby, 2007; Wilcox, Okamoto, Nakahara, & Vinten-
Johansen, 2001). These cytokines may be directly or indirectly related to the mobilisation of 
progenitor cells in the adventitia. TGF-β induced vascular wall resident stem cells differentiate 
into pericytes/SMCs and further facilitate neovascularization (D. Klein et al., 2011). In our 
group, Wong et al. reported that TNF-α mediated vascular progenitor cells to contribute to 
endothelial repair in vein grafts. Furthermore, adventitial cells can potentially release 
chemokines, cytokines or reactive oxygen species that can affect medial SMC tone and 
stimulate the recruitment and retention of inflammatory and progenitor cells from the circulation 
into the vessel wall. After activation, progenitor cells can potentially undergo proliferation, 
migration or differentiation that supports lesion formation. 
1.6.2 Chemokines 
Chemotaxis is a movement of cells directly towards a gradient of chemical attractants (e.g. 
chemokines) (Majumdar, Sixt, & Parent, 2014). The initial research discovered that chemokines 
can be rapidly released from activated cells and attract immune cells such as lymphocytes and 
neutrophils to sites of inflammation, mediating various pathological process (Schall & Bacon, 
1994). Subsequent research identified that they are also involved in fibrosis, tissue remodelling 
and angiogenesis (Lukacs, 2001) Most chemokines contain at least four cysteine residues, in a 
conserved position that is key to forming their 3-dimensional shape, and have three distinct 
domains. Chemokines are a group of small proteins with molecular weights ranging from 8 to 




terminus, members of the chemokine family are classified into four subfamilies namely the CC, 
CXC, C and CX3C (Moser & Loetscher, 2001) (Figure 1.14). As the region of the N-terminus 
can be modified, the integrity of the N-terminus is important for receptor binding and cell 
activity (Proudfoot et al., 1996).  
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Figure 1.14 Classification of chemokines. a. CXC chemokines have the distinct motif of one 
amino acid between the first two cysteine residues. Chemokines from this family are 
chemoattractants to neutrophils, T lymphocytes, B lymphocytes and natural killer cells. b. CC 
chemokines are shown to be identified by the first two cysteine residues being adjacent to one 
another. They attract monocytes, macrophages, basophils, T lymphocytes and eosinophils. c, the 
C chemokine subfamily is distinguished by containing only two conserved cysteine residues. 
The only members of this family are XCL1 and XCL2, which are known chemoattractants of T 
lymphocytes. d, the CX3C chemokine subfamily, which only has one member, CX3CL1, is 
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Figure 1.15 Classification of chemokine receptors and their corresponding ligands. The 
schematic shows the ligand-receptor binding pattern of different groups of chemokine receptors. 
Each receptor in the Shared group binds to several chemokines. In contrast, each receptor in the 
Specific group only binds to one chemokine. Particularly, receptors Duffy and D6 bind to some 
chemokines without transducing signalling of chemokine response.  
All the chemokines exert their biological effects by interacting with 7 transmembrane spanning 
receptors coupled to a heterotrimeric G protein, known as chemokine receptors (Thelen, 2001) 
(Figure 1.15). Chemokines, as kinds of charged proteins, have low affinity to 




homeostasis, each chemokine can non-specifically bind to more than one receptor and vice 
versa. However, in inflammatory conditions, chemokines are constantly confined to their 
corresponding receptors (Rot, 1992). For example, CCL1 is a ligand for its respective receptor, 
CCR1. Some researchers have also shown that some other molecules which are not attributed to 
the chemokine family can bind to and activate chemokine receptors. For example, recently 
adrenomedullin was reported as a ligand for an atypical CXCR7 receptor, which modulates 
cardiac and lymphatic phenotypes (K. R. Klein et al., 2014).  Another study demonstrated that 
HMGB1 (high mobility group box 1) can form a heterocomplex with CXCL12 and exert a 
function in recruiting inflammatory cells by binding to CXCR4 but not other HMGB1 receptors.  
 
1.6.2.1 Chemokines play an important role in post-angioplasty restenosis 
As chemokines play a vital role in recruiting inflammatory cells to the lesion, they are involved 
in nearly all kinds of disease processes, including cardiovascular diseases. Since atherosclerosis 
is a chronic inflammatory disease, chemokines have been reported to participate in nearly all 
stages of the disease. Among them, post-angioplasty restenosis, as a common complication after 
balloon angioplasty and stent implantation, has been extensively studied. Many researchers are 
focusing on the mechanisms behind excessive neointima formation, in which a large number of 
SMCs and inflammatory cells are orchestrated by a variety of chemokines. In an ApoE
-/-
 mouse 
model, CXCL12 and its receptor CXCR4 have been demonstrated to be crucial for neointimal 









muscle progenitor cells into the wire injured carotid arteries (Zernecke et al., 2005). Recently, 
another study showed that in a partial ligation of carotid artery in ApoE
-/- 
mouse model, 







 smooth muscle progenitor cells to the neointima lesion, which increases 
SMC and collagen content but reduces the number of macrophages (Akhtar, Gremse, Kiessling, 
Weber, & Schober, 2013). Furthermore, a recent study identified that endothelial-specific 
CXCR4 deficiency can significantly reduce injury-induced carotid artery neointima formation 










 cells mobilization were 




 mice model (Noels et al., 2014). 
 
1.6.2.2 CCL2 and CCR2 
CCL2 is a potent chemoattractant of monocyte/macrophages, and the recruited monocytes can 
further become lipid-laden macrophages (foam cells) in the vessel wall.  These foam cells  are 
major elements of the fatty streak, a hallmark of early atherosclerotic lesions (Fuster, Badimon, 
& Badimon, 1992). In early studies, elevated CCL2 was found in macrophage-rich 
atherosclerotic lesions in humans (Nelken, Coughlin, Gordon, & Wilcox, 1991) and nonhuman 
primates (X. Yu et al., 1992) and in other animal models (e.g. rabbit (Yla-Herttuala et al., 1991)) 
but not in healthy arteries (Nelken et al., 1991). Many studies have shown modified LDL can 
induce CCL2 expression in a variety of cell types. A dramatic increase in monocytes 
transmigration into the subendothelial region has been attributed to increased levels of CCL2, 
which is released from the human aortic endothelium when it is incubated with mildly oxidized 
LDL (Navab et al., 1991). In the late stages of atherosclerosis, CCL2 is also involved in 
neointima formation. Boring et al. presented the first evidence for the up-regulated expression 
of CCL2 in human atherosclerosis plaques and for lipid-activated endothelial and SMCs in the 




 mouse to show that deficiency of CCR2 decreased 
lesion formation, which indirectly proves a role for CCL2 in the recruitment  of monocytes to 
the atherosclerotic lesion, through the CCL2/CCR2 axis (Boring, Gosling, Cleary, & Charo, 
1998). Recently, Grudzinska et al. performed a rat aortic–allograft model to investigate whether 
labelled adventitial tissue participated in transplant arteriosclerosis. Their data showed that 
fibroblasts and mesenchymal stem cells in the adventitia are the main source of cells which are 
stimulated by CCL2 and migrate into the neointima. Finally, they confirmed the importance of 




 mice (Grudzinska et al., 2013). In a PVAT (perivascular adipose tissue) 
transplantation model, Manka et al. reported that transplantation of PVAT derived from the 
thoracic aortic of WT mice fed a high fat diet to LDLR
-/- 




accelerate neointimal formation, macrophage infiltration and angiogenesis in the adventitia. 
However, deletion of PVAT specific CCL2 can attenuate wire injury-induced neointimal 
hyperplasia and adventitial angiogenesis (Manka et al., 2014). 





 mice showed a marked reduction in atherosclerosis lesion 
area compared to ApoE
-/-
 mice in response to high-fat diet, but no change in lipid or lipoprotein 




 mice lesions were 
found to be less advanced, containing primary foam cells and fatty streaks, which indicates that 
CCR2
-/-
 mice are more resistant to the development of atherosclerosis (T. C. Dawson, Kuziel, 
Osahar, & Maeda, 1999). Notably, the phenotype of CCR2
-/-
 mice is not exactly the same as 
CCL2
-/-
 mice. Compared with WT mice, CCR2
-/-
 mice have a significant deficiency in delayed-
type hypersensitivity responses and production of T helper 1-type cytokines (Boring et al., 
1997). In contrast, CCL2
-/-
 mice have impaired T helper 2 responses (Gu et al., 2000). Moreover, 
Sarafi et al. discovered MCP-5, a new potent murine chemokine for recruitment of peripheral 
blood monocytes, which conducts its signals through CCR2 (Sarafi, Garcia-Zepeda, MacLean, 
Charo, & Luster, 1997).  In humans, MCP-3 has also been identified and it can bind to CCR2b 
receptor (Kurihara & Bravo, 1996). Therefore, when CCR2 is deleted, some manifestation from 
these mutant mice may due to the reduction of signalling pathways mediated by other 
chemokines but not only through CCL2. 
 
1.6.2.3 CXCL1 and CXCR2 
Besides CCL2, which has been established as a potent chemokine for recruitment of 
monocyte/macrophages, CXCL1 was also found to be expressed on activated ECs to arrest 
monocytes in the blood (K. S. Weber, P. von Hundelshausen, et al., 1999). In this important 
study, Weber et al. reported that both mRNA and protein levels of CXCL1 and CCL2 were 
significantly up-regulated in the TNF-α activated endothelium and that they take their effects 




the results of inhibition experiments revealed that CXCL1 was restricted to the endothelium, 
whereas MCP-1 was secreted as a soluble protein.  Accordingly, CXCL1 arrested monocytes 
from rolling in the blood flow to adhere to the CXCR2 expressing endothelium. By contrast, 
CCL2 was involved in the spreading and trans-endothelial migration of the monocytes through 
CCR2.  Two years later, another study by Huo et al. confirmed this conclusion (Huo et al., 
2001). In the carotid arteries of ApoE
-/-
 mice, both CXCL1 and CCL2 were expressed on the 
endothelium. With blockage of CXCL1 or CXCR2, fewer monocytes were arrested in an ex 
vivo flow chamber system, which was not changed in the CCL2 or CCR2 related blocking 
groups. On the contrary, many more monocytes accumulated with pre-perfusion of CXCL1 on 
the carotid arteries compared with treatment of CCL2.   
Interestingly, apart from this monocyte arrest in the early stage of atherosclerosis, in the more 
advanced atheroma, an elevated expression of CXCL1 has also been found to be responsible for 
recruitment of macrophages and lesion progression (Boisvert et al., 2006).  Boisvert et al. 
generated double mutant mice by deletion of CXCL1 in LDLR
-/-
 mice, and found a significant 
reduction in atherosclerosis development in these mice. To further investigate in which stage of 







 mice background and demonstrated a marked decline in macrophage 
accumulation in lesions, only in the advanced stage of atherosclerosis.  Taken together, both 
CXCL1 in the vessel wall and CXCR2 on leukocytes are pivotal to macrophage infiltration in 
established atherosclerotic lesions. 
The CXC family of chemokines show distinct and differing abilities in their angiogenetic effects, 
owing to whether the ELR motif (Glu-Leu-Arg) is included in their structures (Strieter et al., 
1995). As CXCL1 contains an ELR motif, it has been demonstrated to be a potent angiogenic 
factor by different studies. Caunt et al. found that thrombin can significantly induce expression 
of CXCL1 mRNA and protein in endothelial cells and the antibody of CXCL1 can ablate the 




As the receptor of CXCL1, CXCR2 was also detected expressed in the intima of the human 
atherosclerotic plaque, Boisvert et al. further verified the role of leukocyte CXCR2 in the 
recruitment of macrophages and development of atherosclerosis in the mice. They generated 
chimeric mice on an atherosclerosis-prone LDLR
-/-
 background with either mIL-8RH
+/+
 
(CXCR2 homologue) or mIL-8RH
-/-
 bone marrow and found CXCL1 was expressed in the 





BMT mice, the mIL-8RH
-/- 
BMT mice had reduced macrophage infiltration and less 
advanced atherosclerotic lesions, with restricted necrotic cores and diminished SMC 
proliferation (Boisvert, Santiago, Curtiss, & Terkeltaub, 1998).  
In addition, CXCR2 also plays an important role in the homing of EPCs from the circulation to 
the injured sites of vessels and contributing to re-endothelialisation. In the adhesion assay, 
CXCL1 induced EPCs adhesion to platelet coated endothelial matrix can be markedly inhibited 









 injection into nude mice (Hristov et al., 2007). This effect of CXCR2 was further 
demonstrated in another study, which showed that blockage of CXCL1 using monoclonal 
antibody can delay re-endothelialisation and thus aggravate neointima formation via the 
CXCL1/CXCR2 axis (Liehn, Schober, & Weber, 2004).  
However, there are several ligands binding to CXCR2 besides CXCL1 and its human 
orthologue GRO-α, such as CXCL8/IL-8, CXCL7, CXCL2, CXCL3 and CXCL5. Among them, 
CXCL8 has higher affinity with CXCR2 in humans (Richardson, Marjoram, Barak, & 
Snyderman, 2003). CXCL8 can trigger firm adhesion of rolling monocytes in the blood flow 
onto the endothelial cells, with an expression of E-selectin, which is associated with the acute 
inflammatory process (Gerszten et al., 1999). CXCL8 was also found to be present in human 
arterial atherosclerotic fibrous plaques (Rus, Vlaicu, & Niculescu, 1996). Detection of CXCL8 
in carotid plaques of ischaemic stroke patients, but not in asymptomatic patients, revealed that 
CXCL8 was associated with stabilization of atherosclerotic plaques (Peeters et al., 2009).  




CXCR2 (Richardson et al., 2003). This evidence can be used to explain why the reduction of 
atherosclerosis lesions in CXCR2
-/-
 mice is much more robust than the one observed in CXCL1  
deficient mice (Boisvert et al., 2006), as other ligands of CXCR2 can either mediate pro-
atherogenic functions or even compensate the loss due to deficient CXCL1.   
 
1.6.2.4  CCL5 and CCR5 
Several studies have also demonstrated that CCL5 and its receptors CCR1 and CCR5 play 
important roles in atherosclerosis. In the early stage of atheroma, there is a continuous 
production of CCL5, which is a potent chemotactic molecule in the  recruitment of Th1 
lymphocytes and monocytes (Bursill, Channon, & Greaves, 2004). Hundelshausen et al. 
reported that CCL5 was released from thrombin-activated platelets and elicited arrest of 
monocytes in the blood and their adhesion to the surface of the inflamed endothelium (von 
Hundelshausen et al., 2001). In a study from Krohn et al., CCL5 was found to be expressed on 
SMCs, which contributed to neointima formation. With overexpression of transcriptional 
regulator YB-1 in SMCs, the expression of CCL5 is significantly up-regulated which leads to an 
increase in monocyte recruitment. In wire-injured carotid arteries of ApoE
-/-
 mice, intraluminal 
transfection of YB-1 shRNA significantly reduced neointima formation with decreased 
macrophage infiltration in the lesions. Furthermore, in both ApoE
-/- 
mice treated with a CCL5 
antagonist and mice deficient in CCR5, the protective role of YB-1 knockdown in 
atherosclerosis was abrogated (Krohn et al., 2007). Another study with application of a CCL5 





]-RANTES, a potent inhibitor of endogenous CCL5, was shown to diminish 
atherosclerosis in LDLR
-/-
 mice, by decreasing numbers of T cells and macrophages infiltration 
in the plaque and inhibiting secretion of MMP-9. RANTES has also been shown to stabilise the 
atherosclerotic plaque and is associated with plaques with increased collagen and SMCs. 




As the putative receptor of CCL5, CCR5 has also been shown to participate in atherosclerotic 
development. A similar study using the CCL5 receptor antagonist Met-RANTES showed a 
significant reduction of atherosclerosis progression with less leukocyte infiltration and increased 
collagen deposition (Veillard, Kwak, et al., 2004). This finding demonstrated that 
CXCL5/CCR5 is involved in CCL5 attributed atherosclerosis. A study by Potteaux et al. further 
proved that CCR5 derived from bone marrow has the effect of promoting atherosclerosis. They 
generated reconstituted mice on an LDLR
-/-
 genetic background by transplantation of bone 




 mice. In comparison to CCR5
+/+
 bone marrow control 
mice, CCR5
-/-
 bone marrow mice had enhanced IL-10, produced by peritoneal macrophages, 
and reduced TNF-α, released by T cells, which resulted in less recruitment of macrophages in 
lesions, smaller sizes of plaque, a 50% reduction in  MMP-9 expression and double the amounts 
of collagen accumulation during 8-12 weeks (Potteaux et al., 2006).   
 
1.6.3 GTPases 
Small GTP-binding proteins, which have molecular weights ranging from 20kD to 40kD and 
can bind and hydrolyze GTP, are also called small GTPases. More than 100 small G proteins 
have been categorised in this superfamily. According to their primary amino acid sequences, 
they can be classified into five main subfamilies: Ras (Ras, Rap, Rad, Ral, Rin, and Rit), Rho 
(Rho, Rac, Cdc42, and Rnd), Rab, Sar1/ADP ribosylation factor (Arf, Arl, Ard, and Sarl), and 
Ran (Matozaki, Nakanishi, & Takai, 2000). These GTPases take their effects through a 
mechanism of GTP cycling to turn signal transduction on and off (Figure 1.16). GTPases play 
crucial roles in many aspects of cell functions, such as cell proliferation, migration and 





Figure 1.16 Schematic of the GTPase cycle. GTPases function as a molecular switch. GDP-
bound forms serve as an “OFF” state. Once stimulated by upstream signals, they will switch 
into GTP-bound forms (“ON” state), activated by Guanine Nucleotide Exchange Factors 
(GEFs).  Then, the GTP-bound proteins interact with their effectors and transduce signals 
downstream. GTPase-activating proteins (GAPs) catalyse the hydrolysis of GTP which turns the 
“switch” off, returning the GTPase to a GDP-bound form once again.  
 
1.6.3.1 Rho GTPase 
The Rho GTPase family is a subfamily of the small GTPase superfamily, which consists of 22 
members of approximately 21 kD molecular weight, including Rho (A, B, C); Rac (1, 2, 3); 
Cdc42; TC10; TCL; Chp (1, 2); RhoG; Rnd (1, 2, 3); RhoBTB (1, 2); RhoD; Rif; and TTF. The 
well-established members: Rho, Rac1 and Cdc42 of the Rho family have been studied in 
humans, animals, plants and fungi (Boureux, Vignal, Faure, & Fort, 2007). In the last 20 years, 
they have been widely identified as key factors in arranging the cytoskeleton to orchestrate cell 
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Figure 1.17 Cooperation of GTPase Cdc42 and Rac in the organisation of cell 
migration. a. Rho GTPase Cdc42 and Rac are in charge of different regions at the leading edge 
of a cell. Cdc42 manages cell polarity, the formation of filopodia and focal adhesions. Rac 
controls actin polymerization and formation of lamellipodia. b. GTP-bound Cdc42 and Rac 
(activated forms) induce cell actin polymerization and turnover to form filopodia and 
lamellipodia through similar signalling pathways (Heasman & Ridley, 2008).  
 
1.6.3.1.1 Rac1/Cdc42 signalling pathway 
Cdc42 is responsible for cell polarisation and for filopodia formation at the front of the 
migrating cell, while Rac1 is required for cell membrane extension and lamellipodia formation 
at the leading edge of the migrating cell (Raftopoulou & Hall, 2004). In the process of cell 




lamellipodia to re-adhere to the ECM, thus, the coordination of the leading and rear edges of the 
cell results in cell migration (Van Aelst & D'Souza-Schorey, 1997). Activated Rac1 induces 
lamellipodia formation and subsequently activates actin-related protein 2/3 (ARP2/3) complexes 
leading to actin polymerization (Krause & Gautreau, 2014). In ECs Rac1 is responsible for 
regulating adherens junction distribution, to maintain the junctional integrity between adjacent 
cells (Bazzoni & Dejana, 2004). VE-cadherin is a component of adherens junctions and controls 
cytoskeleton rearrangement and endothelial migration, which plays an important role in 
endothelium permeability (Hordijk et al., 1999). A study showed that transformation of active 
mutant Rac1 (Tat-RacV12) into ECs enhanced cell migration, leading to an endothelial 
monolayer permeability increase by means of regulating VE-cadherin distribution (van 
Wetering et al., 2002). Activated Rac1 and Cdc42 can induce VEGF expression in ECs, and 
consequently promote angiogenesis (J. Ma et al., 2013).  In vascular SMCs, NOX1 mediated 
proliferation and migration are dependent on Rac1 activation (Pescatore et al., 2012). In the 
wire injury femoral artery model, neointima formation was inhibited in Nox1
y/-
 mice in 
comparison with wild-type (WT) mice, which further demonstrates that Rac1 participates in 
neointima formation through Nox1 mediated SMCs proliferation and migration (Lee et al., 
2009). Moreover, SMC-specific Kalrn
+/-
 mice show a significant reduction in neointima 
hyperplasia which is mediated by a decrease in Rac1 activation and further diminishment of 
SMC proliferation and migration (Wu et al., 2013). 
 
1.6.3.1.2 RhoA signalling pathway 
In contrast with Rac1 and Cdc42, RhoA promotes cell contraction and stress fibre formation at 
the rear of the cell. Furthermore, RhoA also induces focal adhesion maturation at the front edge 
of the cell but dissociation at the trailing edge (Raftopoulou & Hall, 2004). The effects of Rac1 
and Cdc42 on Rho are either activation or inhibition depending on the cell type, stimulation and 
ECM. In mouse fibroblast cell line Swiss 3T3, they showed a sequence in activation, 




1995). While in N1E-115 neuroblastoma cells, Tiam1 activated Rac1, which subsequently 
antagonised Rho signalling.  This effect could be corrected by co-expression of an activated 
mutant of RhoA (Leeuwen et al., 1997). Thus, a cross-talk between different members of the 
Rho GTPase family keeps the balance of cell movement and allows cells to demonstrate a range 
of responses to specific stimuli (Evers et al., 2000).  
 
1.6.3.2 Rho GTPases are involved in integrin signalling pathways 
Endothelial integrins play pivotal roles in flow-induced signalling transduction. Integrins are 
heterodimeric transmembrane receptors, consisting of two different chains: α and β units. 
Interestingly, integrins are like a bridge, which can transmit signals bi-directionally between 
two cells or between a cell and the ECM. These integrins can not only transmit signals initiated 
by ECM binding to the cells (outside-in signal) but also control binding affinity of ECM with 
their domains through signalling from the inside of the cells (inside-out signal).  For example, 
chemokines first bind to their receptors and “switch on” integrins by inside-out signals, then, the 
activated integrins further transmit the signals into the cell (outside-in signals) (Regelmann, 
Danzl, Wanjalla, & Alexandropoulos, 2006). As a result, the integrins either attach or release 
specific ECM to direct the cells migrating towards the chemotaxis.  The process of cell 
migration is accomplished by binding a series of cytoskeleton adapter proteins to the 
cytoplasmic tails of α and β chains of integrins.  
Talin, as a main adaptor protein, mediates activation of integrins through inside-out signalling 
by binding to the integrin β intracellular tail (Shattil, Kim, & Ginsberg, 2010).Vinculin, as 
another adapter protein, also participates in inside-out signalling transmission, but by binding to 
talin rather than binding to integrins directly. When the actin microfibers are stretched by 
physiological forces, the connected talin exposes more binding sites for vinculin, to increase 
activation of integrins and stabilise focal adhesions (del Rio et al., 2009). The intracellular tails 
of integrins can bind to adapters, G proteins, GEFs, GAPs, tyrosine kinases, serine-threonine 




and cytoskeleton proteins: actin microfibers, intermediate filaments, and microtubules (Hopkins, 
2013). 
When integrins α5β1 and αVβ3 bind to fibronectin, vitronectin, or fibrinogen in the ECM, the 
activated integrins can produce inflammatory signalling through outside-in signals (Sechler, 
Corbett, Wenk, & Schwarzbauer, 1998). These inflammatory signals are transmitted mainly by 
GTPase Rac1 and Cdc42 and their downstream effector, tyrosine kinase PAK, to control NF-кB 
activation (Orr, Hahn, Blackman, & Schwartz, 2008). Furthermore, this inflammatory signalling 
induces paxillin, which binds to the integrin α cytoplasmic tail, while FAK binds to talin and 
paxillin (H. C. Chen et al., 1995) (Turner & Miller, 1994). The tyrosine kinase Ack can 
specifically interact with activated Cdc42 and further inhibits its activity (Galisteo, Yang, Urena, 
& Schlessinger, 2006). PAK-interacting exchange factor β (βPIX) activates and interacts with 
Rac1, which is crucial for Rac1-mediated cell membrane spreading (ten Klooster, Jaffer, 
Chernoff, & Hordijk, 2006). Furthermore, βPIX mediates GTP exchange with Cdc42, by 
binding with it and triggering downstream signalling (Kepner et al., 2011).  
FAK is a remarkable promoter of directional cell migration. Integrin clustering leads to FAK 
activation (A. K. Mitra & Agrawal, 2006) and in turn FAK can further enhance integrins and 
ECM interaction (Michael, Dumbauld, Burns, Hanks, & Garcia, 2009).  As Rho GTPase family 
members are important switches in  cell migration, FAK also plays a key role in regulating their 
activity (Tomar & Schlaepfer, 2009). Rac1 and Cdc42 are involved in cell polarisation by 
regulating the actin cytoskeleton at the leading edge of migrating cells (Fukata, Nakagawa, & 
Kaibuchi, 2003). In contrast to RhoA, usually localises to the cytoplasm, mediating contraction 
of the cell membrane at the trailing edge via the ROCK1 and ROCK2 signalling pathway (Lock, 
Ryan, Poulter, Parsons, & Hotchin, 2012). FAK inactivates RhoA by interacting with RhoGAPs 
(Taylor, Macklem, & Parsons, 1999) during new adhesions assembly at the leading edge of the 
cell. FAK can also induce RhoA activation through RhoGEF, which is required for protrusion 
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Figure 1.18 Schema of the molecular structure of focal contact proteins. The focal 
contact is an interaction site near the cell membrane where various cytoskeleton-related proteins 
are assembled, through which signals are transmitted between the ECM and interior of the 
migrated cell. For example, integrins bind to paxillin and talin and then activate FAK and 
vinculin to further control actin stress fibres.  The focal contact is a dynamic group of focal 
adhesion proteins, in which the component proteins differ, depending upon a variety of external 





1.6.4 The P38 signalling pathway is involved in cell migration 
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Figure 1.19 Schema of the potential downstream signalling pathway of activated Rac1 
in cardiac disease. Rac1 can be activated by many kinds of stimuli (e.g. cytokines, growth 
factors) mediated by different types of receptors. Subsequently, the activated Rac1 stimulates 
various downstream signalling proteins, including activation of the WAVE complex, PAK 
kinase, ROS generation, kinases cascade such as p38 MAPK phosphorylation etc. These 
signalling pathways are involved in cell actin rearrangement, inflammation and regulation of 
nuclear factors in cardiac disease (Nagase & Fujita, 2013). 
Mitogen-Activated Protein Kinases (MAPKs) are a family of Serine/threonine kinases including 
p38 MAPK, ERK and JNK. p38 MAPKs is one cascade of members of the MAPK family, 




Salvador, Fornace, & Ashwell, 2005) (Figure 1.19). The p38 MAPK signalling pathway is 
involved in cell survival and apoptosis, migration and differentiation, and is related to many 
human diseases, such as cancer, cardiovascular dysfunction and Alzheimer’s disease, etc 
(Wagner & Nebreda, 2009) (Cuenda & Rousseau, 2007).  Among them, p38 MAPK plays a 
crucial role in chemotactic cell migration. VEGF mediates HUVEC migration through induction 
of rearrangement of the actin cytoskeleton via p38, but not via either the ERK nor JNK 
signalling pathways (Rousseau, Houle, Landry, & Huot, 1997). PDGF, IL-1β and TGF-β induce 
migration of vascular smooth muscle cells and also activate p38, which can be blocked by its 
inhibitor SB203580 or through transfection of a p38 dominant negative mutant (Hedges et al., 
1999). Migration of Hela cells in response to different chemoattractants, such as CXCL12, 
PDGF-BB or HGF, has been shown to be mediated by the p38 MAPK signalling pathway 
(Rousseau et al., 2006). p38α-deficient mice were reported as embryonic lethal due to defects in 
placental angiogenesis, but once they were rescued, the embryonic cardiovascular development 
was normal (Mudgett et al., 2000) (Adams et al., 2000). 
Many studies focused the on the association of p38α-mediated cell migration with cytoskeleton 
reorganization. Either endothelial cells or SMCs migration induced by growth factors or 
cytokines were modulated by HSP27 phosphorylation and subsequent F-actin polymerization 
which regulates lamellipodia microfilaments regeneration (Hedges et al., 1999; Piotrowicz, 
Hickey, & Levin, 1998). Rac1 is involved in cytoskeleton organization and lamellipodia 
spreading which contributes to cell migration. TGF-β stimulates endothelial cell spreading on 
collagen I activated GTP-Rac1 and increases p38 phosphorylation (Varon et al., 2008). 
Ras/Rac1/p38 signalling pathway is also involved in biomechanical stress induced SMCs 
production of IL-6 (Zampetaki, Zhang, Hu, & Xu, 2005). Tissue factor enhanced cell migration 
dependent on Rac1 activation and p38 phosphorylation. The injured human keratinocyte 
upregulated MMP9 expression through either Rac1/Cdc42-controlled p38 phosphorylation or 
RhoA–stimulated JNK activation, which played an essential role in cell migration. As the 
downstream effector of Rac1, an inactive PAK1 mutant overexpression inhibited PDGF-




A number of studies have shown p38 MAPKs are involved in vascular remodelling. 
Immunohistochemical staining revealed that activated p38 was expressed on medial cells in 
balloon-injured rat carotid arteries (Ohashi et al., 2000). Infection of artery tissue with a 
dominant-negative p38 mutant resulted in a reduction of intimal hyperplasia after balloon injury, 
which indicated the involvement of p38 in vascular smooth muscle cell migration and 
proliferation (Kim & Iwao, 2003). Furthermore, a doxycycline-inducible SMC-specific 
dominant-negative p38α mice model showed significant downregulation of p38 activation in 





1.7 Hypothesis and aims of study 
Recently, a population of progenitor cells has been identified within the adventitia of the vessel 
wall. These cells are found to express progenitor markers including Sca-1, c-kit, CD34, CD90, 
CD73 and CD45 and can either play a reparative role in atherosclerosis or exacerbate neointima 
formation. Previous studies have shown that these cells possess the high potential to 
differentiate into many cell lineages, including endothelial and smooth muscle cells 
(Campagnolo et al., 2015; Wong et al., 2013). However, the precise mechanism of migration 
and functional roles of these cells within the adventitia needs to be fully elucidated. It is known 
that these progenitor cells exist in close contact with SMCs, a population of cells that have been 
established to play important physiological and pathological roles within the media of the vessel 
wall. The hypothesis of the present study is that SMCs are able to release specific chemokines 
to induce migration of vascular progenitor cells that further contribute to neointima 
formation. 
In order to demonstrate this hypothesis, the aim of the first part of the study was to identify the 
migratory ability of vascular progenitor cells in response to SMC-co-cultures or its 
conditioned medium. The experimental design included: isolation and identification of vein 
graft vascular progenitor cells and assessing progenitor cell migratory ability in response to 
SMCs and SMC-derived conditioned medium.  
As these vascular progenitor cells have been shown to significantly increase migration towards 
SMCs, the next aim of the study was to explore the underlying molecular mechanism that 
mediates the chemoattractive effects of SMCs in vitro. The experimental design comprises: 
identify gene and protein levels of chemokines released in SMC-derived conditioned medium, 
investigate the specific chemokines responsible for VPC migration, detect the corresponding 
chemokine receptors expressed on vascular progenitor cells, and explore related signalling 




Since CCL2 and CXCL1 were successfully identified as the main chemokines to take effects on 
vascular progenitor cell migration, the final part of this project aimed to confirm the crucial 
role of vascular progenitor cell migration in contribution to neointimal development in 
response to CCL2 or CXCL1 in vivo. The experimental design contained: comparison of 
vascular progenitor cells migration towards intima (3 days) and contribution to neointima 
formation (2 weeks) after femoral artery wire injury in WT and CCL2
-/-
 mice, comparison of 





(BMT WT) chimeric mice, comparison of vascular progenitor 
cells migration in WT and local knock down of CXCL1 mice, exploration of Sca-1
+
 cells 
















Chapter 2                  






2.1.1 Culture medium, recombinant proteins, antagonists, siRNA and 
shRNA 
Cell culture medium was purchased from ATCC and Foetal Bovine Serum was purchased from 
Millipore. Recombinant murine JE/CCL2 and murine CXCL1 were obtained from Peprotech 
and added to cell culture medium at indicated concentrations.  CCR2 antagonist 
(C28H34F3N5O4S), CXCR2 antagonist Cpd-19 (C18H21N3O4), Rac1 inhibitor NSC23766 
(C24H38Cl3N7) and Cdc42 inhibitor ML141 (C22H21N3O3S) were all purchased from Calbiochem. 
Rho Inhibitor I (CT04, C3 transferase active site) was purchased from Cytoskeleton. p38 
inhibitor SB203580 (C12H16FN3OS) was purchased from Merck Millipore. CCL2 siRNA (m) 
and Control siRNA (fluorescein conjugate)-A were purchased from Santa Cruz Biotechnology 
whereas Silencer
®
 Select mouse CXCL1 siRNA and Negative Control siRNA were purchased 
from Ambion. The CCR2 and CXCR2 mission shRNA Bacterial Glycerol Stocks were 
purchased from Sigma-Aldrich. The shRNA Non-Targeting (NT) vector, SHC002 was used as a 
negative control.  
2.1.2 Mice 
C57BL/6J mice (WT mice) were purchased from Harlan, UK. Both GFP mice (C57BL/6-Tg 




/J) on C57BL/6J genetic 
backgrounds were purchased from The Jackson Laboratory (Bar Harbour, Maine, USA). All the 
mice were housed 2-5 per cage in a temperature-controlled room under specific-pathogen-free 
conditions with a 12 hours light/dark cycle and given free access to autoclaved food and water. 
The mice were routinely screened for major pathogens to exclude any opportunistic infections 
that would possibly affect the experimental results. Mice were used in all procedures at 8 to 16 
weeks of age, according to protocols approved by the Institutional Committee for Use and Care 
of Laboratory Animals.  The CCL2
-/-
 mice were paired with C57BL/6J mice and offspring 




2.1.3 Antibodies, qPCR primers and buffer recipes 
Table 2.1  Antibody list and applications 
Antibodies Company Application 
Mouse anti-Cdc42 Millipore, 17-441 1:1000 WB 
Mouse anti-Rac1 Millipore, 05-389 1:1000 WB 
Rabbit anti-Phospho-p38 MAPK 
Thr180/Tyr182 
Cell Signaling, 4511 1:500 WB 
Mouse anti-p38 MAPK Cell signaling, 9212 1:1000 WB 
Rat anti-Sca-1/ Ly6A/E Abcam, ab51317 1:100 IF 
Mouse anti-Actin, α-Smooth 
Muscle-Cy3 (α-SMA) 
Sigma, C6198 1:500 IF 
Rabbit anti-CCR2 Abcam, ab21667 
1:100 IF 
1:100 Flow Cyt 
Rabbit anti-vinculin Abcam, ab73412 1:100 IF 
Rabbit anti-paxillin Abcam, ab32084 1:100 IF 
Goat anti-PECAM-1 Santa Cruz, sc1506 1:50 IF 
Goat anti-VE-cadherin Santa Cruz, sc-6458 1:50  IF 
Mouse anti-CCL2 R&D, AF-479-SP 
1:100 IF 
1:100 Neut 




Mouse anti-CXCL1 R&D, AF-453-SP 
1:100 IF 
1:100 Neut 
Rabbit anti-calponin Abcam, ab46794 1:100 IF 
Alexa Fluor
®
 488 Phalloidin 
Life Technologies, 
A12379 1:50 IF 





WB: Western Blot; IF: Immunofluorescence; Flow Cyt: Flow cytometry; Neut: Neutralisation 
 
Secondary antibodies for immunostaining were anti-mouse Alexa Fluor 546, anti-rabbit Alexa 
Fluor 546 and anti-rat Alexa546 and were purchased from Life Technologies. Cells were also 
counterstained with 10µg/ml 4', 6-diamidino-2-phenylindole (DAPI). Secondary antibodies for 


























































































































































































































































































































































































































Table 2.3  Homemade buffers and composition 
Buffer Composition 
Protein Lysis Buffer 
25mM Tris-HCl (pH7.5), 150mM NaCl,1mM EDTA (pH 8.0), 1% 




10% sodium dodecyl sulphate, 50% glycerol, 0.05% bromophenol 




30% glycerol, 0.3% bromophenol blue in distilled water 
Phosphate 
Buffered Saline 
137 mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4 • 2 H2O, 1.76mM 
KH2PO4  in distilled water (pH 7.4) 
Tris-Buffered  
Saline-Tween 
50 mM Tris, 150 mM NaCl, 0.1% Tween 20  
in distilled water (pH 7.6) 
   Transfer Buffer 5% NuPAGE
®







2.2.1 Cell isolation and culture procedures 
2.2.1.1 Mouse vascular progenitor cell (VPC) culture  
Mouse VPCs were derived from the outgrowth of adventitial tissues of vein grafts as previously 
described (Iakovou et al., 2005). Briefly, the vena cava from a C57BL/6J or GFP mouse was 
isografted between the two ends of the carotid artery of an isogenic mouse. After 2 weeks, graft 
tissues were carefully harvested and cut into pieces that were explanted on 0.04% gelatin 
(Solution Type B from Bovine Skin, Sigma, G1393 diluted to 0.04% with PBS)-coated flasks. 
The flask was incubated upside down without medium at 37℃, 5% CO2 for 3 hours. The flask 
was then turned over and complete stem cell culture medium, comprised of Dulbecco's 




) supplemented with 10% ES Cell Qualified 
Foetal Bovine Serum (EmbryoMax
®
, Millipore, ES-009-B), 10 ng/ml leukaemia inhibitory 
factor (Millipore), 0.1 mM β-mercaptoethanol,100U/ml penicillin/streptomycin and 2mM L-
glutamine(Life Technologies), added and the flask incubated at 37℃，5%CO2 for 3 days. When 
the outgrowth cells reached 90% confluency, they were washed twice with PBS and trypsinized 
at 37℃ for 2 minutes and then passaged every three days at a ratio of 1:3-1:4. The medium was 
changed every other day. 
2.2.1.2 Isolation of single cell clones from mouse VPCs 
Single cell clones were isolated by serial dilution of VPCs as described by Corning Incorporated. 
Briefly, 96 wells (two 48-well plates) were numbered by rows A to H and columns 1 to 12 
(Figure 2.1). 200μl culture medium was added to each of the 96 wells apart from well A1. 400μl 
cell suspension was added to A1, and 200μl was transferred from A1 to B1. These 1:2 dilutions 
were repeated down the column until H1. 200μl was then discarded from H1. 200μl was next 
transferred from each of the wells in the first column (A1 to H1) to those in the second column 
(A2 to H2). This 1:2 dilution was repeated across the whole 96 wells. 200μl was discarded from 
each well in the last column, column 12. Once prepared, these plates were placed in a 37℃，5% 




wells medium was changed every other day. 7 to 10 days later, single colonies from individual 
wells were sub-cultured into single wells of either a 24-well plate, a 12-well plate or a T25 flask. 
The number of clones that expanded successfully was then recorded. Clones were characterised 
using conventional PCR and immunofluorescent staining for different cell lineage markers.  
 
Figure 2.1 Single cell cloning by serial dilution. 
2.2.1.3 Sca-1 positive cell sorting 
As described in previous studies(X. Yang et al., 2006), heterogeneous VPCs explanted from 
vein grafts were sorted using magnetic cell sorting kits (MACS) with anti-Sca-1 
immunomagnetic microbeads (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany). 
According to the manufacturer’s protocol for the Anti-Sca-1 MicroBead Kit, the cultured VPCs 
were trypsinized and centrifuged at 300g for 10 minutes.  Supernatant was removed completely 
and cell pellets were resuspended in 90 µL of cold buffer (phosphate-buffered saline (pH 7.2), 
0.5% FBS and 2 mM EDTA) and 10 µL of Anti-Sca-1-FITC for at most 10⁷ total cells. The 
cells were then incubated in the refrigerator (4 °C) for 10 minutes.  After adding 1−2 mL of cold 
buffer, the cells were washed and centrifuged at 300g for 10 minutes.  The cell pellet was then 
resuspended in 80 µL of the cold buffer with 20 µL Anti-FITC MicroBeads and incubated for 
15 minutes at 4°C, followed by the same washing step as above. The cells were then 
resuspended in 500 µL of cold buffer and ready for magnetic separation. Briefly, a column filled 




The column was rinsed with 500 µL cold buffer before applying the cell suspension. Unlabelled 
cells were passed through and collected for further analysis. After the column reservoir was 
empty, the fresh 500µl cold buffer was added to the column and this washing step was 
performed 3 times. Finally, the column was placed in a 15 ml collection tube and flushed with 1 
ml cold buffer, by firmly applying the plunger, to harvest the magnetically labelled Sca-1
+
 cells. 
Sca-1 positive VPC populations were expanded for up to 5 population doublings. 
2.2.1.4 Mouse vascular smooth muscle cell culture 
Mouse vascular SMCs were isolated from aortas of C57BL/6 mice as described previously 
(Gallo et al., 1999). In brief, the aortas from the aortic arch to thoracic aorta were removed from 
mice and washed with DMEM. The intima and inner two-thirds of the media were carefully 
dissected from the aortas and cut into pieces, then positioned on a gelatin-coated (0.04%) plastic 
flask. The cells were cultured in Dulbecco's Modified Eagle's Medium (Life Technologies, Inc.) 
supplemented with 10% foetal bovine serum (Gibico 10270), 100U/ml penicillin/streptomycin. 
Cells were incubated at 37°C in a humidified atmosphere of 5% CO2. Cells were passaged at a 
ratio of 1:2 to 1:3 once they reached 90% confluence. The medium was refreshed every 2 days. 
The purity of SMCs was routinely confirmed by immunostaining with α-SMA, SM-22α and 
SMMHC antibodies.  
Smooth muscle cell conditioned medium (in serum free medium) was collected after an 
overnight incubation and centrifuged at 1500 rpm for 15 mins, at 4℃. 
2.2.1.5 Isolation of mouse peritoneal macrophages 
C57BL/6J mice were euthanised by cervical dislocation, and soaked in 70% ethanol for 5 
minutes. The outer skin was cut using a sterile scissors and the intact peritoneum was exposed 
by manual retraction. 10 ml of cold sterile 3% FBS PBS was injected through the peritoneal 
wall into each mouse. After injection, the peritoneum was gently massaged to dislodge any 
attached cells into the PBS solution. Peritoneal fluid was then withdrawn using a syringe with a 
19 gauge needle and centrifuged at 200g for 10 minutes at 4℃. Supernatant was discarded and 




2.2.2 Nucleic acid and protein study 
2.2.2.1 RNA extraction 
Total RNA extraction from vascular progenitor cells or smooth muscle cells was performed 
using the RNeasy
®
 Mini Kit (Qiagen Cat. No 74106) according to the manufacturer’s 
instructions. Briefly, cells from each well of a 6-well plate were washed with PBS twice before 
adding 350μl of RLT lysis buffer directly into each well. The cell lysate was pipetted and 
transferred into a QIAshredder spin column. After centrifugation at full speed for 2 minutes, a 
homogeneous lysate was acquired, by shearing the high-molecular-weight genomic DNA and 
other cellular components to reduce viscosity. An equal volume of 70% ethanol was added to 
the lysate and the sample mixed thoroughly by pipetting. The mixture was then transferred to an 
RNeasy mini column and placed in a 2 ml collection tube. Following centrifugation at full speed 
for 30 seconds, the flow through was discarded and 700μl of RW1 washing buffer was added to 
the column before centrifuging as above. The flow through was again discarded after washing 
with 500μl of RPE buffer. The sample was then washed again with 500μl of RPE buffer, 
followed by centrifugation for 2 mins to ensure that there was no ethanol carried over following 
the RNA elution step. The flow through was discarded and the column was centrifuged within a 
new 2 ml collection tube to remove any  remaining contaminating solution that could be present 
on the outside of the column. Finally, the RNeasy column was placed in a new 1.5ml 
microcentrifuge tube and 25μl of RNase-free water was added to the column membrane 
followed by centrifugation at full speed for 1 minute to elute the RNA. The RNA concentration 
of each sample was determined by measuring absorbance at 280nm using a Nanodrop 
Spectrophotometer (ND-1000, Thermo Scientific, UK). 
2.2.2.2 Reverse transcription (RT)  
1 μg of total RNA of each sample was used to synthesise cDNA in each RT reaction. RT was 
performed using the ImProm-II
TM
 reverse transcription system (Promega Cat. No A3800) in a 
20μl reaction and the components are listed below (Table 2.4, Table 2.5). 10μl Mix A in a thin-
walled PCR tube was heated in an RT-PCR machine (TECHNE TC-412, Bibby Scientific, UK) 




and the tube was removed and chilled on ice for 1 minute followed by the addition of 10µL Mix 
B. The solution in the tube was mixed briefly by pipetting, then placed back in the machine and 
continued on a pre-defined programme. The samples were annealed at 25℃ for 5min and 
extended at 42℃ for 1 hour and 30 minutes. Finally, a temperature of 70℃ was applied for 15 
mins in order for the reverse transcriptase to be deactivated. The cDNA in each 20 µl reaction 
was diluted with 80μl of nuclease-free water to obtain a final concentration of 10ng/µl.  
 
 
Table 2.4  Reverse transcription reaction mix 




RNA  x 0.05µg/µl 
RNase-free water 9.9-x - 
Random Primer 0.1 0.025µg/µl 
Mix B 
RNase-free H2O 0.8 - 
Improm II 5x reaction buffer 4 1x 
25mM MgCl2 2.4 3mM 
25mM dNTPs 0.8 1mM 
RNasin ribonuclease inhibitor 1 1U/µl 










Table 2.5  Reverse transcription program 
Step Temp(°C) Time(min) Note 
1 70 5 Denature the RNA 
2 4 5 Chill on ice prior to incubation 
3 25 5 Anneal 
4 42 90 Extend the first strand 
5 70 5 Inactivate Improm II RT enzyme 
6 4 - - 
 
2.2.2.3 Quantitative real-time polymerase chain reaction (Q-PCR)  
Quantitative  real-time  PCR  (qPCR)  was  performed  to  detect  relative gene expression in  
each  sample using SYBR green (Qiagen, Cat. No. 204057).  The components of each reaction 
and program are shown below (Table 2.6, Table 2.7). First, 18µl of master mix was loaded into 
the 96-well plate (Eppendorf White, Eppendorf, UK) and then 2µL of sample cDNA was added 
to each appropriate well. The plate was centrifuged at 600rpm for 1 minute to ensure the 





, Eppendorf, UK). The threshold cycle (Ct) values were 
automatically obtained and exported to Microsoft Excel. GAPDH was used as an endogenous 
control to normalise the relative expression of RNA in each sample. The fold change compared 
to control in each target gene was calculated using 2
-Δct
. 
Each pair of primers for QPCR was designed using a software provided by DNA Integrated 
Technologies (IDT) http://eu.idtdna.com/scitools/Applications/RealTimePCR/) and sequences 







Table 2.6  qPCR reaction mix 







 2x SYBR green 10 1x 
10µM Primers 
(forward+reverse) 
1.5 0.75 µM 
Nuclease-free water 6.5 - 
 10ng/µl cDNA 2 20ng 
 
Table 2.7  qPCR Program 
Step Temp(°C) Time(mm:ss) Note 
1 95 10:00  
2 95 00:15 repeat step2-3 for 40 cycles 
3 60 01:00 
4 95 00:15 
establish the melting  curve  of  the  primers 5 60 00:15 
6 - 20:00 
7 95 00:15 
 
2.2.2.4 Conventional polymerase chain reaction (PCR) 
Conventional polymerase chain reaction was performed on 50ng cDNA using recombinant Taq 
DNA Polymerase (Invitrogen, 10342-53) to amplify the corresponding DNA. The PCR program 
and the components of the reaction are given below (Table 2.8, Table 2.9). The PCR products 
were analysed on 2% agarose gels and assessed using the BioSpectrum AC Imaging System and 
Vision- WorksLS software.  
Specific primers  for each  PCR  template  were  designed  from  corresponding  mouse mRNA  
sequences using  the  Primer-BLAST  tool  (www.ncbi.nlm.gov.uk/tools/primer-blast).  All  




the  stocks  (100µM) stored at -80℃. The working solution (10µM) was made by mixing 
forward and reverse primers in DEPC water and stored at -20℃. 
 
Table 2.8  Conventional PCR reaction mix 
Reaction Component Volume(μl) 
(µl) 
Final Concentration 
10x PCR Buffer 2.5 1x 
50mM MgCl2 1.2 2.4mM 
25mM dNTPs  0.2 0.2mM 
10µM Forward primer 1 0.4µM 
10µM Forward primer 1 0.4µM 
5U/µl Taq DNA Polymerase 0.2 1U 
RNase-free H2O 13.9 - 
10ng/µl cDNA 5 50ng 
 
Table 2.9 Conventional PCR program 
Step Temp(°C) Time(mm:ss) Note 
1 94 03:00  - 
2 94 00:45 
repeat 2-4 steps for 35 cycles 
3 62 00:30  
4 72 04:00 
5 72 10:00 - 






2.2.2.5 Agarose gel electrophoresis and gel purification 
A 2%  agarose  gel  was  prepared  by  dissolving  2g  agarose  (Invitrogen,  Cat. No. 16500-500)  
in 100ml  1x  Tris-acetate-EDTA (TAE) buffer diluted from a 50x TAE (National Diagnostics, 
Cat. No, EC-872) stock solution (2.0M Tris Acetate + 100mM Na2EDTA) and heated in a 
microwave for 2 minutes at 30-second intervals until it thoroughly melted. After the agarose 
solution cooled down to 60-70 ºC, 10µl of SafeView nucleic acid stain (NBS biologicals, Cat. 
No, NBS-SV) was added to 100ml of liquid gel mixture.  The gel mixture was swirled gently to 
avoid bubbles forming and poured into a Horizon
®
 11.14 horizontal gel cast electrophoresis 
apparatus (Biometra) with the well comb in place.  After 30 minutes, the gel had solidified and 
therefore the comb could be carefully removed. 25µl DNA samples with 5μl of 6x Loading 
Buffer (0.25% (w/v) bromophenol  blue,  30%  (v/v)  glycerol)  were  loaded into each  well 
after the gel had been immersed in 1x TAE buffer. Electrophoresis was performed at 180V for 
30 minutes and the DNA fragments visualised under ultraviolet light using the Biospectrum
®
 
Imaging System 500 with image capture using Vision Works Software (Ultra-Violet Products 
Ltd).  
2.2.2.6 Protein extraction 
Harvested vascular progenitor cells in each 6-well were lysed with 30-50µl lysis buffer (25 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA pH 8.0, 1%Triton X-100 plus protease inhibitors 
(Roche), PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche)) . The lysate was then 
sonicated twice  with  a  Branson  Sonifier  150  at  level 1 for  6  seconds, at  4℃ before they 
were incubated on ice for at least 30 minutes. The lysate was then centrifuged at 15,000g for 10 
min at 4℃. The supernatant was then transferred to a new cold 1.5 ml microcentrifuge tube and 
the concentration of protein in each sample was measured using the Bradford method. Briefly, 
2μl of the protein lysate was added to 998μl of the Bio-Rad Reagent (diluted 1:5 with H20) and 
incubated for at least 5 minutes at room temperature. Duplicates were measured using the Bio-




2.2.2.7  Western blot analysis 
40μg of protein lysate was mixed with 5xSDS loading buffer and boiled at 96℃ for 5 minutes 
before loading onto 4-12% Bis-Tris Protein gels (NuPAPE, Novex). 10 µl of protein  ladder  
(Precision  Plus  Protein  Ladder,  Bio-Rad)  was loaded simultaneously and electrophoresis 
performed in  NuPage
®
 MOPS SDS running buffer in an XCell  SureLock™ Mini-Cell (Life 
technologies (Novex
®
) Cat. No. NP0335BOX) at 160-200V for 1.5 hours.  The gel was then 
transferred onto a nitrocellulose (NC) membrane (Amersham Biosciences), with ice-cold 
transfer buffer (NuPAGE
®
, Novex) in the XCell™ Blot Module (Invitrogen) at 35-45V for 1.5 
hours. The  NC membrane was stained with Ponceau S solution (Sigma-Aldrich) and washed 
with TBS-T before blocking  with  5%  milk  in  TBS-T (0.1% Tween
®
 20 (Sigma-Aldrich)  for  
1  hour  at room  temperature  and  subsequently  incubating  with  the  primary  antibody  
overnight at 4℃.  
The corresponding secondary antibodies diluted in 5% milk TBS-T (1:3000) were incubated at  





 Western Blotting Detection Reagents (GE Healthcare) for 
3mins at room temperature.  Exposure of films  (Amersham,  Kodak)  was  carried  out  using  
the  Compact  X4  (Xograph  Imaging System).  
2.2.3 Cell supernatant study 
2.2.3.1 Mouse common chemokines multi-analyte ELISArray  
The chemokines present in the SMC-conditioned medium were measured using the Mouse 
Common Chemokines Multi-Analyte ELISArray kit (MEM-009A, Qiagen) according to the 
manufacturer’s protocol. As the plate map below (Figure 2.2) indicates, columns 1 to 12 were 
coated with a panel of twelve common mouse chemokine specific capture antibodies (RANTES, 
MCP-1, MIP-1a, MIP-1b, SDF-1, IP-10, MIG, Eotaxin, TARC, MDC, KC, 6Ckine). 50µl 
samples of Serum-free DMEM medium (control) and different batches of SMC-conditioned 
medium samples diluted in reaction buffer were pipetted into appropriate wells along each row 




and Antigen Standard Cocktail (the mixture of all 12 of Antigen Standards with 1:500 dilution 
from provided antigen standards) served as negative controls and positive controls respectively. 
Following the incubations, the plate was inverted and washed with 1x Wash Buffer 3 times and 
blotted on absorbent paper to remove any residual buffer. 100µl of the diluted Detection 
Antibody solution was added to the appropriate rows and incubated for 1 hour at room 
temperature. After incubation, the plate was washed, as above, before adding Avidin-HRP 
solution to each well and incubating for 30 minutes at room temperature in the dark. After 
repeating the washing steps, Development Solution was added and the plate incubated for 15 
minutes at room temperature in the dark before adding 100 μl Stop Solution. The absorbance 
was read at 450 nm subtracting readings at 570 nm for correction within 30 minutes of stopping 
the reaction. 
The change in levels of each chemokine in the different batches of the SMC-conditioned 
medium was then compared with positive and negative controls on the plate. Concentrations of 





Figure 2.2 Layout of multi-analyte ELISArray plate 
2.2.3.2 Enzyme-linked immunosorbent assay (ELISA) 
The concentrations of CXCL1 and CCL2 released into the SMC-conditioned medium were 
detected by mouse CXCL1 (MJE00) and mouse CCL2 (MKC00B) Quantikine
®
 ELISA kits, 
both purchased from R&D Systems. As this was a sandwich ELISA Microwells in the kit 




50μl of mouse CXCL1, CCL2 Standards or SMC-conditioned medium samples were added to 
corresponding wells. This was followed by the addition of 50 µl of Assay Diluent. Samples and 
standards were diluted in an appropriate carrier Diluent.  Standards comprised mouse CXCL1 or 
CCL2 in seven 2-fold serial dilutions with a peak concentration of 1000pg/ml peak and were 
used for the generation of a standard curve.  
After sample or standard addition the plate was mixed by gentle tapping and covered with an 
adhesive strip before 2 hours of incubation at room temperature. After incubation, the wells 
were aspirated and washed with Wash buffer 5 times. Following the final wash, the plate was 
inverted and blotted against clean paper towels. 100μl of an anti-Mouse CXCL1 or CCL2 HRP 
conjugate was then pipetted into each well and the wells incubated for 2 hours at room 
temperature. After incubation, the plate was washed 5 times followed by the addition of 100μl 
Substrate Solution (1:1 mixture of Colour Reagent A (H2O2) and Colour Reagent B 
(Tetramethylbenzidine) used within 15 mins of preparation) to each well and incubated for 30 
mins at room temperature protecting from light. Finally, the reaction was stopped by adding 100 
µl of Stop Solution to each well. The optical density of each well was determined within 30 
mins using a Tecan microplate reader set to 450 nm with wavelength correction at 570 nm. The 
average O.D. of the blank was subtracted from average of the duplicate readings for each 
standard and sample.  A four parameter logistic (4-PL) curve-fit was subsequently generated to 
create a standard curve and the concentration of CXCL1 or CCL2 of each sample was 
calculated in ng/ml. 
2.2.3.3 RT2 profilerTM PCR arrays for mouse chemokines and receptors   
Total RNA (0.5 µg) was extracted from either mouse peritoneal macrophages, VSMCs, Sca-1
+
 
VPCs or single VPC clones cultured in vitro. Reverse transcription was performed using 
QuantiTect
®
 Reverse Transcription Kit (Qiagen) in a 20μl reaction and the components are 
listed below (Table 2.10). Mix A was incubated in an RT-PCR machine for step 1 followed by 
immediate chilling on ice. During this time, Mix B was prepared, before it was added into Mix 
A for each sample. Then samples were placed back into the machine for the continuation of the 




was diluted with 180μl of RNase-free water to get a final concentration of 2.5ng/μl. TR
2
 Profiler 
PCR Arrays (Qiagen, PAMM-022Z) were used to screen mouse chemokine receptors according 
to the manufacturer’s instructions. The PCR components (Table 2.12) for a 96 well plate were 
prepared in a loading reservoir. 25µl of reaction mix well was loaded into each well using an 8-
channel multi-channel pipette and tips were changed following each pipetting step to prevent 
cross contamination.  The 96-well plate (Table 2.14) was centrifuged at 1000RPM for 1min to 





 ep Realplex model 4S using the program shown below (Table 2.13) and acquired 
data were analysed using the 2
-(averageΔCT)
 method to determine the expression level of each 
transcript (Table 2.15) normalized to the expression level of housekeeping gene controls.  
Table 2.10  Reverse transcription reaction mix 





Template RNA  x 0.5 µg 
gDNA Wipeout Buffer 7x  2 1x 





Quantiscript Reverse Transcriptase 1 - 
Quantiscript RT Buffer, 5x  4 1x 
RT Primer Mix 1 - 
 
Table 2.11  Reverse transcription program 
Step Temp(°C) Time(min) Note 
1 42 2  
2 - - pause 
3 42 15  
4 93 3 inactivate Quantiscript Reverse Transcriptase 






Table 2.12  RT2 ProfilerTM PCR Arrays reaction mix for a 96-well plate 
Reaction Component  Volume (µl) Final concentration 
2x RT
2
 SYBR Green Mastermix 1350 1x 
cDNA synthesis reaction  102 - 
RNase-free water 1248 - 
 
Table 2.13  RT2 ProfilerTM PCR arrays program 
 
Table 2.14 Layout of RT2 ProfilerTM PCR Arrays mouse chemokines and receptors 
plate 
 1 2 3 4 5 6 7 8 9 10 11 12 
A C5 C5ar1 Ccbp2 Ccl11 Ccl12 Ccl17 Ccl19 Ccl2 Ccl20 Ccl21 Ccl22 Ccl24 
B Ccl25 Ccl28 Ccl3 Ccl4 Ccl5 Ccl6 Ccl7 Ccl9 Ccr1 Ccr10 Ccr1l1 Ccr2 
C Ccr3 Ccr4 Ccr5 Ccr6 Ccr7 Ccr8 Ccr9 Ccrl2 Cklf Cmklr1 Cmtm2a Cmtm3 
D Cmtm5 Cx3cl1 Cx3cr1 Cxcl1 Cxcl10 Cxcl11 Cxcl12 Cxcl13 Cxcl14 Cxcl16 Cxcl2 Cxcl3 
E Cxcl5 Cxcl9 Cxcr2 Cxcr3 Cxcr4 Cxcr5 Cxcr6 Cxcr7 Fgf2 Fpr1 Gpr17 Hif1a 
F Ifng  Il10 Il16 Il1b Il4 Il6 Il8ra Itgam Itgb2 Kdr Mapk1 Mapk14 
G Pf4 Plau Ppbp Prkca Slit2 Tgfb1 Tlr2 Tlr4 Tnf Tymp Vegfa Xcl1 
H Actb  B2m Hprt1 Ldha Rplp1 RGDC RTC RTC RTC PPC PPC PPC 




























Temp(°C) Time(mm:ss) Note 
1 95 10:00  Activate DNA Taq Polymerase 
40 95 00:15 





Table 2.15  List of genes in RT2 ProfilerTM PCR Arrays 
























A03 NM_011329 Ccl1 Chemokine (C-C motif) ligand 1 
A04 NM_011330 Ccl11 Chemokine (C-C motif) ligand 11 
A05 NM_011331 Ccl12 Chemokine (C-C motif) ligand 12 
A06 NM_011332 Ccl17 Chemokine (C-C motif) ligand 17 
A07 NM_011888 Ccl19 Chemokine (C-C motif) ligand 19 
A08 NM_011333 Ccl2 Chemokine (C-C motif) ligand 2 
A09 NM_016960 Ccl20 Chemokine (C-C motif) ligand 20 
A10 NM_009137 Ccl22 Chemokine (C-C motif) ligand 22 
A11 NM_019577 Ccl24 Chemokine (C-C motif) ligand 24 
A12 NM_009138 Ccl25 Chemokine (C-C motif) ligand 25 
B01 NM_001013412 Ccl26 Chemokine (C-C motif) ligand 26 
B02 NM_020279 Ccl28 Chemokine (C-C motif) ligand 28 
B03 NM_011337 Ccl3 Chemokine (C-C motif) ligand 3 
B04 NM_013652 Ccl4 Chemokine (C-C motif) ligand 4 
B05 NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 
B06 NM_009139 Ccl6 Chemokine (C-C motif) ligand 6 
B07 NM_013654 Ccl7 Chemokine (C-C motif) ligand 7 
B08 NM_021443 Ccl8 Chemokine (C-C motif) ligand 8 
B09 NM_011338 Ccl9 Chemokine (C-C motif) ligand 9 
C12 NM_027022 Cmtm2a CKLF-like MARVEL transmembrane domain containing 2A 
D01 NM_024217 Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 




D03 NM_026066 Cmtm5 CKLF-like MARVEL transmembrane domain containing 5 
D04 NM_026036 Cmtm6 CKLF-like MARVEL transmembrane domain containing 6 
D05 NM_009142 Cx3cl1 Chemokine (C-X3-C motif) ligand 1 
D07 NM_008176 Cxcl1 Chemokine (C-X-C motif) ligand 1 
D08 NM_021274 Cxcl10 Chemokine (C-X-C motif) ligand 10 
D09 NM_019494 Cxcl11 Chemokine (C-X-C motif) ligand 11 
D10 NM_021704 Cxcl12 Chemokine (C-X-C motif) ligand 12 
D11 NM_018866 Cxcl13 Chemokine (C-X-C motif) ligand 13 
D12 NM_019568 Cxcl14 Chemokine (C-X-C motif) ligand 14 
E01 NM_011339 Cxcl15 Chemokine (C-X-C motif) ligand 15 
E02 NM_023158 Cxcl16 Chemokine (C-X-C motif) ligand 16 
E03 NM_009140 Cxcl2 Chemokine (C-X-C motif) ligand 2 
E04 NM_203320 Cxcl3 Chemokine (C-X-C motif) ligand 3 
E05 NM_009141 Cxcl5 Chemokine (C-X-C motif) ligand 5 
E06 NM_008599 Cxcl9 Chemokine (C-X-C motif) ligand 9 
F06 NM_008337 Ifng Interferon gamma 
F07 NM_010551 Il16 Interleukin 16 
F08 NM_008361 Il1b Interleukin 1 beta 
F09 NM_021283 Il4 Interleukin 4 
F10 NM_031168 Il6 Interleukin 6 
G03 NM_019932 Pf4 Platelet factor 4 
G04 NM_023785 Ppbp Pro-platelet basic protein 
G06 NM_011577 Tgfb1 Transforming growth factor, beta 1 
G09 NM_013693 Tnf Tumour necrosis factor 
































A01 NM_007577 C5ar1 Complement component 5a receptor 1 
A02 NM_021609 Ackr2 Chemokine binding protein 2 
B10 NM_009912 Ccr1 Chemokine (C-C motif) receptor 1 
B11 NM_007721 Ccr10 Chemokine (C-C motif) receptor 10 
B12 NM_007718 Ccr1l1 Chemokine (C-C motif) receptor 1-like 1 
C01 NM_009915 Ccr2 Chemokine (C-C motif) receptor 2 
C02 NM_009914 Ccr3 Chemokine (C-C motif) receptor 3 
C03 NM_009916 Ccr4 Chemokine (C-C motif) receptor 4 
C04 NM_009917 Ccr5 Chemokine (C-C motif) receptor 5 
C05 NM_009835 Ccr6 Chemokine (C-C motif) receptor 6 
C06 NM_007719 Ccr7 Chemokine (C-C motif) receptor 7 
C07 NM_007720 Ccr8 Chemokine (C-C motif) receptor 8 
C08 NM_009913 Ccr9 Chemokine (C-C motif) receptor 9 
C09 NM_145700 Ackr4 Chemokine (C-C motif) receptor-like 1 
C10 NM_017466 Ccrl2 Chemokine (C-C motif) receptor-like 2 
C11 NM_008153 Cmklr1 Chemokine-like receptor 1 
D06 NM_009987 Cx3cr1 Chemokine (C-X3-C) receptor 1 
E07 NM_178241 Cxcr1 Chemokine (C-X-C motif) receptor 1 
E08 NM_009909 Cxcr2 Chemokine (C-X-C motif) receptor 2 
E09 NM_009910 Cxcr3 Chemokine (C-X-C motif) receptor 3 
E10 NM_009911 Cxcr4 Chemokine (C-X-C motif) receptor 4 
E11 NM_007551 Cxcr5 Chemokine (C-X-C motif) receptor 5 
E12 NM_030712 Cxcr6 Chemokine (C-X-C motif) receptor 6 
F01 NM_007722 Ackr3 Chemokine (C-X-C motif) receptor 7 




F03 NM_013521 Fpr1 Formyl peptide receptor 1 
F04 NM_001025381 Gpr17 G protein-coupled receptor 17 












F05 NM_010431 Hif1a Hypoxia inducible factor 1, alpha subunit 
F11 NM_008401 Itgam Integrin alpha M 
F12 NM_008404 Itgb2 Integrin beta 2 
G01 NM_011949 Mapk1 Mitogen-activated protein kinase 1 
G02 NM_011951 Mapk14 Mitogen-activated protein kinase 14 
G05 NM_178804 Slit2 Slit homolog 2 (Drosophila) 
G07 NM_011905 Tlr2 Toll-like receptor 2 
G08 NM_021297 Tlr4 Toll-like receptor 4 
G10 NM_138302 Tymp Thymidine phosphorylase 
 
H01 NM_007393 Actb Actin, beta 
H02 NM_009735 B2m Beta-2 microglobulin 
H03 NM_008084 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 
H04 NM_010368 Gusb Glucuronidase, beta 
H05 NM_008302 Hsp90ab1 Heat shock protein 90 alpha(cytosolic), class B member 1 
H06 SA_00106 MGDC Mouse Genomic DNA Contamination 
H07-H09 SA_00104 RTC Reverse Transcription Control 
H10-H12 SA_00103 PPC Positive PCR Control 







2.2.4 In vitro study of cell properties 
2.2.4.1 Transwell chemotaxis assay 
Migration assays were performed using Transwell inserts with 8.0 µm pore-sized membrane 
filters (Corning). Vascular progenitor cells were loaded into the upper chamber at a density of 
5x10
4
 cells in 200µl serum free media, and the bottom chamber contained 800µl SMC 
conditioned medium or serum-free medium with indicated concentrations of recombinant 
murine CCL2 or CXCL1; serum free medium served as the negative control. After an overnight 
incubation, non-migrating cells on the upper side of the filters were carefully washed with PBS 
and removed using a swab. Vascular progenitor cells on the underside of the membrane were 
fixed with 4% PFA in PBS for 10 mins at room temperature followed by 0.1% crystal violet 
solution staining for 15 mins at room temperature. Data were expressed as the fold of migrated 
VPCs compared to the control in 9 fields (Figure 2.3) of each insert (at 20x magnification). For 
experiments that involved inhibitors (i.e. Cdc42 inhibitor and P38 inhibitor), VPCs were pre-
treated with the respective inhibitors for an hour before the cells were transferred to Transwells.  
                                           
Figure 2.3  Layout of fields in each view of a transwell insert at 20x magnification 
2.2.4.2 Scratch wound assay 
Vascular progenitor cells were seeded into 12-well tissue culture plates at a density of 5x10
4 
cells/well. After 24 hours of growth, when cells had formed ~90% confluent monolayers, a 
straight scratch was made using a clean 1ml pipette tip across the centre of the well. While 
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bottom of the well and force applied with the same dynamics and speed.  Another straight line 
was then scratched perpendicular to the first line to create a “+” in each well (same force 
maintained). Following scratching, photos of the wells were taken under the microscope 
immediately to record the initial distance of the gap for comparison after migration. The wells 
were then gently washed with PBS twice, to remove cell debris, prior to treatment with SMC 
conditioned medium or serum-free medium with or without (positive control) recombinant 
murine CCL2 or CXCL1. After an overnight incubation, the cells were washed with PBS and 
fixed with 4% PFA for 10 mins. The migration of vascular progenitor cells was quantified as the 
mean number of the cells which migrated into the “wound” area (the area was decided by 
comparison to the initial distance of the gap) in 8 different views (as shown in Figure 2.4) of 
each well using a phase contrast microscope with a 10x objective.  
                                         
Figure 2.4 Layout of fields in each view of 12-well at 10x magnification  
2.2.4.3 Time-lapse microscopy  
5x10
3
 vascular progenitor cells/well were seeded in 6-well plates. After 4 hours the cells had 
adhered to the bottom of the plate and were treated with either serum-free medium (negative 
control) or SMC conditioned media. The 6-well plate was then placed into the microscope 
chamber, with conditions at 37˚C and 5% CO2, of a fully motorized, multi-field time-lapse 
microscope (Eclipse TE 2000-E; Nikon) with a charge-coupled device camera (ORCA; 
Hamamatsu Photonics). Images were acquired from 10 random fields in each well, every 5 
minutes for a period of 20 hours, using a 10x objective with bright field settings. Images were 




















tracked using ImageJ software (National Institute of Health). Analysis of cells speed and 
persistence of direction during their migration was performed using the Chemotaxis plugin from 
Integrated BioDiagnostics. 
 
2.2.4.4 CCL2 and CXCL1 gene knockdown in SMCs 
Mouse smooth muscle cells were  infected  with  CCL2 siRNA (Santa Cruz Biotechnology, Sc-
43914) or CXCL1 siRNA (Ambion 4390771, ID S67079) by  electroporation  using  an 
Amaxa
TM
 Basic  nucleofector
TM
  Kit  (Lonza, Cat  No:  VPI-1004).  Control siRNA (FITC 
Conjugate)-A (Santa Cruz Biotechnology, sc-36869) was used to infect SMCs as a negative 
control.  Each sample required 1x10
6 
SMC cells and 300nM of control, CCL2 or CXCL1 siRNA. 
Cells were harvested by trypsinization and the cell density determined before centrifugation at 
100 g for 10 mins. The cell pellet (1x10
6
) was then resuspended in 100 µl of room temperature 
Nucleofector
TM
 solution containing the indicated siRNA, followed by transfer into a certified 
cuvette provided by the company. The sample covered the bottom of cuvette without air bubbles. 
The cuvette was inserted into the Lonza Nucleofector
TM
 device and  a  specific  program for  
SMCs applied. After the program was completed, 500μl of pre-warmed culture medium was 
added immediately into the cuvette and the mix was then gently transferred into the prepared 6-
well plate (each well containing 1ml culture medium was pre-equilibrated in a 37℃, 5% CO2 
incubator). Following incubation at 37℃ overnight (approx. 18 hours), the supernatant and 
SMC cells were harvested separately for analysis of gene ablation using ELISA and qPCR 
respectively. 
2.2.4.5 Lentiviral particle generation 
Gene ablation of CCR2 or/and CXCR2 was carried out using short hairpin RNA (shRNA) 
lentiviral plasmid transfer. The bacterial glycerol stock of CCR2 MISSION shRNA (SHCLNG-
NM_009915, TRCN0000001680) and CXCR2 MISSION shRNA (SHCLNG-NM_009909, 
TRCN0000026605) were purchased from Sigma-Aldrich. The bacterium from each tube was 




autoclaved 2.5% LB (Fisher Scientific, LB Broth, Miller) medium supplemented with 100µg/ml 
Ampicillin in individual 50 ml conical tubes. The bacterium was then harvested by 
centrifugation at 4000 RPM for 15 min. Plasmid purification was performed using a QIAprep 
Spin Miniprep kit (Qiagen, Cat. No. 27016) as described in the instructions of the manufacturer. 
The concentration of the plasmid was determined by measuring absorbance at 260nm using a 
Nanodrop Spectrophotometer (ND-1000, Thermo Scientific, UK). The plasmid was stored at -
20℃.  
For the generation of Lentiviral particles 27µl of FuGENE
®
 6 Transfection Reagent (Promega, 
Cat. No. E2691) was mixed with the 4.5 µg lentiviral plasmids (CCR2 shRNA or CXCR2 
shRNA) and packaging plasmids in serum-free DMEM medium.  The mixture was incubated at 
room temperature for 5 minutes before it was added to 60% confluent 293T cells, which were 
seeded one day prior to transfection in a T75 flask with 5 ml serum-free DMEM medium. After 
an overnight incubation, the medium was replaced with 1% FBS DMEM medium. The 
supernatant containing the lentivirus was harvested 48 hours later and filtered through a 0.45µm 
PVDF filter (Millex
®
-HV, SLHV033RS) before storing at -80℃. The transduction unit (TU) 
was calculated as previously described. (Margariti et al., 2010). A non-targeting shRNA vector 
(SHC002) was used to generate the control particles. 
2.2.4.6 CCR2 and CXCR2 gene knockdown in vascular progenitor cells 
To transfect vascular progenitor cells, 2x10
5
 VPCs were plated in a T25 flask coated with 0.04% 
gelatin one day prior to transfection. Upon reaching 30% confluency,  the cells were incubated 
with shCCR2 or/and shCXCR2 lentiviral supernatant in complete culture medium supplemented 
with 10μg/ml of Polybrene Infection / Transfection Reagent (Millipore, TR-1003-G) for 24 
hours. Subsequently, the medium was replaced with complete culture medium and the cells 
incubated for another 48 hours. The infected VPCs were further selected in culture medium 
containing 500ng/ml puromycin for 3-4 days. The gene and protein expression of CCR2 and 





Non-targeting shRNA plasmid that was used as negative controls was kindly generated by Dr 
Mei Mei Wong. 
2.2.4.7 BrdU proliferation Assay 
Vascular progenitor cells were treated with/without SMC-conditioned medium for 18 hours on a 
gelatin-coated 96-well culture plate. The VPC proliferation assay was performed using a Cell 
Proliferation ELISA, BrdU (colourimetric) (Roche). According to the manufacturer’s 
instructions, BrdU labelling solution (final concentration of 10µM) was incubated with cells for 
2 hours at 37℃ after they had been treated. After removing the labelling medium, 200µl of 
FixDenat was added to each well for 30 mins at room temperature. The solution was then 
removed thoroughly before incubating with BrdU conjugated antibody for another 90 mins. 
After 3 washes with PBS, 100µl of substrate solution was added and incubated at room 
temperature. Once a change in colour was detected, 25µl of 1M H2SO4 was added to stop the 
reaction. The absorbance was measured at 450nm with correction at 690nm within 5mins of 
adding the stop solution. A mixture of BrdU labelling solution and its antibody in culture 
medium was used as blank to identify the unspecific binding of BrdU and antibody to the plate. 
The wells in which cells had not been incubated with BrdU but were incubated with antibody 
were used as background controls to evaluate the unspecific binding the antibody to VPCs. 
2.2.4.8 Rac1/Cdc42 GTPase activation assay  
The activation assay of GTP-bound Rac1/Cdc42 was performed using the Rac1/Cdc42 
Activation Assay Kit (Upstate, Millipore) according to the protocol provided. VPCs were serum 
starved overnight upon reaching 90% confluency in 100mm culture dishes. The cells were then 
stimulated with different treatments at indicated time points before they were rinsed twice with 
ice-cold TBS and placed on ice. Cells were scraped using a cell scraper in 500µl 1x MLB 
provided in the kit and transferred into a 1.5ml Eppendorf tube. The cell lysate was precleared 
by adding Glutathione Sepharose 4B beads (GE Healthcare) with gentle rocking for 10mins at 
4℃. The agarose beads were then collected, following centrifugation at 14,000g for 5 seconds, 
before transferring the supernatant into new Eppendorf tubes. Aliquots containing 30µg protein 




analysis. For the preparation of GTPγS or GDP controls, cell lysates were incubated with EDTA 
(final concentration 10mM) and either GTPγS (final concentration 100µM) or GDP (final 
concentration 1mM)  separately in two tubes at 30℃ for 15 mins with agitation. To perform 
GTP-Rac1/Cdc42 pull-down assay, each 0.5ml cell lysate (including GTPγS and GDP controls) 
was mixed with 20µg of PAK-PBD agarose beads at 4 °C for 1 hour with gentle rotation. The 
agarose beads were collected after centrifugation at 4,000g for 3 mins and washed thrice with 
MLB. After thoroughly removing MLB solution, the beads were resuspended in 25µl 2X 
Laemmli sample buffer with reducing agent and boiled for 5 minutes. Finally, samples were 
separated by 4–12% Bis-Tris gels, transferred to a nitrocellulose membrane and blotted with 
Rac1 or Cdc42 antibodies (Upstate, Millipore). 
2.2.5 Mouse genotyping and models 
2.2.5.1 Isolation of DNA from mouse ear punch 
Pieces of ear punch from each mouse were lysed in Eppendorf tubes containing 700µl of lysis 
buffer (Table 2.16) and 350µl 10mg/ml Proteinase K, following an overnight incubation in the 
buffer at 55 ºC until the tissues dissolve. Tubes were inverted periodically during the incubation. 
After the addition of 250µl of 6M NaCl, the tubes were placed on a rocker at 40 RPM for 5 
minutes before they were centrifuged at maximum speed for 10 minutes. The supernatant was 
then transferred to a new tube and 500µl isopropanol was added, the tubes were then shaken at 
40 RPM once more before they were centrifuged at maximum speed for 10 minutes. 500µl of 70% 
ethanol was added to the pellets following the careful removal of the supernatant.  After 
thorough vortexing, the supernatant was removed by centrifugation and the pellets air dried for 
approximately 30 minutes. Finally, DNA was rehydrated by adding 20 µl TE buffer (Table 2.17) 








Table 2.16 DNA Lysis Buffer 
Reaction Component Volume (ml) Final concentration  
Concentration 1M Tris-Hcl pH8.0 10 50 mM 
0.5M EDTA 40 100 mM 
3M NaCl 6.6 99 mM 
20%SDS 10 1% SDS 
ddH2O 133.4 - 
Total 200 - 
 
Table 2.17  TE Buffer 
Reaction Component Volume (ml) Final Concentration 
1M Tris-HCl pH7.4 1 10 mM 
0.5M EDTA 0.2 1 mM 
ddH2O 98.8 - 






 mice using standard PCR (Table 2.18) was performed 
according to a protocol (Table 2.19) provided by The Jackson Laboratory. The following primer 
sequences were used:  
oIMR7415 (CCL2
-/-
 forward) 5’- GCC AGA GGC CAC TTG TGT AG-3’,  
oIMR9219 (CCL2
+/+
 forward) 5’- TGA CAG TCC CCA GAG TCA CA’-3’  









Table 2.18 PCR Reaction Mix 
Raction Component Volume (µl) Final Concentration 
ddH2O 3.33 - 
10 X AB PCR BufferII 1.20 1X 
25 mM MgCl2 0.96 2mM 
2.5 mM dNTP 0.96 0.2 mM 
20 µM oIMR9219 0.60 1µM 
20 µM oIMR9220 0.60 1µM 
20 µM oIMR7415 0.60 1µM 
5 mM DNA Loading Dye 1.66 0.69 mM 
5 U/µl Taq DNA Polymerase 0.09 0.04 U/µl 
DNA 2.00 - 
Total 12 - 
 
Table 2.19 PCR program 
 
Step 
Temp(°C) Time(min) Note 
1 94 3 - 
2 94 0.5 repeat 2-4 steps for 
35 cycles 
3 61 1 
4 72 1 
5 72 2 - 





2.2.5.2 Creation of bone marrow chimeric mice  
Bone marrow transplantation was carried out on both CCL2
+/+
 mice and CCL2
-/-
 mice. Recipient 
CCL2
-/-
 mice or CCL2
+/+
 mice (6-8 weeks of age) received lethal irradiation (950 rads) by whole 




 donor mice were euthanized before removing femurs 
and tibias aseptically. Their bones were rinsed with DMEM medium and bone marrow cells 
were flushed from their marrow cavities using a 27 gauge needle. Preparation of single cell 
suspensions was performed by passing the marrows through the needle repeatedly, followed by 
the application of a cell strainer to remove large clumps. Cells were then spun down at 
1000RPM for 5 mins and resuspended in DMEM to give a final concentration of 5x10
7
 cells/ml. 
Within 24 hours of receiving irradiation, the recipients were warmed up, until their tail veins 
could easily be identified, before they were placed in a restraint with their tails sticking out. 200 
µl (1x10
7
 cells) of cell suspension was injected into their tail vein with a 30 gauge needle for 
each mouse.  If an injection was missed (control) or failed, irradiated recipients were observed 
to die after 7-10 days. Femoral artery wire injury was performed on surviving recipients, 3 
weeks after bone marrow transplantation.   
2.2.5.3 Femoral artery wire injury 
Mice were weighed and anaesthetized by intraperitoneal injection of ketamine (75 mg/kg; 
Ketalar
®
, Pfizer) combined with medetomidine hydrochloride (1 mg/kg; Domitor
®
, Orion).  A 
pinch test was performed on the tail of mouse to confirm that it was fully anaesthetized. The 
lubricating ointment was applied to the eyes of mice to prevent corneal desiccation. Hair was 
removed by application of a depilatory cream from both legs to the lower abdomen. The mouse 
was then put on an aseptic operation board and covered with an aseptic drape. The depilated 
area of skin was sterilized with 70% ethanol and dried with sterile cotton swabs just before 
surgery. An incision into the skin over the femoral artery was made before locating femoral 
artery by blunt dissection of surrounding tissues. The tissues were moistened periodically using 
saline for irrigation. The femoral artery was isolated by gently separating the femoral nerve and 




femoral artery was looped with a 10-0 silk suture before performing an arteriotomy using a 30 
gauge needle at the distal part of the bifurcation.  The opening of the arteriotomy was lifted with 
micro-forceps before a 0.25 mm guide wire (CROSS-IT 100XT, HI-TORQUE) was introduced 
into the artery until it could be inserted no further. The wire was inserted and retracted 5 times 
before it was allowed to remain in the femoral artery for 3 mins. After gently and slowly 
removing the wire, the artery was immediately ligated. The same procedure was applied on the 





 cells) in the presence of 25 µl Matrigel
®
 Basement Membrane Matrix 
(Corning), saline was also used as a negative control. The wound was closed after the matrigel 
had solidified. Anaesthesia was reversed with atipamezole hydrochloride (5 mg/kg; Antisedan, 
Orion) after surgery. Mice were allowed to recover in a warm container. In all experiments, 
mice were monitored continuously during recovery and periodically for 2 days. 
For siRNA knockdown experiments in vivo, either 5 µg CXCL1 or Negative Control siRNA 
dissolved in 30% pluronic Gel-127 was perivascularly delivered to the femoral arteries 
immediately after wire injury. After 3 days, GFP-Sca1
+
 vascular progenitor cells (1x10
6
 cells) 
within 25 μl Matrigel
®
 Basement Membrane Matrix were seeded onto the adventitia of both 
siRNA treated femoral arteries. Arteries were harvested for either RNA extraction or for en face 
staining after 72 hours. 
2.2.6 Immunofluorescence and histology 
2.2.6.1 Immunofluorescent staining of cells 
Cells were seeded at a density of 1x10
4
/well in 500µl culture medium in individual chambers of 
a 4-well chamber slide coated with 0.04% gelatin. After 24 hours, the culture medium was 
replaced with serum-free medium. Following an overnight serum starvation, the cells were 
treated with relevant stimuli (details will be described in corresponding experiments) and then 
washed twice with warm PBS before staining. First, the cells were fixed with 4% 
paraformaldehyde (PFA) for 15 mins at room temperature and washed with PBS, before 




washing with PBS 3 times, the cells were blocked with 5% normal donkey serum (Dako) in 
PBS for 1 hour at room temperature. Incubation of cells with primary antibodies or blocking 
solution only (negative control) was performed at 4℃ overnight. The primary antibodies used 
and the dilutions in blocking solution are shown in Table 2.1. The next day, cells were washed 
with PBS 3 times, each time for 5 minutes. Secondary antibodies (Corresponding fluorescent-
conjugated IgG antibodies were used as secondary antibodies (Invitrogen)) were applied to cells 
for 45 mins at 37℃ and protected from light. Following three 5 minute washes in the dark, the 
cells were counterstained with DAPI (1:1000 in PBS) for 3 minutes at room temperature. They 
were then mounted using fluorescent mounting media (Dako) and images were acquired using 
either an Olympus IX81 microscope with Volocity software (PerkinElmer) or a Leica SP5 
confocal microscope with Leica LAS AF software. 
2.2.6.2 FACS analysis 
The protein expression of CCR2 or CXCR2 on the membrane of vascular progenitor cells was 
analysed by flow cytometry. The VPCs from each well (sample/well) of a 6-well plate after 
different treatments were harvested and transferred into BD falcon tubes (2x10
5
/tube). Samples 
were pooled together for IgG control staining. Cells in each tube were fixed with 4% 
paraformaldehyde at room temperature for 15 mins. The cells were then washed with 3 ml PBS 
and centrifuged at 1500RPM for 5 mins, followed by incubation with either anti-CCR2 antibody 
(Abcam) or PBS (IgG control tube) on ice for 1 hour.  After further washing with PBS, the cells 
were incubated with either anti-CXCR2 PE‑conjugated antibody (R&D) or mouse IgG PE (BD 
biosciences) (IgG control tube) on ice for 30 mins in the dark. Following washing and 
centrifugation, the cells were analysed using BD Accur
TM
 C6 Flow Cytometer with a 488nm 
laser. Data analysis was carried out using FlowJo_V10 (FLOWJO, LLC) software. 
2.2.6.3 Harvesting femoral arteries for histology 
Euthanasia was performed on each mouse using cervical dislocation. After death, a small 
incision was made in the right atrium to create an outlet for blood. The mouse was perfused 




The clearing of blood in the liver served as an indicator of a good perfusion. Fixation was then 
performed by replacing saline with 10ml of 4% formaldehyde. The fixation tremors of the 
whole body were observed within seconds. An incision into the skin was made over the femoral 
artery, and the distal end of the injured artery was located by identification of the silk suture for 
ligation. The artery was excised from surrounding tissues from the distal part, near the suture, to 
the proximal part, beside the abdominal aorta. The artery was then transferred into 4% 
formaldehyde solution at 4℃ for the further process of histology.  For paraffin section 
preparation, the fixed artery was transferred to 70% ethanol at 4℃ 24 hours before embedding 
in paraffin blocks. For the preparation of frozen sections, dehydration of the fixed arteries was 
performed in 30% sucrose solution at 4℃ overnight followed by embedding them within Bright 
Cryo-m-Bed (Bright Instruments). The samples were then placed in liquid nitrogen for fast and 
adequate cooling before being cut into 5 mm thick sections. Paraffin sections were stored at 
room temperature while frozen sections were stored at -20℃ before performing histological and 
immunofluorescence staining to assess the extent of the injury and neointima formation. 
2.2.6.4 Haematoxylin and Eosin (HE) staining of paraffin section 
Deparaffinization and rehydration were performed on paraffin sections before H&E staining. 
The slides were first immersed in xylene for 10mins and this was then repeated in fresh xylene 
solution.  Rehydration was then performed using the following concentrations of ethanol: 100% 
ethanol for two 5 minute immersions; 70% ethanol for one 5 minute immersion. The slides were 
washed briefly in tap water before H&E staining. After blotting excess water from the slides 
with a paper towel, the slides were stained in haematoxylin solution for 5 mins, followed by 
washing under running tap water for 5 mins. Differentiation of the staining was performed by 
repeatedly dipping the slides into 1% acid ethanol 5 times. Subsequently, the slides were 
washed under running tap water for 5-10 mins and it was confirmed that the nuclei had turned 
blue under the microscope. Next, counterstaining with eosin solution was performed for 5 mins 
before dehydration. Following brief washing in water, the slides were immersed in first 70% 
ethanol and then 100% ethanol twice, 2 minutes for each step. The excess ethanol was blotted 




slides were mounted with xylene based DPX mounting medium (Fisher Scientific) and dried 
overnight. All steps took place in a flow hood. 
2.2.6.5 Immunofluorescent staining of frozen sections 
The slides containing frozen sections were thawed at room temperature for 30 minutes before 
staining. Rehydration of frozen sections was performed in PBS for 5 mins to remove tissue 
freezing matrix. To fix the tissue sections, the slides were immersed in pre-cooled acetone (-
20°C) for 10 min at room temperature. After briefly washing twice with PBS, the tissue sections 
were blocked with 5% normal donkey serum (Dako) in PBS for 1 hour at room temperature. 
Following removal of the block buffer, incubation of cells with primary antibodies or blocking 
buffer (negative control) was performed at 4℃ overnight in a humidified chamber. The slides 
were rinsed thrice in PBS, 5 mins each time before the application of appropriate secondary 
antibodies for 45 mins at 37℃ protected from light. Following repeated 5mins washes, tissue 
sections were counterstained with DAPI for 5 mins at room temperature. The slides were 
mounted with fluorescent mounting media (Dako) and images were acquired using an Olympus 
IX81 microscope with Volocity software (PerkinElmer) or an SP5 confocal microscope with 
Leica LAS AF software. 
2.2.6.6 En face staining 
After fixation with 4% paraformaldehyde overnight, the femoral arteries were permeabilized 
and blocked with 0.5% Triton X-100 and 5% donkey serum together for 2 hours. Incubation of 
vessels with primary antibodies was performed at 4℃ overnight, followed by incubation with 
corresponding fluorescent-conjugated secondary antibodies (Invitrogen) or IgGs as negative 
controls for 2 hours at room temperature. Then nuclei were counterstained with DAPI for 5 
mins at room temperature before dissection of the arteries. One end of the artery was pinned on 
rubber and the other end was opened, allowing micro-scissors to be inserted into the lumen of 
the artery. The artery was split continuously from one end to the other end, avoiding injury in 
the inner layer of the vessel. Subsequently, the opened artery was cut transversely into several 
segments and these cuts allowed the unfolded artery segments to be flattened. The segments 




the 1.5 cover glass. Images were taken using a Leica TCS SP5 confocal microscope and 
assessed using LAS AF Lite software.  
2.3 Statistical analysis 
Data for this study are presented as the mean ± standard error of the mean (S.E.M.) of at least 
three separate experiments. The analysis was performed using GraphPad Prism V.6 (GraphPad 
Software, San Diego CA) using analysis of variance (one-way ANOVA) followed by Dunnett’s 



























3.1 Characterization of vascular progenitor cells (VPCs) 
Previous work from our group has described a population of progenitor cells identified within 
pathological vessels in a mouse vein graft model (C. W. Chen et al., 2013; Margariti et al., 
2012). This earlier work showed that 2 weeks after implantation of vein grafts, a large 
heterogeneous population of cells migrated from the adventitia of vessels and contributed to 
neointima formation (Hu et al., 2004). To further characterise the migrated progenitor cells in 
this heterogeneous population in the current study, single cell clones were isolated and cultured 
in stem cell medium. 2 days after serial dilution of VPCs to obtain individual cells, 4 single cell 
clones showing different morphologies were seen (Figure 3.1).  
Clones were characterised using conventional PCR and immunofluorescent staining. Clones 
were evaluated for their gene expression of a panel of lineage markers for a range of cell types 
such as hematopoietic stem cells (CD133), mesenchymal stem cells (CD105, CD90), 
monocyte/macrophages (CD14), progenitor cells (Sca-1, c-kit, CD34), endothelial cells (EC) 
(eNOS, vWF, Flk-1, CD31 and CD144) and smooth muscle cells (SMC) (SM22, Calponin, 
SMα-actin) using conventional PCR. The clones expressed a high level of progenitor cell 
marker Sca-1 and a panel of SMC markers (Calponin, SM22α and α-SMA), very low levels of 
CD34, CD105, CD90, CD14 but no EC markers (Figure 3.2). 
 The clones were further characterised by staining for cell surface markers, using fluorescent 
antibodies, and were consistently found to show high levels of Sca-1 expression, but no 
expression of endothelial or smooth muscle cell markers (Figure 3.3). Although the expression 
of SMC markers was present at the gene level, the cells did not show positive staining for either 
calponin or SM-MHCII at the protein level. While the clones had different morphologies 
(Figure 3.1) they expressed a similar panel of cell markers at the gene (Figure 3.2) and protein 
levels (Figure 3.3).  
In order to purify the Sca-1
+
 progenitor cell population from the heterogeneous population 
derived from vein graft outgrowth, anti-Sca-1 immunomagnetic microbeads were used.  
Approximately 15% of total cells collected were identified as Sca-1
+




sorting.   The purity of cells sorted for Sca-1via this method was shown to be 98% in a previous 
study (Wong et al., 2013). Clones and Sca-1
+
 progenitor cells were further characterised using a 
qPCR array, showing gene expression of chemokines and chemokine receptors. Data are shown 
in Figure 3.4 and Table 3.1, Table 3.2, Table 3.3 indicates the presence of a variety of 
chemokine receptors in VPCs and importantly, CCR2 and CXCR2 (receptors of CCL2 and 
CXCL1, respectively). 
 
Figure 3.1 Morphology of different single cell clones. Cells were cloned by serial dilution 
and single cell clones were picked 2 days after seeding cells in 48 well plates. Approximately 3 
to 5% of cells formed clones that could be gradually expanded. Images A, B, C, and D represent 
four different single cell clones, two cells (arrows) from each clone are shown in the represented 















Figure 3.2 Characterisation of vascular progenitor cells at the gene level. Representative 
images of conventional PCR show that clones express high levels of Sca-1 (progenitor marker), 
SM22, calponin, α-SMA (SMC markers), and also lower levels of CD90, CD105 (mesenchymal 
stem cell markers) and CD14 (monocyte/macrophage marker), but no EC markers. The result 
















Figure 3.3 Characterization of vascular progenitor cells at the protein level. Clone 
colonies were characterised using immunofluorescence staining for progenitor cell marker (Sca-
1), SMC markers (SM-MHCII, Calponin) or endothelial cell markers (CD31，CD144).  The 
nuclei were counterstained with DAPI. Images of indirect immunofluorescent staining are 






Figure 3.4 The gene expression of chemokines and chemokines receptors in different 
cell lines. The cluster grams show the expression of chemokines (A), and other chemotactic 
cytokines (B) on macrophages, smooth muscle cells, clones and Sca-1
+ 
VPCs individually. The 





Table 3.1 Gene expression of chemokines and chemotactic cytokines in different cell 
lines (2-AvgΔCt )(x10-4) 
Refseq Symbol Description Mφ SMC clone 
Sca-1+ 
VPC 
NM_011329 Ccl1 Chemokine (C-C motif) ligand 1 1.06 7.16 0.8 0.83 
NM_011330 Ccl11 Chemokine (C-C motif) ligand 11 0.68 7.16 3.14 15.81 
NM_011331 Ccl12 Chemokine (C-C motif) ligand 12 78.92 560.56 0.46 0.42 
NM_011332 Ccl17 Chemokine (C-C motif) ligand 17 3.12 175.55 2.05 2.95 
NM_011888 Ccl19 Chemokine (C-C motif) ligand 19 0.65 7.16 1.6 1.6 
NM_011333 Ccl2 Chemokine (C-C motif) ligand 2 1225.41 11916.8 1677.83 7981.14 
NM_016960 Ccl20 Chemokine (C-C motif) ligand 20 0.41 309.91 0.67 1.21 
NM_009137 Ccl22 Chemokine (C-C motif) ligand 22 5.61 7.16 0.58 0.45 
NM_019577 Ccl24 Chemokine (C-C motif) ligand 24 46.28 7.16 0.61 0.47 
NM_009138 Ccl25 Chemokine (C-C motif) ligand 25 28.69 100.48 73.64 116.09 
NM_0010134
12 
Ccl26 Chemokine (C-C motif) ligand 26 0.58 7.16 1.15 0.62 
NM_020279 Ccl28 Chemokine (C-C motif) ligand 28 0.57 7.16 7.42 6.88 
NM_011337 Ccl3 Chemokine (C-C motif) ligand 3 363.48 600.79 0.5 0.42 
NM_013652 Ccl4 Chemokine (C-C motif) ligand 4 161.16 191.44 0.79 1.17 
NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 1484.45 26.1 38.74 263.02 
NM_009139 Ccl6 Chemokine (C-C motif) ligand 6 64591.01 617.68 0.89 6.35 
NM_013654 Ccl7 Chemokine (C-C motif) ligand 7 527.26 25105.4 4055.64 13329.9 




Refseq Symbol Description Mφ SMC clone 
Sca-1+ 
VPC 
NM_011338 Ccl9 Chemokine (C-C motif) ligand 9 937.31 156.03 3.76 9.6 
NM_027022 Cmtm2a 
CKLF-like MARVEL 
transmembrane domain containing 
2A 
0.41 7.16 0.46 0.42 
NM_024217 Cmtm3 
CKLF-like MARVEL 
transmembrane domain containing 
3 
1143.35 1464.01 1536.8 1350.28 
NM_153582 Cmtm4 
CKLF-like MARVEL 
transmembrane domain containing 
4 
10.87 193.44 56.33 91.29 
NM_026066 Cmtm5 
CKLF-like MARVEL 
transmembrane domain containing 
5 
0.41 7.26 0.49 2.62 
NM_026036 Cmtm6 
CKLF-like MARVEL 
transmembrane domain containing 
6 
185.56 158.21 78.02 52.8 
NM_009142 Cx3cl1 
Chemokine (C-X3-C motif) ligand 
1 
0.55 82.47 84.59 111.61 
NM_008176 Cxcl1 Chemokine (C-X-C motif) ligand 1 208.76 5598.06 965.89 4179.3 
NM_021274 Cxcl10 
Chemokine (C-X-C motif) ligand 
10 
111.87 24.1 8.59 95.39 
NM_019494 Cxcl11 
Chemokine (C-X-C motif) ligand 
11 
0.41 7.16 0.46 1.13 
NM_021704 Cxcl12 
Chemokine (C-X-C motif) ligand 
12 








Chemokine (C-X-C motif) ligand 
13 
9062.62 7.16 0.46 0.42 
NM_019568 Cxcl14 
Chemokine (C-X-C motif) ligand 
14 
42.79 233.25 5.32 8.33 
NM_011339 Cxcl15 
Chemokine (C-X-C motif) ligand 
15 
0.55 9.82 450.6 44.19 
NM_023158 Cxcl16 
Chemokine (C-X-C motif) ligand 
16 
322.33 264.24 175.14 249.41 
NM_009140 Cxcl2 Chemokine (C-X-C motif) ligand 2 720.26 133.04 3.83 3.22 
NM_203320 Cxcl3 Chemokine (C-X-C motif) ligand 3 69.67 29.56 0.75 0.54 
NM_009141 Cxcl5 Chemokine (C-X-C motif) ligand 5 5.18 1351.84 34058.2 
22058.4
8 
NM_008599 Cxcl9 Chemokine (C-X-C motif) ligand 9 0.94 8.4 0.46 2.33 
NM_008337 Ifng Interferon gamma 2.57 7.16 0.46 0.42 
NM_010551 Il16 Interleukin 16 145.25 7.57 231.64 95.17 
NM_008361 Il1b Interleukin 1 beta 882.66 34.79 1.02 0.74 
NM_021283 Il4 Interleukin 4 6.4 7.16 0.63 0.54 
NM_031168 Il6 Interleukin 6 109.32 183 366.85 2128.63 
NM_019932 Pf4 Platelet factor 4 2620.66 149.16 2.99 1.26 
NM_023785 Ppbp Pro-platelet basic protein 12.26 7.16 2.72 2.65 
NM_011577 Tgfb1 Transforming growth factor, beta 1 884.7 386.87 210.7 221.69 
NM_013693 Tnf Tumour necrosis factor 66.06 42.1 0.46 0.42 
















factor 1, alpha subunit 
485.18 1209.93 3514.36 2109.05 
NM_008401 Itgam Integrin alpha M 4286.88 89 0.46 0.42 
NM_008404 Itgb2 Integrin beta 2 6695.82 226.87 17.62 15.13 
NM_011949 Mapk1 
Mitogen-activated 
protein kinase 1 
322.33 910.62 694.12 526.05 
NM_011951 Mapk14 
Mitogen-activated 
protein kinase 14 
230.04 159.87 208.76 191.66 
NM_178804 Slit2 
Slit homolog 2 
(Drosophila) 
0.47 1105.68 276.1 276.74 
NM_011905 Tlr2 Toll-like receptor 2 131.82 59.33 34.59 61.21 








Table 3.3 Gene expression of chemokine receptors and chemotactic cytokine receptors 
in different cell lines (2-AvgΔCt )(x10-4) 




Complement component 5a 
receptor 1 
437.27 118.66 0.46 0.42 
NM_021609 Ackr2 Chemokine binding protein 2 0.89 7.16 0.59 0.65 
NM_009912 Ccr1 
Chemokine (C-C motif) 
receptor 1 
1836.04 30.5 2.13 3.99 
NM_007721 Ccr10 
Chemokine (C-C motif) 
receptor 10 
0.72 7.16 6.23 3.11 
NM_007718 Ccr1l1 
Chemokine (C-C motif) 
receptor 1-like 1 
0.64 7.16 0.46 0.42 
NM_009915 Ccr2 
Chemokine (C-C motif) 
receptor 2 
892.92 7.29 0.51 0.42 
NM_009914 Ccr3 
Chemokine (C-C motif) 
receptor 3 
854.56 45.75 0.46 0.42 
NM_009916 Ccr4 
Chemokine (C-C motif) 
receptor 4 
0.96 7.16 0.46 0.42 
NM_009917 Ccr5 
Chemokine (C-C motif) 
receptor 5 
756.07 126.74 0.47 0.42 
NM_009835 Ccr6 
Chemokine (C-C motif) 
receptor 6 
36.99 7.16 0.48 0.42 
NM_007719 Ccr7 
Chemokine (C-C motif) 
receptor 7 
99.44 7.16 0.78 0.45 
NM_007720 Ccr8 
Chemokine (C-C motif) 
receptor 8 








Chemokine (C-C motif) 
receptor 9 
2.76 7.16 1.03 0.88 
NM_145700 Ackr4 
Chemokine (C-C motif) 
receptor-like 1 
0.41 7.16 3.72 2.02 
NM_017466 Ccrl2 
Chemokine (C-C motif) 
receptor-like 2 
224.78 7.16 10.26 4.99 




20.05 80.77 0.46 0.42 
NM_178241 Cxcr1 
Chemokine (C-X-C motif) 
receptor 1 
3.42 7.16 0.46 0.42 
NM_009909 Cxcr2 
Chemokine (C-X-C motif) 
receptor 2 
63.52 7.16 0.46 0.42 
NM_009910 Cxcr3 
Chemokine (C-X-C motif) 
receptor 3 
48.36 7.16 0.46 0.42 
NM_009911 Cxcr4 
Chemokine (C-X-C motif) 
receptor 4 
283.86 63.59 0.46 0.59 
NM_007551 Cxcr5 
Chemokine (C-X-C motif) 
receptor 5 
36.99 7.16 0.46 0.42 
NM_030712 Cxcr6 
Chemokine (C-X-C motif) 
receptor 6 
11.95 7.16 9.02 1.31 
NM_007722 Ackr3 
Chemokine (C-X-C motif) 
receptor 7 
60.23 145.08 779.13 795.5 
NM_010045 Darc 
Duffy blood group, 
chemokine receptor 




Refseq Symbol Description Mφ SMC clone 
Sca-1+ 
VPC 
NM_013521 Fpr1 Formyl peptide receptor 1 806.6 33.72 1.16 0.91 
NM_001025381 Gpr17 G protein-coupled receptor 17 0.52 7.16 1.24 0.87 
NM_011798 Xcr1 
Chemokine (C motif) 
receptor 1 








3.2 SMC-conditioned medium induced VPC migration 
To investigate whether SMCs affect the migratory ability of VPCs, a transwell migration assay 
was performed. Increasing numbers of SMCs were seeded on the lower chamber while a fixed 
number of VPCs were seeded on the 8.0 µm pore membrane in the upper chamber.  Using an 
increasing ratio of VPCs to SMCs (from 1:0 to 1:5), and allowing an overnight incubation, we 
found that the migration of VPCs increased as the number of SMCs increased and that this 
reached its peak when the ratio was 1:2 (Figure 3.5). Next, the SMC-conditioned medium was 
collected from SMCs cultured overnight in serum-free medium and used for migration assays. 
The addition of conditioned medium resulted in consistent VPC migration in both transwell and 
wound healing assays. VPCs treated with conditioned medium demonstrated a 3 to 5 fold 
increase in migration compared to the serum free medium control (Figure 3.6).  
Time-lapse microscopy was used to track the speed and the persistence of single progenitor cells 
during their migration when treated overnight. Intriguingly, the persistence, which is the 
capacity of cells to maintain the direction of migration towards targets, was increased in 
response to SMC conditioned medium compared to the control (Figure 3.7). Subsequent BrdU 
cell proliferation assays confirmed that the increased migration was not due to VPC 
proliferation (Figure 3.8 A).  Further qPCR analysis revealed that the mRNA levels of SMC 
markers (calponin and α-SMA) and endothelial marker (CD31) in VPCs did not significantly 
change (Figure 3.8 B, C, D). VPCs also maintained progenitor characteristics, as Sca-1 
expression did not significantly change compared to the control (Figure 3.8 E). Additionally, 
immunofluorescence staining for paxillin, vinculin and phosphorylated FAK showed that 
relocation of cytoskeleton-related proteins was increased (Figure 3.9). Taken together, the 
results support the notion that both co-culture with SMC and SMC-derived conditioned medium 









Figure 3.5  SMCs induce vascular progenitor cell migration. A, B.  Chemotaxis of 
vascular progenitor cells (5×10
4
 cells/well) toward an increasing number of SMCs (the ratios of 
VPCs to SMCs were shown in the figure) in 8.0 μm transwells after 18 hours was documented 
after 0.1% crystal violet staining. Serum-free culture media was used as a control for all 











Figure 3.6 SMC conditioned medium induces vascular progenitor cell migration. 
Migration assays using transwell (A) and wound healing (B) show a significant increase in VPC 
migration towards SMC conditioned medium (CM). Representative images were taken from 
transwell and wound healing assays with a 20× objective. Chemotaxis index was defined by 
counting 10 fields of view and is presented as fold increase compared to the control. Graphs are 
shown as mean ± SEM of at least three independent experiments.  **p<0.01, ***p<0.001. 











Figure 3.7 SMC conditioned medium increases vascular progenitor cell persistence 
during its migration but makes no difference to migration speed. Vascular progenitor 
cells were incubated with SMC conditioned medium or control medium for 18 hours. Time- 
lapse microscopy was performed to observe the movement of single cells. Trajectory plots of 
migrating VPCs are shown per cell in (A) and centred in (B), 100 tracked single cells in each 
group are displayed. Quantification analysis of the speed (C) and persistence (the capacity of 
cells to maintain their migration direction from the start point to the end point) (D) of VPCs was 
performed in 3 independent experiments. All graphs are shown as mean ± SEM. *p<0.05, 







Figure 3.8 SMC conditioned medium has no effect on VPC proliferation and 
differentiation. A. Evaluation of vascular progenitor cell proliferation after 18 hours in 
response to SMC conditioned medium, CXCL1 or CCL2 treatments in comparison to an 
untreated control was by BrdU incorporation assay. B, C, D, E. Total RNA from vascular 
progenitor cells was harvested and subjected to qPCR for analysis of expression of SMC 
markers (α-SMA, SM-MHCII), an endothelial cell marker (CD31) and a progenitor cell marker 












Figure 3.9  SMC conditioned medium increases paxillin, vinculin and phosphorylated 
FAK expression.  Vascular progenitor cells were treated with SMC conditioned medium for 5 
minutes before immunofluorescence staining for paxillin, vinculin and phosphorylated FAK. 
ctrl, control. CM, SMC conditioned medium. p-FAK, phosphorylated FAK. White arrows 














3.3 SMC-released CCL2 and CXCL1 induced VPC 
migration  
To further investigate which mediators released by SMCs that were responsible for inducing 
VPC migration, we performed a chemokine multi-ELISA array. This revealed that CXCL1 and 
CCL2 levels were markedly increased in the SMC-conditioned medium when compared to 
serum-free medium (Figure 3.10 A). Further experiments using murine CCL2 or CXCL1 
Quantikine kits confirmed that the amounts of CCL2 and CXCL1 in the conditioned medium 
were 4.63±1.29 ng/ml and CXCL1 3.08±0.99 ng/ml, respectively (Figure 3.10 B, C). While the 
level of CCL5 was also up-regulated in comparison to the control, subsequent transwell 
migration assays found that it did not affect VPC migration (Figure 3.13). To confirm the roles 
of CCL2 and CXCL1 in mediating VPC migration, we performed transwell and wound healing 
assays using exogenous mouse recombinant CCL2 and CXCL1 proteins. VPC migration was 
enhanced in response to CCL2 and CXCL1 treatment and peaked at 5 ng/ml (a 6 fold increase 
in CCL2 (Figure 3.11 A) and a 2 fold increase in CXCL1 (Figure 3.12 A) treated cells). These 
were similar concentrations of CCL2 and CXCL1 to those measured in the SMC-derived 
conditioned medium. That a 5ng/ml CCL2 (Figure 3.11 B) or CXCL1 (Figure 3.12 B) treatment 
enhanced VPC migration was confirmed by wound healing assay. Silencing of CCL2 or 
CXCL1 in the SMCs using siRNAs resulted in significant down-regulation of CCL2 and 
CXCL1 at both the mRNA and protein levels (Figure 3.14). Importantly, CCL2 or CXCL1 
depleted SMCs failed to stimulate VPC migration in transwell assays (Figure 3.15). To further 
investigate the relationship between CCL2 and CXCL1 in SMC conditioned medium induced 
VPC migration，CCL2 and/or CXCL1 concentrations were depleted using their corresponding 
neutralising antibodies. The antibodies were found to be effective and selective as they 
significantly reduced the availability of their target chemokine, while they had no effect on the 
other chemokine studied. Depletion of either CCL2 or CXCL1 did not result in a compensatory 
release of the other chemokine and there appeared to be no interactions between the two 
antibodies (Figure 3.16). Having confirmed the effectiveness of the neutralising antibodies they 





or CXCL1 in SMC conditioned medium inhibited migration of VPCs by nearly 50%.  However, 
simultaneous depletion of CCL2 and CXCL1 in SMC conditioned medium did not further 
reduce this migration level (Figure 3.17).  Finally, incubation with various concentrations of 
CCL2 or CXCL1 did not stimulate VPCs autocrine production of the other chemokine (Figure 
3.18).  Therefore, these results suggest that CCL2 and CXCL1 derived from SMCs are 
responsible for SMC-induced VPC migration. Furthermore, their interaction is neither 




























Figure 3.10 Chemokine profiling in SMC conditioned medium. The identification of 
chemokines in SMC conditioned medium using a Chemokine Multiarray ELISA kit. The graph 
shows the absorbance at 450nm of each chemokine, with the serum-free culture medium as a 
control. B, C. This ELISA is not quantitative, but merely identifies the presence of the 
chemokine. The concentrations of CCL2 and CXCL1 in SMC conditioned medium were 
precisely quantified using the murine CCL2 or CXCL1 Quantikine ELISA kit. The 














Figure 3.11   CCL2 induced vascular progenitor cell migration.  A. Changes in vascular 
progenitor cell migration in response to a gradient of CCL2 in serum-free culture medium were 
evaluated using a transwell assay. B. The wound healing assay was performed on vascular 
progenitor cells with or without treatment with CCL2 (5ng/ml). Graphs show the fold increase 














Figure 3.12  CXCL1 induced vascular progenitor cell migration.  A. Changes in vascular 
progenitor cell migration in response to a gradient of CXCL1 in serum-free culture medium 
were evaluated using a transwell assay. B. The wound healing assay was performed on vascular 
progenitor cells with or without treatment with CXCL1 (5ng/ml). Graphs show the fold increase 












Figure 3.13 CCL5 has no effect on VPCs migration. A. The transwell assay was performed 
on vascular progenitor cells that migrated toward either serum-free medium (control) or serum 
free media containing murine recombinant CCL5 (5ng/ml, 50ng/ml). Transwell migration 
assays show VPCs migrated towards serum-free medium with or without mouse recombinant 















Figure 3.14  Silencing of CCL2 or CXCL1 in the SMCs using siRNAs. SMCs were 
transfected either with control noncoding small interfering RNA (siRNA), CCL2 siRNA 
(300nM) or CXCL1 siRNA (100nM) to knockdown corresponding mRNA. The real-time 
quantitative PCR and Quantikine ELISA kit showed a fold decrease in mRNA (A, C) and 
protein (B, D) levels in CCL2 or CXCL1 siRNA transfected SMCs and their conditioned 
medium respectively. n=3. All graphs are presented as mean ± SEM.  **p<0.01, ***p<0.001. 











Figure 3.15  Induction of VPC migration was markedly inhibited by conditioned 
medium derived from siRNA knocked down SMC. Transwell assay was performed on 
vascular progenitor cells migrating towards SMC (transfected either with noncoding siRNA, 
CCL2 siRNA or CXCL1 siRNA) conditioned medium. n=5. All graphs are presented as mean ± 
SEM.  ***p<0.001. NCsi, noncoding siRNA. siCCL2, CCL2 siRNA. siCXCL1, CXCL1 siRNA. 















Figure 3.16   The neutralizing antibodies are effective and selective for CXCL1 and 
CCL2 respectively. The SMC conditioned medium was treated with either neutralising 
antibodies for CCL2 and/or CXCL1 or the relevant control IgG for 1 hour at 37℃ , before pull-
down of chemokines combined with antibodies using protein G beads. The supernatant was 
collected and used to measure the concentrations of CCL2 (A) and CXCL1 (B) using 









Figure 3.17  The effects of CCL2 and CXCL1 are neither cumulative nor redundant in 
mediating VPC migration. The transwell assay was performed on VPCs that migrated toward 
SMC conditioned medium (positive control) or SMC conditioned medium after depletion of 










Figure 3.18 CCL2 and CXCL1 cannot stimulate VPCs to produce each other. VPCs 
were treated with either CXCL1 or CCL2 at indicated concentrations overnight followed by 
measurement of concentrations of CCL2 and CXCL1 using ELISA. The graphs are presented as 







3.4 VPC migration is mediated by CCR2 and CXCR2 
To identify the panel of chemokine receptors that are expressed in VPCs, a qPCR-array of Sca-
1
+ 
VPCs was performed; a cloned population of VPCs and SMCs were used as controls. Data 
shown in Figure 3.4C and Table 3.3 indicates the presence of a variety of chemokine receptors 
in VPCs including CCR2 and CXCR2. Both mRNA and protein expression of these receptors 
were significantly upregulated after treatment with SMC-derived medium (Figure 3.19). To 
silence CCR2 and CXCR2 in VPCs at the gene level, VPCs were infected with CCR2 or 
CXCR2 lentiviral shRNA; a null shRNA was used as a control. The cells were selected for 4-5 
days with neomycin and maintained in complete culture medium. Subsequent transwell 
migration experiments with CCR2 or CXCR2 silencing resulted in a significant decrease in 
VPC migration (Figure 3.20). Consistently, pre-treatment with antagonists of CCR2 or CXCR2 
led to a downregulation of VPC migration in response to chemokines (Figure 3.21). These 
findings suggest that CCL2 and CXCL1 released from SMCs induced VPC migration via 




















Figure 3.19  The upregulation of chemokine receptors CXCR2 and CCR2 was 
analysed using flow cytometry. The mRNA (A, C) and cell-surface protein (B, D) expression 
of CCR2 or CXCR2 was confirmed using real-time quantitative PCR and flow cytometry. n=3. 

















Figure 3.20   SMC-mediated migration was decreased in CCR2 or CXCR2 silenced 
VPCs. Vascular progenitor cells were infected with lentiviral short hairpin RNA (shRNA) 
(noncoding shRNA, CCR2 shRNA or CXCR2 shRNA) for ablation of CCR2 or CXCR2 before 
migration toward SMC conditioned medium. Noncoding shRNA served as the control. n=3. All 
graphs are presented as mean ± SEM. ***p<0.001. NCsh, noncoding shRNA. shCCR2, CCR2 












Figure 3.21  Antagonists of CCR2 or CXCR2 inhibited SMC-mediated VPC migration. 
The transwell assay was performed on vascular progenitor cells that were pre-treated with a 
range of concentrations of either an antagonist of CXCR2 or CCR2 for 1 hour prior to the 
migration toward SMC conditioned medium study.  A. Images represent each group in 20x view 





3.5 CCL2 and CXCL1 induced VPCs migration through the 
Rac1-p38 pathway 
The Rho GTPase family members Rac1 and Cdc42 have been implicated as important 
regulators of cell migration(Fonseca, Freund, Bornhauser, & Corbeil, 2010). To investigate 
whether Cdc42 and Rac1 are involved in VPC migration, we measured the levels of GTP-Cdc42 
and GTP-Rac1 using pull-down assays. Stimulation of VPCs with mouse recombinant CCL2 or 
CXCL1 resulted in both Cdc42 and Rac1 activation (Figure 3.22). Treatment with either ML141 
(an inhibitor of Cdc42) (Figure 3.23) or NSC23766 (an inhibitor of Rac1) (Figure 3.24) resulted 
in a significant reduction in VPC migration induced by CXCL1 and CCL2 when compared to 
control.  
p38 MAPK has been identified as the downstream signal transducer of active forms of Cdc42 
and Rac1 and the p38 signalling pathway can induce rearrangements of the cytoskeleton that 
regulate cell migration (Malchinkhuu et al., 2005; S. Zhang et al., 1995). A time course, using 
Western blotting analysis, showed that p38 phosphorylation occurred in VPCs after treatment 
with SMC conditioned medium for 20 minutes (Figure 3.26 A). p38 phosphorylation was up-
regulated in response to mouse recombinant CCL2 and CXCL1 treatment (Figure 3.26 B), and 
suppressed in response to conditioned medium derived from CCL2 siRNA or CXCL1 siRNA 
depleted SMCs (Figure 3.26 C). p38 phosphorylation was also suppressed in VPCs where 
CCR2 or CXCR2 had been knocked down using the corresponding shRNA(Figure 3.27 A). Pre-
treatment of VPCs with CCR2 or CXCR2 antagonists consistently reduced p38 phosphorylation 
(Figure 3.27 B). Importantly, p38 phosphorylation was significantly reduced in VPCs pre-
treated with NSC23766 (a Rac1 inhibitor) (Figure 3.29) but not ML141 (a Cdc42 inhibitor) 
(Figure 3.28). Finally, migration of VPCs was reduced in the presence of SB203580 (an 
inhibitor of the p38-MAPK signalling pathway) (Figure 3.31). These indicate that Rac1 
regulates CCL2 and CXCL1 induced VPC migration via the p38-signalling pathway. RhoA, 
another important small GTPase, has also been reported to regulate the cell migration process 




did not alter VPC migration (Figure 3.25) or p38 phosphorylation (Figure 3.30). We therefore 








Figure 3.22  CCL2 and CXCL1 activated GTPase Cdc42 and Rac1. Vascular progenitor 
cells were treated with either CCL2 or CXCL1 for 5 minutes. GTP-bound Cdc42/Rac1 were 
pulled down by PAK-PBD beads in whole cell lysates. Cdc42 and Rac1 antibodies were applied 
to detect GTP-Cdc42 and GTP-Rac1 in pulled down protein lysate and total Cdc42 and total 











Figure 3.23  The Cdc42 signalling pathway is involved in SMC-induced VPC 
migration. A. The transwell assay was performed on VPCs that were pretreated with either 
vehicle (DMSO) or ML141 (20 µM) for 1 hour before migration toward either SMC 
conditioned medium or recombinant CCL2, CXCL1. B. The quantification of the transwell 
assay results is presented as the fold change in cell migration towards each treatment in 









Figure 3.24  The Rac1 signalling pathway is involved in SMC-induced VPC migration. 
A. The transwell assay was performed on VPCs that were pre-treated with either vehicle 
(control) or NSC23766 (50 µM) for 1 hour before migration toward either SMC conditioned 
medium or recombinant CCL2, CXCL1. B. The quantification of the transwell assay shows the 
fold change between cells migrating toward each treatment and cells pre-treated with the vehicle. 













Figure 3.25  The RhoA signalling pathway is not involved in SMC-induced VPC 
migration. A. The transwell assay was performed on VPCs that were pre-treated with either 
vehicle or C3 transferase (2 µg/ml) for 2 hours before migration toward either SMC conditioned 
medium or recombinant CCL2, CXCL1. B. The quantification of the transwell assay is 
presented as the fold change in cell migration toward each treatment compared to cells pre-














Figure 3.26 SMC conditioned medium induced p38 phosphorylation via CCL2 and 
CXCL1.  A. Western blotting was performed on SMC conditioned medium-treated vascular 
progenitor cells for the detection of phosphorylated p38 (p-p38, Thr1 80/ Tyr1 82) and total p38 
(t-p38) at indicated time points.  B. Vascular progenitor cells were treated with recombinant 
CCL2 or CXCL1 respectively at 20 mins followed by Western blotting to detect p38 
phosphorylation. C. The p-p38 and t-p38 on vascular progenitor cells after treatment with SMC 
(transfected with CCL2 siRNA or CXCL1 siRNA) conditioned medium was analysed by 


















Figure 3.27 SMC-conditioned medium induced p38 phosphorylation via CCR2 and 
CXCR2.  A. Cell lysates from CCR2 shRNA or CXCR2 shRNA transfected vascular 
progenitors cultured in SMC conditioned medium were harvested for the detection of p-p38 and 
t-p38. B. After pre-treatments with either DMSO or antagonists of CCR2 or CXCR2, p-p38 and 
t-p38 of vascular progenitor cells in response to SMC conditioned medium was detected using 


































Figure 3.28 SMC conditioned medium induced p38 phosphorylation but not via the 
Cdc42 signalling pathway. After pre-treatment with DMSO (vehicle) or ML141 for 1 hour, 
VPC were stimulated with SMC conditioned medium or CCL2, CXCL1 before cell lysates were 





























Figure 3.29 SMC conditioned medium induced p38 phosphorylation via the Rac1 
signalling pathway. After pretreatment with vehicle (H2O) or NSC23766 for 1 hour, VPCs 
were stimulated with SMC conditioned medium or CCL2, CXCL1 before cell lysates were 

























Figure 3.30 SMC conditioned medium induced p38 phosphorylation but not via the 
RhoA signalling pathway. After pre-treatment with vehicle or C3 transferase for 1 hour, 
VPCs were stimulated with SMC conditioned medium or CCL2, CXCL1 before cell lysates 














Figure 3.31  SMC conditioned medium induced VPCs migration via the p38 signalling 
pathway. After pre-treatment with DMSO or SB203580 for 1 hour, VPC were stimulated with 
SMC conditioned medium or CCL2, CXCL1 before cell lysates were harvested for detection of 








3.6 Lack of CCL2 inhibits Sca-1
+
 cell migration and 
neointima formation 
SMCs can be described as activated and switched into the synthetic phenotype when they are 
cultured in vitro (Stegemann, Hong, & Nerem, 2005) and under these conditions they might 
constitutively release CCL2 and CXCL1. To study chemokine release in in vivo conditions, a 
mouse femoral artery wire injury model was used to assess whether native SMCs only produce 
chemokines, which attract VPC migration, after cell injury. Co-immunofluorescence staining of 
α-SMA and CCL2 or CXCL1 showed that in intact vessels, SMCs are quiescent and do not 
produce CCL2 or CXCL1 (Figure 3.32). However, once SMCs are injured they release 
increasing levels of CCL2 and CXCL1 (both at a short time point (6 hours) and a long time 
point (2 weeks) (Figure 3.32). These chemokines may play a role as potent and persistent 
attractants for VPC migration. To verify this, GFP-Sca-1
+
-VPCs (additionally  labelled using a 
Qtracker
®
 655 Cell Labeling Kit) were seeded on the adventitia of vessels that were injured. En 
face confocal microscopy revealed that 72 hours after injury the number of migrated cells found 
on the intimal side of the vessel wall was significantly lower in CCL2
-/-
 mice when compared to 
WT mice (Figure 3.35). CCL2
-/-
 mice were identified by genotyping mice and measuring CCL2 
levels in peripheral blood (Figure 3.34). Quantification based on either GFP-Sca-1
+
-VPCs or 
Qtracker showed similar results (Figure 3.35). Sca-1 immunofluorescence staining in sections of 
injured arteries 2 weeks post injury, showed that GFP-Sca-1
+
-VPCs remained Sca-1 positive 
after 2 weeks in vivo but that fewer cells migrated into the intimal side to contribute to 
neointima formation in CCL2
-/-
 mice compared to the WT mice (Figure 3.36).  These results 
suggest a role for CCL2 in VPC migration from the adventitia to the intima, where they may 
contribute to neointima formation. 
To further investigate the role of CCL2 in VPC neointima formation, wire-injured femoral 
arteries were seeded with VPCs or PBS in the adventitia. HE stained sections showed neointima 
formation in the vessel at 1 or 2 weeks after wire injury (Figure 3.37). Quantification of the data 




the 2-week post injury group, the difference in the ratio of neointima to media with VPCs or 
PBS was higher than that in the 1-week group. However, neointimal lesions in CCL2
-/-
 mice 
were decreased in vessels with either VPCs seeded in the adventitia or PBS. There is a 
significant reduction in neointimal lesion area of vessels with VPC seeding in CCL2
-/-
 mice 
when compared to the WT mice at 2 weeks.   
To characterise cells contributing to neointima formation, immunofluorescence staining of α-
SMA and Sca-1 was used; data showed that the cells in the neointima of PBS-treated vessels 
were approximately 70% α-SMA
+
 and 10% Sca-1
+ 
2 weeks after injury (Figure 3.33). Staining 
of α-SMA and CCR2 in Figure 3.38 revealed that the cell numbers in the neointima of VPC 
seeded vessels were increased, albeit fewer were α-SMA positive
 
. These results indicate that in 
the PBS treated vessels, most cells contributing to neointima formation are α-SMA positive.  
These cells are either from media SMC migration and proliferation or from progenitor cell 
differentiation. When Sca-1
+
 VPC were seeded in the adventitia, the ratio of α-SMA positive 
cells was significantly decreased, which implies that VPCs possess the high potential to migrate 
and proliferate. Over a short time, most cells maintained their progenitor cell characteristics, 
even though several had differentiated into SMCs (Figure 3.38 A, B). CCR2 was more highly 
expressed on the cells in the neointima of VPC-seeded vessels (Figure 3.38 C, D). Cumulatively, 
these data suggest that VPCs applied to the adventitia significantly increased neointima 
formation after vessel injury, largely through their migration and with a lesser effect via their 
differentiation into SMCs. Furthermore, lack of CCL2 markedly inhibits the effect of VPCs on 










Figure 3.32  CCL2 and CXCL1 are expressed on wire-injured vessels in vivo. Femoral 
arteries of C57BL/6J mice were harvested after wire injury or from uninjured animals. Frozen 
sections of intact vessels or vessels 6 hours or 2 weeks after wire injury were co-stained with 











Figure 3.33  Characterisation of cells in the neointima. A. Femoral arteries that had not 
been seeded with VPC in the adventitia were harvested 2 weeks after wire injury from 
C57BL/6J mice and stained with Sca-1 and α-SMA (white dotted line indicates internal elastin, 
and the circled part is neointima area). B. The ratios of positively stained cells with each marker 
in the neointima area were quantified and are shown in the graph. Graph is presented as 







Figure 3.34  Identifying the CCL2
-/-
 mouse genotype and CCL2 levels in the 
peripheral blood. A. To expand CCL2
-/-
 mice number, CCL2
-/-
 mice were crossed with 
CCL2
+/+
 mice. A piece of ear tissue from each mouse was used to genotype offspring. The 
image shows heterozygote (CCL2
+/-
) with bands at 287bp and 179bp and the mutant (CCL2
-/-
) 
with only one band at 179bp. B. Peripheral blood was collected from the vena cava before 
euthanasia of WT or CCL2
-/-
 mice. The CCL2 level was measured in serum using a murine 






Figure 3.35  Lack of CCL2 inhibits Sca-1+ vascular progenitor cell migration in vivo. A. 
After using a mouse femoral artery wire injury model, GFP-Sca-1
+





) were seeded in the adventitia of each injured vessel. En face 
staining shows that the cells migrated to the intimal side of the vessels 72 hrs post injury of WT 
and CCL2
-/-
 mice. B. The percentage of GFP-Sca-1
+
-VPC within respective DAPI
+
 nucleated 
populations in each view was quantified. C. Sca-1
+
 vascular progenitor cells (1x10
6
), which 
were labelled with Q-tracker to locate them as they migrated, were seeded in the adventitia of 
each injured femoral artery. 72 hrs post injury, the vessels were harvested. En face staining 
shows that cells migrated to the intimal side of the vessels of WT and CCL2
-/-
 mice.  D. The 
ratio of the fluorescence intensity (Qtracker: DAPI) is represented in the graphs as mean ± SEM 






Figure 3.36 Lack of CCL2 inhibits Sca-1+ cell participation in neointima formation. A. 
The femoral artery sections from WT and CCL2
-/-
 mice 2 weeks post injury were prepared for 





 cells within the DAPI
+
 nucleated cells in the neointima (white line indicates internal 
elastin, the neointima area is surrounded by the line). Representative images and graphs are 












Figure 3.37  Lack of CCL2 reduces neointima formation. A. Animals were euthanized at 
indicated time points after injury and the femoral arteries were fixed in 4% phosphate-buffered 
(pH=7.2) formaldehyde, embedded in paraffin, sectioned in 5 µm thick preparations and stained 
with haematoxylin–eosin. B. The ratio of neointima (the area between arrows) to media was 












Figure 3.38  Lack of CCL2 inhibits Sca-1+ cells migration and differentiation into 
SMCs. A, C. Vessel sections were also prepared for immunofluorescent α-SMA and CCR2 
staining 2 weeks post wire injury (white dotted line indicates internal elastin, and the above is 
neointima area).  B, D. Quantification of the percentage of positively stained cells within the 
neointima was shown in graphs as mean ± SEM of n=8 mice/group.  ***P<0.001. WT, wild 










3.7 Role of CCL2 released from non-bone marrow tissue  
Previous studies show that SMCs, ECs and other tissues(Rollins, Yoshimura, Leonard, & Pober, 
1990; X. Yu et al., 1992) are also able to secrete CCL2. To investigate which source of CCL2 
plays the most important role in VPC migration-induced neointima formation, chimeric mouse 
models were created. Wild-type bone marrow was transplanted into an irradiated CCL2
-/-
 mouse 
to form a CCL2 chimera. Conversely, a wild-type chimeric mouse model was prepared by 
transplanting CCL2
-/-
 mouse bone marrow cells into an irradiated wild-type mouse. The levels 
of CCL2 in the serum of peripheral blood were measured using a murine CCL2 ELISA kit. In 
the wild-type chimeric mouse model, the level of CCL2 in peripheral blood was increased, 
despite transplantation with CCL2
-/-
 bone marrow cells, when compared to a non-transplanted 
wild-type mouse control. This indicated that CCL2 is mostly released from non-bone marrow 
tissues. In contrast, the level of CCL2 has increased in CCL2
-/-
 mice with transplanted wild-type 
bone marrow cells, but to a much lesser extent, thus indicating that only a small proportion of 
CCL2 is released from bone marrow-derived cells (Figure 3.39). Data from HE-stained sections 
showed that neointima lesion area correlated with the CCL2 level in the blood (Figure 3.40). 
These results support the observations that CCL2-induced VPC migration contributes to 
neointima formation. 
 












Figure 3.39 Levels of CCL2 in peripheral blood of chimeric mice. After bone marrow 
transplantation in chimeric mouse models, CCL2 levels in peripheral blood of indicated mice 
after 1w and 2w was determined using a CCL2 Quantikine ELISA kit. Data is shown as mean ± 
SEM of n=5 mice/group. *p<0.05, **p<0.01, ***p<0.001. WT+CCL2
-/-
 BMT，wild type mice 
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Figure 3.40  CCL2 released from peripheral tissue plays an important role in 
contribution to neointima formation. The vessel sections of indicated mice at various time 
points were stained with HE, and the neointima area (the area between arrows) is shown in the 
represented images (A) and quantified in the graphs (B) presented as mean ± SEM of n=5 
mice/group. *p<0.05, **p<0.01, ***p<0.001. WT+CCL2
-/-
 BMT，wild type mice in which 
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3.8 CXCL1 plays a role in Sca-1 positive cell migration in 
vivo 
Previous studies have demonstrated that CXCL1 can induce endothelial cell migration and tube 
formation in vitro (D. Wang et al., 2006) , and can also act as an angiogenic factor to promote 
tumour growth (Haghnegahdar et al., 2000). To further investigate the role of CXCL1 in the 
induction of VPC migration in vivo, VPCs were mixed with matrigel containing either PBS or 
mouse recombinant CXCL1 and injected subcutaneously in WT mice. After 2 weeks, the 
number of cells that migrated into the matrigel was found to be significantly more in the 
CXCL1 group than in PBS controls (Figure 3.41). Immunofluorescence staining of Sca-1, CD31 
and α-SMA showed that most of the migrated cells in matrigel plugs were Sca-1 positive, whilst 
some were CD31 positive, and only very few were α-SMA positive (Figure 3.42). In addition, 
CXCL1 or control siRNA in a pluronic gel mixture was also delivered to the adventitial side of 
wire-injured vessels, to assess the effect of local CXCL1 knockdown on Sca-1
+
 VPC migration 
in vivo. Successful in vivo knockdown of CXCL1 mRNA level in injured femoral arteries was 
confirmed after 6 days, using real-time quantitative PCR (Figure 3.43), demonstrating a marked 
reduction in CXCL1 expression levels. Furthermore, En face confocal microscopy revealed that  
the number of migrated cells found on the intimal side of the vessel wall was lower in CXCL1 
siRNA treated vessels compared to the control siRNA, 72 hours after seeding GFP-Sca-1
+
VPC 
in the adventitia (Figure 3.44). These results indicated the importance of CXCL1 in Sca-1
+
 cells 










Figure 3.41  CXCL1 can induce cell migration in vivo. Using a matrigel plug assay, 
matrigel mixtures containing either vehicle (PBS) or mouse recombinant CXCL1 were injected 
subcutaneously into C57BL/6J mice. The matrigel plugs were harvested 2 weeks later and the 
frozen sections were stained with haematoxylin–eosin. Graphs are presented as mean±SEM of 





Figure 3.42  CXCL1 can induce Sca-1 positive cell migration in vivo. Using a matrigel 
plug assay, matrigel including PBS or mouse recombinant CXCL1 was injected subcutaneously 
into C57BL/6J mice. The matrigel plugs were harvested 2 weeks later and corresponding frozen 
sections were stained with immunofluorescent markers (Sca-1, CD31, α-SMA). The numbers of 
cells migrated into the matrigel (quantification from bottom images in A) or positively stained 
with each marker were quantified and shown in the graphs. Graphs are presented as mean±SEM 






Figure 3.43 CXCL1 small interfering RNA knocked down CXCL1 mRNA level in 
arteries.  Quantification of CXCL1 mRNA level by qPCR 6 days after perivascular application 
of CXCL1 or negative control siRNA dissolved in the pluronic gel. Graphs are presented as 















Figure 3.44 CXCL1 small interfering RNA inhibits Sca-1+ cells migration in vivo.  
Representative images of En face staining show that cells migrated to the intimal side of the 




) in the adventitia of femoral arteries treated 













Atherosclerosis, as a main underlying pathogenesis of cardiovascular disease, is one of the 
leading causes of morbidity and mortality in the world. Currently, percutaneous coronary 
intervention (PCI) is the most effective treatment for obstructive coronary atherosclerosis. 
However, post-angioplasty restenosis is still the main complication that exacerbates the 
outcome of coronary artery disease treatment (Hoffmann et al., 1996; Keeley, Boura, & Grines, 
2003; Serruys et al., 1988).  
For many years, researchers have been working to elucidate the mechanisms behind post-
angioplasty restenosis. Though neointimal hyperplasia and restenosis development involves a 
complicated series of cellular and molecular responses in the injured vessel, SMC proliferation 
and migration have putatively been viewed as central factors in these processes (Christopoulos 
& Havlir, 2013). However, in recent decades, adult stem/progenitor cells, which reside in the 
vascular wall, have been found to be activated and mobilised to participate in vascular 
remodelling after vessel injury (Hu et al., 2004). The exact mechanisms behind stem cells 
contribution to post-angioplasty restenosis are still uncertain. 
In an attempt to explore the underlying cause of VPCs activation and mobilisation, a co-culture 
system of vascular SMCs and progenitor cells was developed and revealed that SMCs can 
release molecules into the supernatant, which stimulate progenitor cells migration towards them. 
To further investigate which molecules produce this effect, a multiple chemokine ELISA array 
was performed that showed the levels of CCL2 and CXCL1 were markedly increased in SMC 
conditioned medium when compared to controls.  Treating progenitor cells with recombinant 
proteins CCL2 or CXCL1 significantly increased VPC migration. Furthermore, we found that 
the relationship between CCL2 and CXCL1 in progenitor cells migration is neither cumulative 
nor redundant.   
Next, the mechanism of CCL2 and CXCL1 promotion of vascular progenitor cell migration was 
studied, by identification of their corresponding receptors CCR2 and CXCL2, which were 




either chemokine in SMC conditioned medium or inhibition of either receptor on progenitor 
cells can abolish SMC-induced progenitor cell migration. Rho GTPase family members are 
important molecular switches which orchestrate rearrangement of the cytoskeleton to control 
cell migration, so, for this reason a GTPase Rac1/Cdc42 activation assay was carried out on 
progenitor cells treated with SMC conditioned medium. Both Rac1 and Cdc42 were activated 
into their GTP-bound forms. Antagonists of either Rac1 or Cdc42 can significantly reduce the 
migratory ability of progenitor cells. p38 phosphorylation was upregulated in SMC treated 
progenitor cells and inhibition of the p38 MAPK signalling pathway markedly abrogated 
progenitor cells migration. Furthermore, inhibition of Rac1 but not Cdc42 significantly 
diminished p38 phosphorylation, indicating that SMC-induced progenitor cell migration is via 
CCL2 or CXCL1 binding to their corresponding receptors and activating the Rac1/p38 
signalling pathway. Additionally, the expression of cytoskeleton-related proteins, such as 
paxillin, vinculin and phosphorylated FAK were upregulated in SMC-treated progenitor cells. 
Following in vitro mechanistic studies, animal models were utilised to further confirm CCL2 
and CXCL1 roles in progenitor cell migration in vivo. In a femoral artery wire injury model, 
CCL2
-/- 
mice showed reduced progenitor cell migration from the adventitia to the intima in 3 
days, and less neointima area after 2 weeks in comparison with WT mice. The comparison of 
the neointimal area in two types of chimeric mice (CCL2
-/-
 (BMT WT), WT (BMT CCL2
-/-
)) 
further indicates that the effect of CCL2 on progenitor cell migration is mostly dependent on 
peripheral-derived CCL2. Additionally, in vivo injection of CXCL1 within matrigel 
significantly attracted Sca-1
+
 cells migration. Furthermore, local application of CXCL1 siRNA 
may inhibit progenitor cells inward migration from the adventitia to the intima. 
With these findings, we present the first evidence that vascular smooth muscle cell produced 
chemokines CCL2 and CXCL1 play a key role in mediating vascular progenitor cell migration 
from the adventitia to intima, where these cells contribute to neointimal formation in a mouse 
femoral artery wire injury model. This provides key evidence as to why restenosis and delayed 
re-endothelialisation persist after angioplasty and stenting and this may be fundamental for 




4.1 Characterization of vascular progenitor cells (VPCs) 
In recent years, more and more studies from different laboratories have identified the presence 
of stem/progenitor cells that reside in the adventitia of vessel walls. They are thought to 
maintain the homeostasis of the vessel wall during physiological conditions but can be activated 
and participate in repair of the injured vessel under pathological conditions. They can 
differentiate into various cell types such as ECs or SMCs to participate in vascular repair or 
neointima formation, depending upon the variety of stimulations under the specific 
circumstance. Nevertheless, a conundrum remains that the identification and characterisation of 
adventitia progenitor cells still lack consistency between different research groups (Table 4.1). 
To date, there remains a lack of specific progenitor cell markers that can exclusively 
characterise and distinguish these progenitor cells from other cell types. Furthermore, several 
important questions still remain to be addressed: 1) What are the differentiation capacities of the 
vascular progenitor cells into ECs or SMCs? 2) What are their roles in vascular repair, re-
endothelialisation and neointima formation?  3) Do their responses to stimuli differ while in the 
same microenvironment? 4) Why are the conclusions from different research groups so varied?  
Thus, there is still much progress to be made in the field of progenitor cell research. Although 
some progenitor cells are identified by specific markers using in situ immune-staining in the 
vessel wall or antibody selection from isolated cells, it is still uncertain whether they are 
activated after vascular injury and differentiate to play a role in vascular events. The current 
models of differentiation in vitro are unable to replicate the dynamic and complicated 





Table 4.1 Vascular stem/progenitor cells in adventitia 
Year 2004 2006 2007 2008 
Reference (Hu et al., 2004) 













































































(Tigges, Komatsu, & 
Stallcup, 2013) 
(Psaltis et al., 
2014) 













































































progenitor cells residing in the adventitia of ApoE
-/-
 mice aortic roots contributed to hyperplasia 
in atherosclerosis. They found that these Sca-1
+
 adventitia progenitor cells can differentiate into 
SMCs in response to PDGF-BB in vitro. Furthermore, a chimeric mouse model was generated 
to demonstrate that Sca-1
+ 




contribute to neointima lesions in a vein graft model and simultaneously differentiated into Lac 
Z-SMCs in vivo. This study postulates that adventitia Sca-1
+
 cells have the capacity to migrate 
across vessel walls and subsequently differentiate into SMCs to contribute to neointima 
formation. Subsequently, our laboratory also identified another population of progenitor cells 
derived from the adventitia of vein grafts, which are Sca-1
+
 and are able to differentiate into 
SMCs in response to Collagen IV.  An ex vivo model additionally revealed increased migratory 
abilities of these progenitor cells in response to SDF-1 and in a carotid artery vein graft model 
of ApoE
-/-
 mice, the arteries enveloped with these progenitor cells showed significant 
exacerbation of atherosclerotic lesions. 
In our study, we chose to utilise vein graft-derived adventitia Sca-1
+
 progenitor cells because 
these cells are derived from the pathological adventitia of an injured vessel wall, which is more 
comparable to the disease microenvironment. Application of these Sca-1
+
 vein graft progenitor 
cells to the wire-injured artery model appears a reasonable representation of the disease setting. 
Several seminal works on Sca-1
+
 progenitor cell differentiation have been published by our lab 
(Y. Chen et al., 2013; Hu et al., 2004; Wong et al., 2013) , but work is lacking regarding their 
migratory behaviour and their role in contribution to neointima formation. We chose to study 
mouse due to easy access to specific gene knockout models and their fast breeding in 
comparison to animals with a circulatory system more similar to humans.  We think our 
findings will be informative for future study of human disease. 
The aim of the present study was to further examine the underlying mechanisms of the 
contribution of these pathological adventitia progenitor cells to neointima formation in injured 
vessels. Our data demonstrate that chemokines and their corresponding receptors play a key role 
in SMCs-induced Sca-1
+
 progenitor cell migration. Whilst there exists an abundance of studies 
that demonstrate chemokine receptor expression on various cell types such as granulocytes, 
monocytes, mast cells, T cells, and endothelial cells (de Nigris, Schiano, Infante, & Napoli, 
2012; Katsumoto & Kume, 2013), little is known about the presence/absence of chemokine 
receptors on vascular progenitor cells. We further characterised these vein graft adventitia-
derived Sca-1
+




chemokines and chemokine receptors. Unstimulated VPCs were found to express several 
chemokines and a number of chemokine receptors, however at markedly lower levels in 
comparison to SMCs (the main cell type in the vessel wall) and macrophages (a positive 
control). These data provide the first evidence of the presence of chemokines and their receptors 





4.2 SMCs induce VPC migration via CCL2 and CXCL1 
SMCs are the main type of cell in the vascular wall and play a crucial role in both physiology 
and pathology of vessel events. It has been well established that SMCs change their phenotypes 
from contractile to synthetic after vessel injury and that their proliferation and migration have a 
major effect on neointima formation (Y. Cheng et al., 2009; Rudijanto, 2007; Yoshida, Kaestner, 
& Owens, 2008). Furthermore, activated SMCs can also release inflammatory cytokines and 
growth factors, resulting in an inflammatory microenvironment in the vascular wall after vessel 
injury (Fabunmi, Baker, Murray, Booth, & Newby, 1996; Rakesh & Agrawal, 2005). Many 
studies have shown that cytokines and growth factors are potent molecules that can mobilise 
circulating progenitor cells (Sprague & Khalil, 2009). However, only a few studies are focused 
on whether these local inflammatory factors can also activate resident progenitor cells in the 
vascular wall. As they are known to be located within close proximity to SMCs within the 
vessel wall, it is tempting to postulate that adventitia progenitor cells can also be activated by 
inflammatory molecules existing in the same microenvironment.  
In our study, we demonstrated that proliferating SMCs can significantly induce vascular 
progenitor cell migration using in vitro migration assays and single cell tracking experiments in 
real time, indicating that the cells are migrating directionally and efficiently but not randomly. 
In vivo, GFP-Sca-1
+
 cells were applied to the adventitial side of injured femoral arteries, after 72 
hours GFP
+
 cells can be easily detected on the intimal side by en face staining, while, 2 weeks 
later,  neointima formation was significantly increased in these treated vessels compared to 
injured vessels where no cells had been applied. These data indicate that either when cultured in 
vitro or when injured in vivo, mouse SMCs are transformed into a proliferative phenotype, and 
in this condition, they are a potent attractant for VPC migration both in vitro and in vivo. 
After the endothelial injury, an inflammatory response occurs in the vessel wall and chemokines 
can be released from both mononuclear cells and SMCs and participate in vascular events 
(Saederup, Chan, Lira, & Charo, 2008; Veillard et al., 2005). In our study, we utilised a wire 




the major cell type remaining in the vessel wall would be activated SMCs which, would 
transmit an inflammatory response to neighbouring adventitia progenitor cells through 
chemokines. A multiple chemokine ELISA on supernatant from cultured activated SMCs 
demonstrated that several chemokines were up-regulated. Amongst them, CXCL1, CCL2 and 
CCL5 show the highest level of secretion. It is also noteworthy that in a qPCR array, the gene 
expression levels of both CCL2 and CXCL1 were much higher in SMCs when compared to 
other cells, which is consistent with our finding at the protein level. Furthermore, in vivo, 
immunofluorescence staining of α-SMA, CCL2 and CXCL1 on femoral arteries revealed that 
few chemokines are expressed on the intact vessel wall, however after injury, there is a time-
dependent increase in CCL2 and CXCL1, much of which co-localises with SMC markers. This 
demonstrates that once activated, SMCs can release large amounts of CCL2 and CXCL1.  
We found that stimulation of VPCs with recombinant CXCL1 and CCL2 stimulated VPC 
migration, however, stimulation with CCL5 did not. 
CXCL1 is a chemokine which has been studied in cardiovascular disease by a number of 
research groups in recent years. Oxidized LDL has been reported to trigger CXCL1 release from 
endothelial cells, which recruit atherogenic monocytes to promote atherosclerosis (Zhou et al., 
2011). Additionally, CXCL1 is expressed on human endothelial cells and induces angiogenesis 
through enhancement of endothelial cell migration and proliferation (Miyake, Goodison, 
Urquidi, Gomes Giacoia, & Rosser, 2013).  Microarray data revealed that the basal level of 
CXCL1 mRNA in untreated mouse aorta SMCs is low, but that it is significantly upregulated 
after TNF or/and α-LTβR treatment (Lotzer et al., 2010). The CXCL1 expressed on human 
arterial SMCs mediates endothelial progenitor cell adhesion in a flow chamber (Hristov et al., 
2007).  In rat aortic SMC, the mRNA level of CXCL1 was markedly enhanced by depletion of 
PTEN (Furgeson et al., 2010).  
In contrast, CCL2 involvement in atherosclerosis and neointima formation is well established. 
In the vessel wall, CCL2 has been shown to be released by both endothelial cells (Loyer et al., 




muscle cells (X. L. Chen, Tummala, Olbrych, Alexander, & Medford, 1998; Cushing et al., 
1990; Meng, Yan, Deng, Gao, & Niu, 2013), and to facilitate inflammation and induce SMC 
proliferation and migration.  
We also identified CCL5 expression in the multi-analytic ELISA.  The CCL5 expression has 
been identified in endothelial cells of transplant-associated accelerated atherosclerotic arteries 
(Pattison, Nelson, Huie, Sibley, & Krensky, 1996). It is produced by endothelial cells in 
response to TNF-α and IFN-γ, which regulates macrophage and T memory lymphocyte 
accumulation (Marfaing-Koka et al., 1995). Following artery injury, CCL5 has also been shown 
to be released by vascular smooth muscle cells and to induce an acute vascular inflammatory 
response by recruitment of inflammatory cells (Kovacic et al., 2010). Previous studies have 
reported that CCL5 mediates trafficking and homing of T cells, monocytes, basophils and 
eosinophils (Alam et al., 1993; Bischoff et al., 1993; Schall, Bacon, Toy, & Goeddel, 1990; Sun, 
Wang, Zhang, Zeng, & Wang, 2005). However, in our system, the migration of progenitors after 
stimulation with CCL5 did not change significantly when compared to the control. This result 
may indicate that CCL5, as a versatile chemokine, is upregulated in SMCs but does not play a 
functional role in cell migration, suggesting that vascular stem cells may selectively or 
specifically respond to certain chemokines. 
 To further confirm that the induction of VPC migration by SMC-conditioned medium was 
mediated by these chemokines in our study, we stimulated stem cells with exogenous mouse 
recombinant proteins CCL2, CXCL1 and CCL5 individually, and found that CCL2 and CXCL1 
can significantly induce vascular progenitor cell migration. More importantly, the 
concentrations of each chemokine which displayed the optimum migration results were in the 
same range as the concentrations measured in SMC conditioned medium. In contrast following 
knockdown of CCL2 or CXCL1 in SMCs by their respective siRNAs, there was a significant 
decrease in VPC migration towards conditioned medium.  Meanwhile, a BrdU assay revealed 
that during VPC migration, neither SMC conditioned medium nor CCL2 or CXCL1 affected 
VPC proliferation, which ruled out any proliferative effects on analysis of cell migratory ability. 




differentiate into mature vascular cells without LIF in their culture medium, so we tested SMCs 
and endothelial cells markers in the VPCs which had migrated. The results excluded the effects 




4.3 The mechanism underlying CCL2 and CXCL1 induced 
VPC migration  
As the above results show, CCL2 and CXCL1 contribute to VPC migration equally, so we 
wanted to further investigate possible interactions between the two chemokines. At 
inflammatory sites, more than one chemokine takes an effect and they may cooperate with 
others to activate subsequent downstream signalling events. Many studies have reported 
synergistic effects of chemokines in leukocyte recruitment and migration, which enhance 
inflammation both in vitro and in vivo. For example, CXCL6 acts with CCL2 and regakine-1 
acts IL-8 to induce neutrophil mobilisation synergistically (Gijsbers et al., 2005; Gouwy, Struyf, 
Catusse, Proost, & Van Damme, 2004); and the co-injection of CXCL10 with CCL5 
significantly enhances T lymphocytes recruitment in vivo (Stanford & Issekutz, 2003). However, 
in our study, simultaneous depletion of two chemokines CCL2 and CXCL1 in SMC-conditioned 
medium did not further inhibit VPC migration when compared to inhibition of a single 
chemokine, thus indicating that there is no additive effect on VPC migration due to CCL2 
acting with CXCL1.  
To ensure some fundamental activities are carried out in vivo, redundancy is an important 
characteristic of many cell signalling pathways, particularly in chemokine and chemokine 
receptor activity (Mantovani, 1999). This redundancy is present in several forms. Chemokine 
receptors expressed on leukocytes usually bind to multiple chemokines to produce the same 
response. For example MCP-1, 2, and 3 can similarly bind to CCR2 on monocytes and activated 
T lymphocytes  and NK cells (Campbell et al., 2001) and both IL-8 and CXCL1 bind to CXCR2 
on neutrophils (White et al., 1998). This also explains why chemokine receptor knockout mice 
do not always have the same phenotype as mice in which one of the corresponding chemokines 
was knocked out (Boring et al., 1997; Gu et al., 2000). For this reason, in order to precisely 
study the functional roles of CCL2 and CXCL1 in vivo, we chose CCL2
-/- 
mice and applied 








A single cell can also produce many different chemokines in response to a single stimulus. 
Homocysteine induces human aortic endothelial cells to release both MCP-1 and IL-8 (Poddar, 
Sivasubramanian, DiBello, Robinson, & Jacobsen, 2001), and enriched monocytes stimulate 
HUVEC to produce both IL-8 and MCP-1 (Lukacs et al., 1995). Both MCP-1 and MIP-1β were 
strongly expressed on macrophages in multiple sclerosis lesions (Simpson, Newcombe, Cuzner, 
& Woodroofe, 1998). As mentioned previously, we also found that several chemokines were 
released from proliferating SMCs, such as CCL2 and CXCL1 which confirmed this redundant 
chemokine production. 
In addition, there is redundancy in that target cells can be activated in the same way by multiple 
chemokines, for example the CXCR3 ligands CXCL9 and CXCL10 play a redundant role in 
mediating obliterative bronchiolitis in mice (Medoff et al., 2006) and both CCR7 and CXCR4 
contribute to B cell homing to lymph nodes (Okada et al., 2002). In the present study, depletion 
of either CCL2 or CXCL1 partially inhibits VPCs migration, but treatment with each individual 
chemokine fails to stimulate VPCs to release the other. Thus, we conclude that after the loss of 
one chemokine, the reduced induction of VPCs migration is not compensated for by the other 
chemokine. Simultaneous depletion of both chemokines did not further inhibit VPC migration 
when compared to inhibition of a single chemokine. Taken together, the effects of CCL2 and 
CXCL1 are neither cumulative nor redundant in the mediation of VPCs migration. There may 
also be additional factors in SMC conditioned medium which play a role in inducing VPC 
migration as the migratory ability was not completely abolished on depletion of both 
chemokines. Further experiments are required to determine what other chemotactic factors 
would additionally effect VPC migration. 
As many reports have shown, CCL2/CCR2 and CXCL1/CXCR2 signal transduction mediates 
recruitment of neutrophils, monocytes or macrophages into inflammatory sites during 
progression of various diseases (Boisvert et al., 2006; Boring et al., 1998; J. Dawson, Miltz, Mir, 
& Wiessner, 2003; Ritzman et al., 2010; Shea-Donohue et al., 2008).  Most studies report the 
expression of CCR2 and CXCR2 on inflammatory cells, such as monocytes/macrophages (Lei 




T lymphocytes (Lippert, Zachmann, Henz, & Neumann, 2004; Sebastiani et al., 2001). Several 
studies have also demonstrated that CCR2 is present on vascular wall cells. CCR2 was detected 
on human umbilical cord vein ECs and found to mediate a role for CCL2 in endothelial wound 
repair (K. S. Weber, Nelson, Grone, & Weber, 1999) and angiogenesis (Salcedo et al., 2000). 
CCR2 was also found to be activated in response to CCL2 in rat aortic smooth muscle cells and 
to alter SMC function in age-related arterial remodelling (Spinetti et al., 2004). CCR2 has also 
been identified on human saphenous vein SMCs where it mediates the induction of vein graft 
thickening by CCL2 (Schepers et al., 2006). In contrast, there are fewer studies into the 
expression of CXCR2 on vascular cells. CXCR2 has been found on human intestinal 
microvascular endothelial cells and umbilical vein endothelial cells and to induce angiogenic 
events, including endothelial cell proliferation and migration in response to CXCL8 
(Heidemann et al., 2003; A. Li, Dubey, Varney, & Singh, 2002). IL-8 increased both CXCR2-
expressing human and mouse endothelial monolayer permeability, to induce vascular leakage-
related disease (Gavard et al., 2009). Interestingly, a study detected CXCR2 in intima/media 
layers of the coronary artery, which mediated IL-8-downregulation of VCAM-1 production by 
SMC (Hastings, Feaver, Lee, Wamhoff, & Blackman, 2009). Therefore, in this case, we are not 
able to exclude that other cells which express CCR2 or CXCR2 in the vessel wall, such as 
migrated endothelial cells.  However, as most endothelial cells were detached during wire injury 
and the VPCs possess the higher capacity of migration into the neointima than SMCs, we can 
deduce that most cells expressing CCR2 and CXCR2 in our data are VPCs. 
 
In our study, we found that basal levels of CCR2 and CXCR2 expression were much lower on 
VPCs in comparison to macrophages, potentially due to their quiescent status in conditions 
without stimuli. However, following treatment with SMC conditioned medium, both gene and 
protein levels of the receptors were significantly up-regulated. The ability of VPCs to migrate 
after CCR2 and CXCR2 genes were permanently silenced by shRNA was significantly reduced. 
Furthermore, the application of antagonists of each chemokine markedly abrogated induction 




the first evidence of expression of CCR2 and CXCR2 on vascular progenitor cells in response to 
SMC-derived soluble factors. Together, these results also indicate that SMC-induced VPC 
migration is mediated by both the CCL2/CCR2 and CXCL1/CXCR2 axis.   
To elucidate the mechanism(s) of VPC migration, we studied the roles of the Rho GTPase 
family. Cdc42, Rac1 and RhoA are the main Rho GTPase family members that are known to 
regulate the formation of lamellipodia, filopodia and focal adhesions, respectively, thus 
orchestrating subsequent cell movement (Nobes & Hall, 1999). Some reports have demonstrated 
that chemokines induce cell migration via activation of Rho GTPase family members. RhoA, 
Rac1 and Cdc42 are all activated in the regulation of SDF-1 induced human gastric cancer cells 
and T cell migration (G. Chen et al., 2012; del Pozo, Vicente-Manzanares, Tejedor, Serrador, & 
Sanchez-Madrid, 1999). CXCL12 activates Rac1 during its regulation of lung alveolar epithelial 
cell migration(Ghosh, Makena, Gorantla, Sinclair, & Waters, 2012).  Depletion of Cdc42 in 
dendritic cells resulted in a reduction of cell migratory abilities driven by CCL19, and in 
comparison with WT cells, their velocity decreased 20%, but directionality dropped 40% 
(Lammermann et al., 2009). Inhibiting RhoA activity using a dominant–negative mutant can 
significantly down-regulate CCL19 elicited T cell migration (Rougerie et al., 2013).  
In our study, we found that both Cdc42 and Rac1 in VPCs were activated by either CCL2 or 
CXCL1 via their respective receptors CCR2 and CXCR2. To determine whether Cdc42 and 
Rac1, as other studies have shown, also play roles in CCL2 or CXCL1-induced VPC migration, 
we applied their specific inhibitors in migration assays. The inhibition of either Cdc42 or Rac1 
impaired VPC migration in response to CCL2 or CXCL1. This indicated that both CCL2 and 
CXCL1 promoted VPC migration were mediated by activated Cdc42 and Rac1.  
In contrast, the addition of a RhoA inhibitor did not alter VPC migration driven by SMC 
conditioned medium or CCL2, CXCL1, which revealed that the RhoA signalling pathway is not 
involved in VPC migration.  
Additionally, p38 MAPK, as a stress-activated protein kinase, has been widely reported to be 




human mesenchymal stem cell migration to wounded areas through the CXCL12/CXCR4/p38 
MAPK signalling pathway (Yuan, Sakamoto, Song, & Sato, 2013). p38 phosphorylation is also 
involved in CXCL1-induced leukocyte migration in mice (Cara, Kaur, Forster, McCafferty, & 
Kubes, 2001). Cytokines such as IL-4 and TNF-α can activate stress-activated pathways leading 
to phosphorylation of p38 MAPK, which is dependent on Rac1 and Cdc42 (Wery-Zennaro, 
Zugaza, Letourneur, Bertoglio, & Pierre, 2000).  PAK1, as an established effector of Rac1 and 
Cdc42, mediates tracheal smooth muscle cell migration by activation of the p38 MAPK 
pathway (Dechert et al., 2001). In our study,  p38 phosphorylation was up-regulated in response 
to mouse recombinant CCL2 or CXCL1 and was suppressed by CCL2/CXCL1 knockdown or 
CCR2/CXCR2 inhibition, which indicates that CCL2 and CXCL1 activate p38 phosphorylation 
via CCR2 or CXCR2.  These results suggest that progenitor cell migration is induced by CCL2 
or CXCL1 through the p38 MAPK signalling pathway. We also found that p38 phosphorylation 
was markedly down-regulated by Rac1 inhibition but not inhibition of Cdc42 or RhoA, 
suggesting that progenitor migration is induced via a Rac1/p38 signalling pathway. Although 
the migration assay showed the participation of Cdc42 in SMC-induced progenitor migration, it 
may act through an as yet unidentified signalling pathway, for example, CCL19 activates 
ERK1/2 and JNK, but not p38 phosphorylation in migration of cells in squamous cell carcinoma 
of the head and neck via the PI3K/Cdc42 signalling pathway (Liu et al., 2014; Zhao et al., 2011). 
In addition, FAK, paxillin and vinculin are critical in responding to various extracellular stimuli 
(e.g. chemokines) to regulate cell adhesion molecule structures and the cytoskeleton and to 
process the signalling pathways for cell mobility. It has been reported that CXCL12 can induce 
pro-adhesion of progenitor B cells mediated by FAK phosphorylation (Glodek et al., 2007; Le, 
Honczarenko, Glodek, Ho, & Silberstein, 2005). Suppress of cytokine signalling 3 regulates 
Pro-B cells development through the CXCL12/CXCR4/FAK signalling pathway (Le et al., 
2007). In another study, CXCL8-induced FAK phosphorylation is adhesion-dependent in 
CXCR2-expressing cells but adhesion-independent in CXCR1-expressing cells (Cohen-Hillel et 
al., 2006), and phosphorylated FAK can subsequently activate paxillin which plays an important 




Furthermore, CCL5 was reported to activate T lymphocytes via FAK, paxillin and ZAP-70 
compound (Bacon, Szabo, Yssel, Bolen, & Schall, 1996). MCP-1-induced lymphocyte adhesion 
to endothelial cells regulates vinculin and paxillin expression in lymphocytes (Mullaly, Moyse, 
Nelson, & Murray, 2002). In our study, immunofluorescence staining revealed that SMC-
conditioned medium induced FAK phosphorylation, paxillin and vinculin-regulated VPC 
migration. Further studies could be focused on the interactions between CCR2/CXCR2 and 












Figure 4.1  Schematic illustration of the roles of CCL2 and CXCL1 released from 
SMCs in enhancing VPCs chemotaxis. SMCs release CCL2 and CXCL1 into the medium. 
When VPCs are treated with this SMC-CM, these chemokines bind to their corresponding 
receptors CCR2 and CXCR2 on the VPCs. The GTPases Rac1 and Cdc42 become activated and 
then p38 is phosphorylated via Rac1, finally leading to increased VPC migration. SMC-CM also 
induces expression of cytoskeleton-related proteins paxillin, vinculin and phosphorylated FAK, 





4.4 The role of CCL2 and CXCL1 in VPC migration in vivo 
Reports using different animal models have shown that CCL2 plays an important role in 
neointimal hyperplasia (Egashira et al., 2002; Tanaka, Sata, Hirata, & Nagai, 2003; Usui et al., 
2002). Most studies suggest that CCL2 recruits monocyte/macrophages. In ApoE
-/-
 mice, after 
wire injury, CCL2 was immediately released by SMCs in the vessel wall and this was 
associated with platelets adherence to the denuded endothelium and subsequent mediation of 
monocyte recruitment at  an early stage to induce neointima formation (Schober et al., 2004). In 
another femoral artery ligation model, local infusion of CCL2 significantly increased collateral 
hindlimb flow, which was accompanied by increased infiltration of monocytes, both in the 
perivascular and whole blood system. (van Royen et al., 2003). Furthermore, intramuscular 
transfection of a mutant CCL2 gene in hypercholesterolemic rabbits using a balloon injury 
model, confirmed the facilitative role of CCL2 in monocyte infiltration and restenosis (Mori et 
al., 2002). Other studies have demonstrated that CCL2 enhances SMC migration, proliferation 
and invasion to remodel vessels. Blockage of CCR2 using 7ND-CCL2 gene transfer in ApoE
-/- 
mice diminished vein graft-induced neointima hyperplasia through a direct inhibitory effect on 
SMCs proliferation (Schepers et al., 2006). Increased expression of CCL2 and CCR2 in aged rat 
aorta enhanced migration and invasion of SMCs (Spinetti et al., 2004). All these studies indicate 
that CCL2 is a crucial factor in the development of neointima formation by association with 
different essential factors. 
It is noteworthy that CCL2-mediated neointimal hyperplasia not only formed in hyperlipidemic 
animals (e.g. ApoE
-/-
 mice), but has also been found in animals with normal blood lipid (e.g. 
C57BL/6J mice, Wistar-Kyoto rats, Sprague-Dawley rats and cynomolgus monkeys) (Egashira 
et al., 2002; Furukawa et al., 1999; Usui et al., 2002). For this reason, as well as due to the time- 




 mice, in our study we chose C57BL/6J mice as the 
background of the control and used CCL2
-/-
 mice to validate the role of CCL2 in vascular 




Vascular progenitor cells have previously been identified as playing a role in neointima 
formation (Y. Chen et al., 2013; Hu et al., 2004), in the present study, the immunofluorescence 
staining of wire injury-induced neointima confirmed that after 2 weeks approximately 70% of α-
SMA
+ 
cells and about 10% cells in the neointima were  Sca-1
+ 
cells. We then applied Sca-1
+
 
progenitor cells to the adventitia of wire-injured femoral arteries to confirm the role of CCL2 in 
Sca-1
+
 progenitor cells-induced neointima formation. We found that CCL2 not only enhanced 
VPC migration from the adventitia to the intima in a short time period (3 days) but also 
accelerated neointima formation (in 1-2 weeks) by inducing VPC migration. We demonstrated 
that migrated progenitor cells are an important cellular component of CCL2 mediated neointima 
formation because CCL2 knockout resulted in a lower number of progenitor cells and reduced 
lesion formation. We also identified that the majority of cells contributing to neointima 
formation in our system were not α-SMA
+ 
but express a stem cell marker (Sca-1), which 
indicates that though some VPCs participating in neointima formation differentiate into SMCs, 
most of them retain progenitor cell characteristics as they migrate. This effect was diminished 
by knockout of CCL2 in mice. From the above data, we confirmed other studies’ viewpoints on 
the role of CCL2 in SMCs-contributed neointima formation. Additionally we showed that the 
ratio of α-SMA
+ 
cells to other cells in the  neointima is much lower in VPC seeded arteries than 
control arteries, which indicates that no matter whether these α-SMA
+ 
cells are media-derived 
SMCs or VPC differentiated SMCs, VPC may inhibit SMCs contribution to neointima 
formation by their higher capacity of migration towards the intima and their maintenance of 
stem cell properties.  A possible explanation for the higher migratory ability of the 
explanted/cultured VPCs compared to vascular resident VPCs might be due to the difference 
between culture conditions their original niche and the microenvironment in the vessel wall.  To 
maintain local microenvironment homeostasis in the vessel wall, some inhibitory factors for 
stem cell migration may exist preventing resident VPC from showing as high motility as 
cultured VPCs. Furthermore, based on our experience of culturing VPCs in vitro, they display a 
higher proliferation and migration property only when they are seeded at a high cell density, so 
in vivo, we seeded 1x10
6
 cells outside each injured vessel to maintain their higher migratory 




from the adventitia to the intima where they contribute to lesion formation, but more work 
needs to be done to observe native adventitial cells.  
In addition, as CCL2 takes its effect via CCL2/CCR2 axis, the significantly enhanced 
expression of CCR2 in neointimal cells in VPC seeding group suggests that the participation of 
VPCs in neointima formation may be dependent on CCL2-driven recruitment. However, 
according to previous published studies, monocytes (Han et al., 2000), peripheral EPCs (Spring, 
Schuler, Arnold, Hammerling, & Ganss, 2005) and activated endothelial cells (Stamatovic, 
Keep, Kunkel, & Andjelkovic, 2003; K. S. Weber, P. J. Nelson, et al., 1999) can also express 
CCR2. That is why in our study, after wire injury, 20% of cells were CCR2 positive in both the 
lumen face and the vessel wall of the injured arteries treated with PBS. A possible explanation 
is that injured endothelial cells are activated and peripheral EPCs and monocytes can be 
recruited to the lumen face, additionally, some monocytes also transmigrate into the vessel wall 
which express CCR2. 
Many studies have demonstrated that bone marrow stromal cells are the main source of CCL2, 
which plays important roles in myeloma cell homing (Vande Broek et al., 2003), monocyte 
mobilization (Jung, Mithal, Park, & Miller, 2015), macrophage bone marrow homing (Y. Li et 
al., 2015) and arteriogenesis (Kinnaird et al., 2004). On the other hand, other studies proved that 
CCL2 was released from the vessel wall, by cells such as endothelial cells (Shyy, Hsieh, Usami, 
& Chien, 1994), smooth muscle cells (X. L. Chen et al., 1998) and adventitial macrophages. 
Thus, the cellular source of CCL2 that can contribute to VPC migration in vivo needs to be 
further investigated. 
In our study, through the use of chimeric mouse models, we found that after bone marrow 
transplantation, CCL2 can be detected in the peripheral blood of a CCL2
-/-
 chimeric mouse 
(bone marrow was from WT mouse), where it was originally undetectable. This indicates that 
CCL2 in the blood is released from transplanted bone marrow cells, which confirms the notion 
that CCL2 is bone marrow-derived. However, in a WT chimeric mouse (bone marrow was from 
CCL2
-/-




an even higher increase compared to the CCL2
-/-
 chimeric mouse. This indicates that CCL2 
from non-bone marrow tissues (e.g. SMC) contributes more to systemic CCL2 levels in the 
peripheral blood than in bone marrow. The quantitative data from neointimal lesions of each 
type of chimeric mice showed a consistent increase in neointima area with higher CCL2 levels 
in the blood, which further confirmed that the CCL2 from non-bone marrow tissues-induced 
progenitor cell migration and contribution to neointima formation. Taken together, in the 
present study, we confirm that CCL2 is produced from both bone marrow cells and peripheral 
tissues. Furthermore, we also demonstrate that CCL2 released from non-bone marrow tissues 
(e.g. SMCs) plays a more crucial role in accelerating neointima formation through induction of 
progenitor cell migration from the adventitia to the neointima.  
CXCL1 has been well established as a potent chemoattractant for leukocyte arrest and migration, 
which contributes to several inflammatory diseases (Boisvert et al., 2006; Reutershan et al., 
2006; Zhou et al., 2011). In cardiovascular disease, human endothelial cell-released CXCL1 
induces angiogenesis and blockage of CXCL1, resulting in inhibition of endothelial cell 
migration and proliferation, which further abrogates angiogenesis in vivo (Lo, Lai, Li, & Wu, 
2014; Miyake et al., 2013). The roles CXCL1 plays in neointima formation are distinct in 
different studies. CXCL1 released from activated SMCs or endothelial cells promotes neointima 
formation or atherosclerosis (Furgeson et al., 2010; Zhou et al., 2011). Furthermore, CXCL1 is 
also associated with vascular inflammation, matrix degradation and lipid deposition that leads to 
unstable atherosclerotic lesions (Breland et al., 2008). According to other studies, CXCL1 can 
also mediate circulating endothelial progenitor cells which contributes to re-endothelialisation 
after arterial injury (Hristov et al., 2007). Blockage of CXCL1 delayed endothelium recovery 
and increased neointimal area (Liehn et al., 2004). The underlying mechanism of CXCL1-
related neointima formation is still poorly understood.   
In the present study, the quantification of cells with different markers attracted by local 
administration of CXCL1 in vivo revealed that CXCL1 had a robust chemotactic effect on Sca-
1
+
 cells migration but not on endothelial cells and SMCs. We next attempted to confirm that 






 mouse is not commercially available, we could not perform the neointima formation 
model in them. We therefore applied CXCL1 siRNA to the adventitia of injured femoral arteries 
to create a local silencing of CXCL1 to investigate its effect on VPC migration into arteries. As 
siRNA silencing is transient, we evaluated Sca-1
+ 
progenitor cells migratory ability from 
adventitia to intima over a short time point.  Data from these experiments suggest that 
knockdown of CXCL1 with siRNA may result in a reduction in VPC migration, which indicates 
that CXCL1 may accelerate neointimal development through induction of VPC migration. To 
obtain more robust evidence for the role of CXCL1 in VPC contribution to neointima formation 
this study will be repeated in CXCL1
-/-





4.5 Future work 
4.5.1 The role of chemokines derived from various cell types in VPC 
migration 
In the present study, we demonstrated that once activated by vascular injury, SMCs can release 
chemokines to induce vascular progenitor cell migration and subsequent contribution to 
neointima formation. The scope of our study only enabled us to examine the chemokines which 
were markedly increased in SMC-conditioned medium, though other chemokines may have a 
potent effect on VPCs, despite their expression levels not being significantly up-regulated. 
However, in addition to chemokines, cytokines and growth factors other chemoattractants may 
also participate in VPC migration, thus a proteomic study or ELISA array could be performed 
on SMC conditioned medium to determine other important factors released by SMCs. Aside 
from SMCs, endothelial cells in the intima and other cell types residing in the adventitia can 
also release chemokines after stimulation by a number of factors, which may also become 
important chemoattractants for vascular progenitor cell mobilisation. In this case, it would be of 
great interest to study the effects of other cell types (e.g. endothelial cells) and their released 
chemokines on VPC mobilisation. 
 
4.5.2 Potential interaction between CCR2 and CXCR2 
As previously discussed, CCL2 and CXCL1 in our study showed neither a cumulative nor 
redundant relationship in the mediation of VPCs migration. What is the potential relationship 
between both chemokines and their receptors? Previous studies have found that a heterodimer of 
PF4 and CCL5 augmented CCL5-midated monocyte adhesion on the endothelium (von 
Hundelshausen et al., 2005) . Simultaneous treatment with CCL2 and CCL5 also induced 
CCR2-CCR5 heterodimer formation on the cell membrane, which significantly increased the 
sensitivity of cells response to each chemokine alone (Mellado et al., 2001). In contrast, another 
study demonstrated that the specific ligands of either CCR5 or CCR2 have negative cooperation 




receptor can only interact with a single chemokine at a time (El-Asmar et al., 2005). In fact, 
heterodimerization is a general interaction between distinct chemokines or chemokine receptors, 
and may generate various cascades of events that are antagonistic, synergistic or have new 
unknown effects. These phenomena then increase the complexity of cross talk among different 
signalling pathways. Thus, further studies should be carried out to explore the potential 
heterophilic interactions between CCL2 and CXCL1 or CCR2 and CXCR2, which would be an 
ideal model for understanding the underlying mechanisms of CCL2 and CXCL1’s effects on 
SMC-induced VPC migration. 
4.5.3 Underlying signalling pathways in vivo 
In our study, we elucidated that CCL2 and CXCL1 induce VPC migration via CCR2 
andCXCR2 and subsequently activate Rac1 and the p38 MAPK signalling pathway. However, 
we have not yet confirmed this result in wire injury-induced VPC migration in vivo. To address 
this, VPCs could be modified in three ways and then seeded in the adventitia of wire-injured 
arteries in WT mice to evaluate their migratory ability: 1) Knockdown of either CCR2 or 
CXCR2 on the VPCs to see whether the migration would be downregulated in comparison with 
the WT VPCs. 2) Overexpress dominant-active or -negative mutant of Rac1 in VPCs 
respectively, to compare whether the migration of VPCs with constitutively active Rac1 would 
show a significant increase. 3) Transfect VPCs with constructs encoding dominant-active or -
negative mutants of p38 and test whether overexpression of dominant-active p38 would enhance 
VPC migration. It would be interesting to verify the roles of CCL2/CCR2/Rac1/p38 and 
CXCL1/CXCL2/Rac1/p38 signalling pathways in VPC migration in vivo.   
 
4.5.4 Generation of SMC-specific conditional CCL2/CXCL1 knockout 
mice 
In the present study, we explicitly demonstrated that SMCs induced VPC migration via the 
release of CCL2 and CXCL1 in vitro. Furthermore, we showed a significant decrease of VPC 
contribution to neointima formation in CCL2 knockout mice, then further demonstrated that this 




that peripheral tissues such as endothelial cells in vessel wall can also release CCL2, data from 
the present study do not totally exclude other sources of CCL2. To conclusively assess the role 
of SMC-derived CCL2 in VPC migration and neointima formation, it would be interesting to 
generate a SMC-specific CCL2 conditional knockout mouse by crossing a Myh11-CreERT2 
mouse with a Floxed CCL2 mouse, which are both commercially available. However, as there is 
no commercial Floxed CXCL1 mouse, it would be challenging but more innovative to create a 
Floxed CXCL1 mouse followed by generation of an SMC-specific CXCL1 mouse. 
 
4.5.5 Application of lineage tracing of Sca-1 vascular progenitor cells 
in vivo 
In our study, we utilised an accelerated model for analysing neointima formation by wrapping 
injured arteries with GFP-labelled VPC. There are two reasons why we chose this model: 1) to 
study the role of VPC migration in the early stages of neointima formation; 2) to trace the GFP-
labelled VPC in vivo. However, as this model still lacks direct evidence for native vascular 
progenitor cells contribution to neointima formation, it would be better to trace the native 
vascular progenitor cells in vivo. Furthermore, as previous studies from our group showed 
vascular progenitor cells have high potential to differentiate into SMCs, it is a controversial 
issue as to whether SMCs present in the neointima are VPC-derived or medial SMC-derived 
and the percentage each source contributes to the neointima.It would be more convincing to 
obtain quantitative data on how many cells in neointimal lesions are derived from VPC. For this 
reason, a lineage tracing for progenitor cells in an animal model is essential. Specifically, we 
could use Sca-1-GFP transgenic mice as a control and further create SMC-specific 
CCL2/CXCL1 knockout mice to study the native vascular progenitor cell in SMC-derived 





4.5.6 Design of a CCL2, CXCL1 related drug-coated stent 
As mentioned previously, CCL2 can both induce SMC proliferation and VPC migration to 
facillitate neointima formation. In the future, we could design new drugs to inhibit CCL2 effects 
on angioplasty restenosis. CXCL1 is reported to induce endothelial cells proliferation and 
accelerate re-endothelialisation. From our data, CXCL1 can also induce VPC migration towards 
impaired sites of the vessel wall. Thus, we could incorporate  CXCL1 with factors for VPC EC-
differentiation in new drugs, which will both further enhance endothelium repair by induction of 





It was believed that neointimal formation in response to endothelial injury was predominantly 
caused by the accumulation of inflammatory cells via their recruitment into the 
microenvironment (Galkina & Ley, 2007; Christian Weber, Fraemohs, & Dejana, 2007) and 
also from medial-derived SMCs (Yunhui Cheng et al., 2009; X. Yang et al., 2006). In this study, 
we utilised an accelerated model of in vivo neointima formation by inducing endothelial injury. 
From data generated in non-VPC seeded groups, we found that during the short time period of 
1-2 weeks, very few cells contributed to the spontaneous development of neointimal lesions.  In 
contrast, an obvious neointima was found in VPC seeded groups, which suggests that neointima 
formation is largely generated by VPC migration in the early stage of the model. The objective 
of this model was to show that after wire injury SMCs of the vessel wall are activated and can 
release chemokines able to induce VPC migration from the adventitia to the lumenal side of the 
vessel.  
These findings have two implications. The cells accumulating in neointimal lesions may be 
derived from migration/proliferation of vascular stem cells, which can differentiate into SMC-
like cells, although mononuclear cells and medial SMCs contribute to this process. To obtain 
quantitative data on how many cells in neointimal lesions are derived from progenitor cells, 
lineage tracing for progenitor cells in animal models would be essential. Secondly, a new 
treatment strategy for restenosis could be considered. Current treatments used in the clinic are 
based on inhibition of cell proliferation (Hong et al., 2003; Sousa, Serruys, & Costa, 2003) 
using drugs such as sirolimus. A recent report from our group suggests that sirolimus can 
enhance vascular stem/progenitor cell differentiation into SMCs, but inhibits endothelial 
differentiation (Wong et al., 2013). Our current findings that large numbers of stem/progenitor 
cells are recruited to the intima in response to CCL2 and CXCL1 provide potential to direct cell 
differentiation into the endothelial lineage. In other words, a high number of stem cells exist 
during neointima formation, which may differentiate into endothelial cells if a new drug-coated 











5.1 Journal Articles 
5.1.1 Published  
1) Yu B, Wong MM, Potter CMF, Simpson RML, Karamariti E, Zhang Z, Zeng L, Warren D, 
Hu Y, Wang W, Xu Q. Vascular Stem/Progenitor Cell Migration Induced by SMC-
derived CCL2 and CXCL1 Contributes to Neointima Formation. Stem Cells. 2016 Jun 14. 
doi: 10.1002/stem.2410. 
2) Wong MM, Yin X, Potter CMF, Yu B, Cai H, Di Bernardini E, Xu Q. Overexpression of 
HSP47 augments mouse embryonic stem cell smooth muscle differentiation and 
chemotaxis. PLoS One. 2014 Jan 16;9(1):e86118.  
3) Wong MM, Winkler B, Karamariti E, Wang X, Yu B, Simpson R, Chen T, Margariti A, Xu 
Q. Sirolimus stimulates vascular stem/progenitor cell migration and differentiation into 
smooth muscle cells via epidermal growth factor receptor/extracellular signal-regulated 
kinase/β-catenin signaling pathway. Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2397-
406.  
5.1.2 In preparation 
1) Karamariti E, Zhai C, Yu B, et al. DKK3 stabilizes atherosclerotic plaque via promoting 
vascular progenitor and fibroblast differentiation to smooth muscle cells. (submitted 
manuscript) 
2) Le Bras A, Yu B, Issa Bhaloo S, Hong X, Hu Y, Xu Q. Directed differentiation of stem 
cells into endothelial cells through epigenetic modulation. The implication for vascular 







5.2 Meeting Abstracts 
1) Yu B, Wong MM, Potter C, Hu Y, Wang W, Xu Q. Smooth Muscle Cells Are Crucial 
for Vascular Stem Cells Migration and Vasculogenesis via Keratinocyte Cell-
derived Chemokine. Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral 
Vascular Disease (ATVB | PVD) 2015 Scientific Sessions May 7–9, 2015 , San 
Francisco, Calif.(Oral Presentation) 
2) Yu B, Wong MM, Wang W, Hu Y, Xu Q. Vascular Stem Cell Migration in Response 
to Monocyte Chemoattractant Protein-1 Promotes Neointima Lesion Formation. 
Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 
(ATVB | PVD) 2015 Scientific Sessions May 7–9, 2015, San Francisco, California. 
(Poster Presentation) 
3) Yu B, Wong MM, Potter C, Hu Y, Wang W, Xu Q. Smooth Muscle Cells Are Crucial 
for Vascular Stem Cells Migration and Vasculogenesis via Keratinocyte Cell-
derived Chemokine. American Heart Association Scientific Sessions Best of AHA 
Specialty Conference,  Nov. 7-11, 2015, Orlando, Florida ( Invited Poster Presentation) 
4) Yu B, Wong MM, Potter C, Hu Y, Wang W, Xu Q. Smooth Muscle Cells Are Crucial 
for Vascular Stem Cells Migration and Vasculogenesis via Keratinocyte Cell-
derived Chemokine. 2015 BHF Centre Postgraduate Symposium 2015, King’s college 
London (Oral Presentation) 
5) Yu B, Wong MM, Hu Y, Wang W, Xu Q. Smooth Muscle Cells Induce Vascular 
Progenitor Cell Migration via Chemokine MCP-1. 2013 SEMS Postgraduate 











Abedin, M., Tintut, Y., & Demer, L. L. (2004). Mesenchymal stem cells and the artery wall. Circ 
Res, 95(7), 671-676. doi: 10.1161/01.RES.0000143421.27684.12 
Adams, R. H., Porras, A., Alonso, G., Jones, M., Vintersten, K., Panelli, S., . . . Nebreda, A. R. 
(2000). Essential role of p38alpha MAP kinase in placental but not embryonic 
cardiovascular development. Mol Cell, 6(1), 109-116.  
Akhtar, S., Gremse, F., Kiessling, F., Weber, C., & Schober, A. (2013). CXCL12 promotes the 
stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in 
Apoe-deficient mice. Arterioscler Thromb Vasc Biol, 33(4), 679-686. doi: 
10.1161/ATVBAHA.112.301162 
Alam, R., Stafford, S., Forsythe, P., Harrison, R., Faubion, D., Lett-Brown, M. A., & Grant, J. A. 
(1993). RANTES is a chemotactic and activating factor for human eosinophils. J 
Immunol, 150(8 Pt 1), 3442-3448.  
Alberding, J. P., Baldwin, A. L., Barton, J. K., & Wiley, E. (2005). Effects of pulsation frequency 
and endothelial integrity on enhanced arterial transmural filtration produced by 
pulsatile pressure. Am J Physiol Heart Circ Physiol, 289(2), H931-937. doi: 
10.1152/ajpheart.00775.2004 
Alessandri, G., Girelli, M., Taccagni, G., Colombo, A., Nicosia, R., Caruso, A., . . . Parati, E. (2001). 
Human vasculogenesis ex vivo: embryonal aorta as a tool for isolation of endothelial 
cell progenitors. Lab Invest, 81(6), 875-885.  
Aoi, T., Yae, K., Nakagawa, M., Ichisaka, T., Okita, K., Takahashi, K., . . . Yamanaka, S. (2008). 
Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science, 
321(5889), 699-702. doi: 10.1126/science.1154884 
Armulik, A., Genove, G., & Betsholtz, C. (2011). Pericytes: developmental, physiological, and 
pathological perspectives, problems, and promises. Dev Cell, 21(2), 193-215. doi: 
10.1016/j.devcel.2011.07.001 
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., . . . Isner, J. M. (1997). 
Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275(5302), 
964-967.  
Bacon, K. B., Szabo, M. C., Yssel, H., Bolen, J. B., & Schall, T. J. (1996). RANTES induces tyrosine 
kinase activity of stably complexed p125FAK and ZAP-70 in human T cells. J Exp Med, 
184(3), 873-882.  
Bajpai, V. K., Mistriotis, P., Loh, Y. H., Daley, G. Q., & Andreadis, S. T. (2012). Functional 
vascular smooth muscle cells derived from human induced pluripotent stem cells via 
mesenchymal stem cell intermediates. Cardiovasc Res, 96(3), 391-400. doi: 
10.1093/cvr/cvs253 
Bajwa, A., Wesolowski, R., Patel, A., Saha, P., Ludwinski, F., Smith, A., . . . Modarai, B. (2014). 
Assessment of tissue perfusion in the lower limb: current methods and techniques 
under development. Circ Cardiovasc Imaging, 7(5), 836-843. doi: 
10.1161/CIRCIMAGING.114.002123 
Baker, M. (2009). Why hES cells make teratomas. Nature Reports Stem Cells.  
Barber, C. L., & Iruela-Arispe, M. L. (2006). The ever-elusive endothelial progenitor cell: 
identities, functions and clinical implications. Pediatr Res, 59(4 Pt 2), 26R-32R. doi: 
10.1203/01.pdr.0000203553.46471.18 
Bavry, A. A., & Bhatt, D. L. (2008). Appropriate use of drug-eluting stents: balancing the 
reduction in restenosis with the concern of late thrombosis. Lancet, 371(9630), 2134-
2143. doi: 10.1016/S0140-6736(08)60922-8 
Bazzoni, G., & Dejana, E. (2004). Endothelial cell-to-cell junctions: molecular organization and 
role in vascular homeostasis. Physiol Rev, 84(3), 869-901. doi: 
10.1152/physrev.00035.2003 
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012). Induced pluripotent stem 




Bendeck, M. P., Irvin, C., & Reidy, M. A. (1996). Inhibition of matrix metalloproteinase activity 
inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. 
Circ Res, 78(1), 38-43.  
Bergers, G., & Song, S. (2005). The role of pericytes in blood-vessel formation and maintenance. 
Neuro Oncol, 7(4), 452-464. doi: 10.1215/S1152851705000232 
Bischoff, S. C., Krieger, M., Brunner, T., Rot, A., von Tscharner, V., Baggiolini, M., & Dahinden, C. 
A. (1993). RANTES and related chemokines activate human basophil granulocytes 
through different G protein-coupled receptors. Eur J Immunol, 23(3), 761-767. doi: 
10.1002/eji.1830230329 
Blum, A., Sclarovsky, S., & Shohat, B. (1995). T lymphocyte activation in stable angina pectoris 
and after percutaneous transluminal coronary angioplasty. Circulation, 91(1), 20-22.  
Bochaton-Piallat, M. L., Gabbiani, G., & Pepper, M. S. (1998). Plasminogen activator expression 
in rat arterial smooth muscle cells depends on their phenotype and is modulated by 
cytokines. Circ Res, 82(10), 1086-1093.  
Boisvert, W. A., Rose, D. M., Johnson, K. A., Fuentes, M. E., Lira, S. A., Curtiss, L. K., & 
Terkeltaub, R. A. (2006). Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in 
atherosclerotic lesions plays a central role in macrophage accumulation and lesion 
progression. Am J Pathol, 168(4), 1385-1395.  
Boisvert, W. A., Santiago, R., Curtiss, L. K., & Terkeltaub, R. A. (1998). A leukocyte homologue 
of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in 
atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest, 101(2), 353-363. 
doi: 10.1172/JCI1195 
Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Jr., Broxmeyer, H. E., & Charo, 
I. F. (1997). Impaired monocyte migration and reduced type 1 (Th1) cytokine responses 
in C-C chemokine receptor 2 knockout mice. J Clin Invest, 100(10), 2552-2561. doi: 
10.1172/JCI119798 
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998). Decreased lesion formation in CCR2-/- 
mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 
394(6696), 894-897. doi: 10.1038/29788 
Boureux, A., Vignal, E., Faure, S., & Fort, P. (2007). Evolution of the Rho family of ras-like 
GTPases in eukaryotes. Mol Biol Evol, 24(1), 203-216. doi: 10.1093/molbev/msl145 
Bradley, J. A., Bolton, E. M., & Pedersen, R. A. (2002). Stem cell medicine encounters the 
immune system. Nat Rev Immunol, 2(11), 859-871. doi: 10.1038/nri934 
Braun, J., Kurtz, A., Barutcu, N., Bodo, J., Thiel, A., & Dong, J. (2013). Concerted regulation of 
CD34 and CD105 accompanies mesenchymal stromal cell derivation from human 
adventitial stromal cell. Stem Cells Dev, 22(5), 815-827. doi: 10.1089/scd.2012.0263 
Braunersreuther, V., Steffens, S., Arnaud, C., Pelli, G., Burger, F., Proudfoot, A., & Mach, F. 
(2008). A novel RANTES antagonist prevents progression of established atherosclerotic 
lesions in mice. Arterioscler Thromb Vasc Biol, 28(6), 1090-1096. doi: 
10.1161/ATVBAHA.108.165423 
Breland, U. M., Halvorsen, B., Hol, J., Oie, E., Paulsson-Berne, G., Yndestad, A., . . . Aukrust, P. 
(2008). A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque 
destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol, 28(5), 
1005-1011. doi: 10.1161/ATVBAHA.108.162305 
Bu, D. X., Griffin, G., & Lichtman, A. H. (2011). Mechanisms for the anti-inflammatory effects of 
statins. Curr Opin Lipidol, 22(3), 165-170. doi: 10.1097/MOL.0b013e3283453e41 
Burke, A. P., Kolodgie, F. D., Farb, A., Weber, D., & Virmani, R. (2002). Morphological predictors 
of arterial remodeling in coronary atherosclerosis. Circulation, 105(3), 297-303.  
Bursill, C. A., Channon, K. M., & Greaves, D. R. (2004). The role of chemokines in 
atherosclerosis: recent evidence from experimental models and population genetics. 
Curr Opin Lipidol, 15(2), 145-149.  
Byrne, R. A., Neumann, F. J., Mehilli, J., Pinieck, S., Wolff, B., Tiroch, K., . . . investigators, I.-D. 




patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a 
randomised, open-label trial. Lancet, 381(9865), 461-467. doi: 10.1016/S0140-
6736(12)61964-3 
Cai, H. (2005). NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and 
vascular disease. Circ Res, 96(8), 818-822. doi: 10.1161/01.RES.0000163631.07205.fb 
Campagnolo, P., Cesselli, D., Al Haj Zen, A., Beltrami, A. P., Krankel, N., Katare, R., . . . Madeddu, 
P. (2010). Human adult vena saphena contains perivascular progenitor cells endowed 
with clonogenic and proangiogenic potential. Circulation, 121(15), 1735-1745. doi: 
10.1161/CIRCULATIONAHA.109.899252 
Campagnolo, P., Hong, X., di Bernardini, E., Smyrnias, I., Hu, Y., & Xu, Q. (2015). Resveratrol-
Induced Vascular Progenitor Differentiation towards Endothelial Lineage via MiR-
21/Akt/beta-Catenin Is Protective in Vessel Graft Models. PLoS One, 10(5), e0125122. 
doi: 10.1371/journal.pone.0125122 
Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., . . . Butcher, E. C. 
(2001). Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes 
identified by chemokine receptor expression repertoire. J Immunol, 166(11), 6477-
6482.  
Cara, D. C., Kaur, J., Forster, M., McCafferty, D. M., & Kubes, P. (2001). Role of p38 mitogen-
activated protein kinase in chemokine-induced emigration and chemotaxis in vivo. J 
Immunol, 167(11), 6552-6558.  
Chaabane, C., Otsuka, F., Virmani, R., & Bochaton-Piallat, M. L. (2013). Biological responses in 
stented arteries. Cardiovasc Res, 99(2), 353-363. doi: 10.1093/cvr/cvt115 
Chen, C. W., Okada, M., Proto, J. D., Gao, X., Sekiya, N., Beckman, S. A., . . . Huard, J. (2013). 
Human pericytes for ischemic heart repair. Stem Cells, 31(2), 305-316. doi: 
10.1002/stem.1285 
Chen, G., Chen, S. M., Wang, X., Ding, X. F., Ding, J., & Meng, L. H. (2012). Inhibition of 
chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis 
(CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin 
(mTOR) pathway in human gastric carcinoma cells. J Biol Chem, 287(15), 12132-12141. 
doi: 10.1074/jbc.M111.302299 
Chen, H. C., Appeddu, P. A., Parsons, J. T., Hildebrand, J. D., Schaller, M. D., & Guan, J. L. (1995). 
Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem, 
270(28), 16995-16999.  
Chen, S., & Lechleider, R. J. (2004). Transforming growth factor-beta-induced differentiation of 
smooth muscle from a neural crest stem cell line. Circ Res, 94(9), 1195-1202. doi: 
10.1161/01.RES.0000126897.41658.81 
Chen, X. L., Tummala, P. E., Olbrych, M. T., Alexander, R. W., & Medford, R. M. (1998). 
Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat 
vascular smooth muscle cells. Circ Res, 83(9), 952-959.  
Chen, Y., Wong, M. M., Campagnolo, P., Simpson, R., Winkler, B., Margariti, A., . . . Xu, Q. 
(2013). Adventitial stem cells in vein grafts display multilineage potential that 
contributes to neointimal formation. Arterioscler Thromb Vasc Biol, 33(8), 1844-1851. 
doi: 10.1161/ATVBAHA.113.300902 
Cheng, L., Mantile, G., Pauly, R., Nater, C., Felici, A., Monticone, R., . . . Capogrossi, M. C. (1998). 
Adenovirus-mediated gene transfer of the human tissue inhibitor of 
metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and 
modulates neointimal development in vivo. Circulation, 98(20), 2195-2201.  
Cheng, Y., Liu, X., Yang, J., Lin, Y., Xu, D.-Z., Lu, Q., . . . Zhang, C. (2009). MicroRNA-145, a novel 
smooth muscle cell phenotypic marker and modulator, controls vascular neointimal 
lesion formation. Circ Res, 105(2), 158-166.  
Cheng, Y., Liu, X., Yang, J., Lin, Y., Xu, D. Z., Lu, Q., . . . Zhang, C. (2009). MicroRNA-145, a novel 
smooth muscle cell phenotypic marker and modulator, controls vascular neointimal 




Chien, S. (2007). Mechanotransduction and endothelial cell homeostasis: the wisdom of the 
cell. Am J Physiol Heart Circ Physiol, 292(3), H1209-1224. doi: 
10.1152/ajpheart.01047.2006 
Christopoulos, K. A., & Havlir, D. V. (2013). Overcoming the human immunodeficiency virus 
obstacle course. JAMA Intern Med, 173(14), 1344-1345. doi: 
10.1001/jamainternmed.2013.7943 
Cipollone, F., Marini, M., Fazia, M., Pini, B., Iezzi, A., Reale, M., . . . Mezzetti, A. (2001). Elevated 
circulating levels of monocyte chemoattractant protein-1 in patients with restenosis 
after coronary angioplasty. Arterioscler Thromb Vasc Biol, 21(3), 327-334.  
Cleaver, O., & Melton, D. A. (2003). Endothelial signaling during development. Nat Med, 9(6), 
661-668. doi: 10.1038/nm0603-661 
Cohen-Hillel, E., Mintz, R., Meshel, T., Garty, B. Z., & Ben-Baruch, A. (2009). Cell migration to 
the chemokine CXCL8: paxillin is activated and regulates adhesion and cell motility. Cell 
Mol Life Sci, 66(5), 884-899. doi: 10.1007/s00018-009-8447-5 
Cohen-Hillel, E., Yron, I., Meshel, T., Soria, G., Attal, H., & Ben-Baruch, A. (2006). CXCL8-
induced FAK phosphorylation via CXCR1 and CXCR2: cytoskeleton- and integrin-related 
mechanisms converge with FAK regulatory pathways in a receptor-specific manner. 
Cytokine, 33(1), 1-16. doi: 10.1016/j.cyto.2005.11.006 
Colombo, A., & Sangiorgi, G. (2004). The monocyte: the key in the lock to reduce stent 
hyperplasia? J Am Coll Cardiol, 43(1), 24-26.  
Covas, D. T., Panepucci, R. A., Fontes, A. M., Silva, W. A., Jr., Orellana, M. D., Freitas, M. C., . . . 
Zago, M. A. (2008). Multipotent mesenchymal stromal cells obtained from diverse 
human tissues share functional properties and gene-expression profile with CD146+ 
perivascular cells and fibroblasts. Exp Hematol, 36(5), 642-654. doi: 
10.1016/j.exphem.2007.12.015 
Crisan, M., Yap, S., Casteilla, L., Chen, C. W., Corselli, M., Park, T. S., . . . Peault, B. (2008). A 
perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem 
Cell, 3(3), 301-313. doi: 10.1016/j.stem.2008.07.003 
Cuenda, A., & Rousseau, S. (2007). p38 MAP-kinases pathway regulation, function and role in 
human diseases. Biochim Biophys Acta, 1773(8), 1358-1375. doi: 
10.1016/j.bbamcr.2007.03.010 
Cushing, S. D., Berliner, J. A., Valente, A. J., Territo, M. C., Navab, M., Parhami, F., . . . Fogelman, 
A. M. (1990). Minimally modified low density lipoprotein induces monocyte 
chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl 
Acad Sci U S A, 87(13), 5134-5138.  
da Silva Meirelles, L., Caplan, A. I., & Nardi, N. B. (2008). In search of the in vivo identity of 
mesenchymal stem cells. Stem Cells, 26(9), 2287-2299. doi: 10.1634/stemcells.2007-
1122 
Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C., . . . Serruys, P. W. 
(2007). Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-
eluting stents in routine clinical practice: data from a large two-institutional cohort 
study. Lancet, 369(9562), 667-678. doi: 10.1016/S0140-6736(07)60314-6 
Dawson, J., Miltz, W., Mir, A. K., & Wiessner, C. (2003). Targeting monocyte chemoattractant 
protein-1 signalling in disease. Expert Opin Ther Targets, 7(1), 35-48. doi: 
10.1517/14728222.7.1.35 
Dawson, T. C., Kuziel, W. A., Osahar, T. A., & Maeda, N. (1999). Absence of CC chemokine 
receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis, 
143(1), 205-211.  
Dechert, M. A., Holder, J. M., & Gerthoffer, W. T. (2001). p21-activated kinase 1 participates in 
tracheal smooth muscle cell migration by signaling to p38 Mapk. Am J Physiol Cell 
Physiol, 281(1), C123-132.  
del Pozo, M. A., Vicente-Manzanares, M., Tejedor, R., Serrador, J. M., & Sanchez-Madrid, F. 




cytoskeletal ERM components in T lymphocytes. Eur J Immunol, 29(11), 3609-3620. doi: 
10.1002/(SICI)1521-4141(199911)29:11&#60;3609::AID-IMMU3609&#62;3.0.CO;2-S 
del Rio, A., Perez-Jimenez, R., Liu, R., Roca-Cusachs, P., Fernandez, J. M., & Sheetz, M. P. (2009). 
Stretching single talin rod molecules activates vinculin binding. Science, 323(5914), 
638-641. doi: 10.1126/science.1162912 
Dellavalle, A., Sampaolesi, M., Tonlorenzi, R., Tagliafico, E., Sacchetti, B., Perani, L., . . . Cossu, G. 
(2007). Pericytes of human skeletal muscle are myogenic precursors distinct from 
satellite cells. Nat Cell Biol, 9(3), 255-267. doi: 10.1038/ncb1542 
Deloose, K., Bosiers, M., Callaert, J., Verbist, J., Vermassen, F., Scheinert, D., . . . Peeters, P. 
(2014). Primary stenting is nowadays the golden standard treatment for TASC II A & B 
iliac lesions: The definitive MISAGO 1-year results. J Cardiovasc Surg (Torino).  
Di Bernardini, E., Campagnolo, P., Margariti, A., Zampetaki, A., Karamariti, E., Hu, Y., & Xu, Q. 
(2014). Endothelial lineage differentiation from induced pluripotent stem cells is 
regulated by microRNA-21 and transforming growth factor beta2 (TGF-beta2) 
pathways. J Biol Chem, 289(6), 3383-3393. doi: 10.1074/jbc.M113.495531 
Diacovo, T. G., Roth, S. J., Buccola, J. M., Bainton, D. F., & Springer, T. A. (1996). Neutrophil 
rolling, arrest, and transmigration across activated, surface-adherent platelets via 
sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood, 88(1), 146-
157.  
Doetschman, T. C., Eistetter, H., Katz, M., Schmidt, W., & Kemler, R. (1985). The in vitro 
development of blastocyst-derived embryonic stem cell lines: formation of visceral 
yolk sac, blood islands and myocardium. J Embryol Exp Morphol, 87, 27-45.  
Doherty, M. J., Ashton, B. A., Walsh, S., Beresford, J. N., Grant, M. E., & Canfield, A. E. (1998). 
Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res, 
13(5), 828-838. doi: 10.1359/jbmr.1998.13.5.828 
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., . . . Horwitz, 
E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315-
317. doi: 10.1080/14653240600855905 
Donners, M. M., Daemen, M. J., Cleutjens, K. B., & Heeneman, S. (2003). Inflammation and 
restenosis: implications for therapy. Ann Med, 35(7), 523-531.  
Duda, S. H., Bosiers, M., Lammer, J., Scheinert, D., Zeller, T., Oliva, V., . . . Beregi, J. P. (2006). 
Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the 
superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther, 
13(6), 701-710. doi: 10.1583/05-1704.1 
Duda, S. H., Bosiers, M., Lammer, J., Scheinert, D., Zeller, T., Tielbeek, A., . . . Beregi, J. P. (2005). 
Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery 
disease: the SIROCCO II trial. J Vasc Interv Radiol, 16(3), 331-338. doi: 
10.1097/01.RVI.0000151260.74519.CA 
Duda, S. H., Pusich, B., Richter, G., Landwehr, P., Oliva, V. L., Tielbeek, A., . . . Beregi, J. P. (2002). 
Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery 
disease: six-month results. Circulation, 106(12), 1505-1509.  
Dworacka, M., Winiarska, H., Borowska, M., Abramczyk, M., Bobkiewicz-Kozlowska, T., & 
Dworacki, G. (2007). Pro-atherogenic alterations in T-lymphocyte subpopulations 
related to acute hyperglycaemia in type 2 diabetic patients. Circ J, 71(6), 962-967.  
Eckfeldt, C. E., Mendenhall, E. M., & Verfaillie, C. M. (2005). The molecular repertoire of the 
'almighty' stem cell. Nat Rev Mol Cell Biol, 6(9), 726-737. doi: 10.1038/nrm1713 
Egashira, K., Zhao, Q., Kataoka, C., Ohtani, K., Usui, M., Charo, I. F., . . . Takeshita, A. (2002). 
Importance of monocyte chemoattractant protein-1 pathway in neointimal 
hyperplasia after periarterial injury in mice and monkeys. Circ Res, 90(11), 1167-1172.  
El-Asmar, L., Springael, J. Y., Ballet, S., Andrieu, E. U., Vassart, G., & Parmentier, M. (2005). 
Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol 




Ergun, S., Hohn, H. P., Kilic, N., Singer, B. B., & Tilki, D. (2008). Endothelial and hematopoietic 
progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer 
cells. Stem Cell Rev, 4(3), 169-177. doi: 10.1007/s12015-008-9028-y 
Ergun, S., Tilki, D., Hohn, H. P., Gehling, U., & Kilic, N. (2007). Potential implications of vascular 
wall resident endothelial progenitor cells. Thromb Haemost, 98(5), 930-939.  
Evangelista, V., Manarini, S., Rotondo, S., Martelli, N., Polischuk, R., McGregor, J. L., . . . Cerletti, 
C. (1996). Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: 
evidence of adhesion cascade and cross talk between P-selectin and the beta 2 
integrin CD11b/CD18. Blood, 88(11), 4183-4194.  
Evanko, S. P., Angello, J. C., & Wight, T. N. (1999). Formation of hyaluronan- and versican-rich 
pericellular matrix is required for proliferation and migration of vascular smooth 
muscle cells. Arterioscler Thromb Vasc Biol, 19(4), 1004-1013.  
Evans, M. J., & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from 
mouse embryos. Nature, 292(5819), 154-156.  
Evers, E. E., Zondag, G. C., Malliri, A., Price, L. S., ten Klooster, J. P., van der Kammen, R. A., & 
Collard, J. G. (2000). Rho family proteins in cell adhesion and cell migration. Eur J 
Cancer, 36(10), 1269-1274.  
Fabunmi, R. P., Baker, A. H., Murray, E. J., Booth, R. F., & Newby, A. C. (1996). Divergent 
regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue 
inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. 
Biochem J, 315 ( Pt 1), 335-342.  
Fakhrejahani, E., & Toi, M. (2012). Tumor angiogenesis: pericytes and maturation are not to be 
ignored. J Oncol, 2012, 261750. doi: 10.1155/2012/261750 
Farb, A., Burke, A. P., Kolodgie, F. D., & Virmani, R. (2003). Pathological mechanisms of fatal 
late coronary stent thrombosis in humans. Circulation, 108(14), 1701-1706. doi: 
10.1161/01.CIR.0000091115.05480.B0 
Farb, A., Sangiorgi, G., Carter, A. J., Walley, V. M., Edwards, W. D., Schwartz, R. S., & Virmani, R. 
(1999). Pathology of acute and chronic coronary stenting in humans. Circulation, 99(1), 
44-52.  
Farrington-Rock, C., Crofts, N. J., Doherty, M. J., Ashton, B. A., Griffin-Jones, C., & Canfield, A. E. 
(2004). Chondrogenic and adipogenic potential of microvascular pericytes. Circulation, 
110(15), 2226-2232. doi: 10.1161/01.CIR.0000144457.55518.E5 
Feng, J., Mantesso, A., De Bari, C., Nishiyama, A., & Sharpe, P. T. (2011). Dual origin of 
mesenchymal stem cells contributing to organ growth and repair. Proc Natl Acad Sci U 
S A, 108(16), 6503-6508. doi: 10.1073/pnas.1015449108 
Ferns, G. A., Konneh, M., Rutherford, C., Woolaghan, E., & Anggard, E. E. (1995). Hyaluronan 
(HYAL-BV 5200) inhibits neo-intimal macrophage influx after balloon-catheter induced 
injury in the cholesterol-fed rabbit. Atherosclerosis, 114(2), 157-164.  
Finn, A. V., Joner, M., Nakazawa, G., Kolodgie, F., Newell, J., John, M. C., . . . Virmani, R. (2007). 
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a 
marker of endothelialization. Circulation, 115(18), 2435-2441. doi: 
10.1161/CIRCULATIONAHA.107.693739 
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285(21), 1182-
1186. doi: 10.1056/NEJM197111182852108 
Fonseca, A. V., Freund, D., Bornhauser, M., & Corbeil, D. (2010). Polarization and migration of 
hematopoietic stem and progenitor cells rely on the RhoA/ROCK I pathway and an 
active reorganization of the microtubule network. J Biol Chem, 285(41), 31661-31671. 
doi: 10.1074/jbc.M110.145037 
Forough, R., Koyama, N., Hasenstab, D., Lea, H., Clowes, M., Nikkari, S. T., & Clowes, A. W. 
(1996). Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits 
vascular smooth muscle cell functions in vitro and in vivo. Circ Res, 79(4), 812-820.  
Fukata, M., Nakagawa, M., & Kaibuchi, K. (2003). Roles of Rho-family GTPases in cell 




Fukuda, D., Shimada, K., Tanaka, A., Kawarabayashi, T., Yoshiyama, M., & Yoshikawa, J. (2004). 
Circulating monocytes and in-stent neointima after coronary stent implantation. J Am 
Coll Cardiol, 43(1), 18-23.  
Furgeson, S. B., Simpson, P. A., Park, I., Vanputten, V., Horita, H., Kontos, C. D., . . . Weiser-
Evans, M. C. (2010). Inactivation of the tumour suppressor, PTEN, in smooth muscle 
promotes a pro-inflammatory phenotype and enhances neointima formation. 
Cardiovasc Res, 86(2), 274-282. doi: 10.1093/cvr/cvp425 
Furman, M. I., Benoit, S. E., Barnard, M. R., Valeri, C. R., Borbone, M. L., Becker, R. C., . . . 
Michelson, A. D. (1998). Increased platelet reactivity and circulating monocyte-platelet 
aggregates in patients with stable coronary artery disease. J Am Coll Cardiol, 31(2), 
352-358.  
Furukawa, Y., Matsumori, A., Ohashi, N., Shioi, T., Ono, K., Harada, A., . . . Sasayama, S. (1999). 
Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating 
factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res, 
84(3), 306-314.  
Fuster, V., Badimon, J. J., & Badimon, L. (1992). Clinical-pathological correlations of coronary 
disease progression and regression. Circulation, 86(6 Suppl), III1-11.  
Galisteo, M. L., Yang, Y., Urena, J., & Schlessinger, J. (2006). Activation of the nonreceptor 
protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A, 
103(26), 9796-9801. doi: 10.1073/pnas.0603714103 
Galkina, E., & Ley, K. (2007). Vascular adhesion molecules in atherosclerosis. Arterioscler 
Thromb Vasc Biol, 27(11), 2292-2301.  
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., . . . Badimon, J. J. 
(1999). Inhibition of intimal thickening after balloon angioplasty in porcine coronary 
arteries by targeting regulators of the cell cycle. Circulation, 99(16), 2164-2170.  
Gavard, J., Hou, X., Qu, Y., Masedunskas, A., Martin, D., Weigert, R., . . . Gutkind, J. S. (2009). A 
role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and 
chronic vascular permeability. Mol Cell Biol, 29(9), 2469-2480. doi: 
10.1128/MCB.01304-08 
Gerhardt, H., & Betsholtz, C. (2003). Endothelial-pericyte interactions in angiogenesis. Cell 
Tissue Res, 314(1), 15-23. doi: 10.1007/s00441-003-0745-x 
Gerszten, R. E., Garcia-Zepeda, E. A., Lim, Y. C., Yoshida, M., Ding, H. A., Gimbrone, M. A., Jr., . . . 
Rosenzweig, A. (1999). MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular 
endothelium under flow conditions. Nature, 398(6729), 718-723. doi: 10.1038/19546 
Ghosh, M. C., Makena, P. S., Gorantla, V., Sinclair, S. E., & Waters, C. M. (2012). CXCR4 
regulates migration of lung alveolar epithelial cells through activation of Rac1 and 
matrix metalloproteinase-2. Am J Physiol Lung Cell Mol Physiol, 302(9), L846-856. doi: 
10.1152/ajplung.00321.2011 
Gijsbers, K., Gouwy, M., Struyf, S., Wuyts, A., Proost, P., Opdenakker, G., . . . Van Damme, J. 
(2005). GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in 
neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. 
Exp Cell Res, 303(2), 331-342. doi: 10.1016/j.yexcr.2004.09.027 
Ginis, I., Luo, Y., Miura, T., Thies, S., Brandenberger, R., Gerecht-Nir, S., . . . Rao, M. S. (2004). 
Differences between human and mouse embryonic stem cells. Dev Biol, 269(2), 360-
380. doi: 10.1016/j.ydbio.2003.12.034 
Glass, C. K., & Witztum, J. L. (2001). Atherosclerosis. the road ahead. Cell, 104(4), 503-516.  
Glodek, A. M., Le, Y., Dykxhoorn, D. M., Park, S. Y., Mostoslavsky, G., Mulligan, R., . . . 
Silberstein, L. E. (2007). Focal adhesion kinase is required for CXCL12-induced 
chemotactic and pro-adhesive responses in hematopoietic precursor cells. Leukemia, 
21(8), 1723-1732. doi: 10.1038/sj.leu.2404769 
Gouwy, M., Struyf, S., Catusse, J., Proost, P., & Van Damme, J. (2004). Synergy between 
proinflammatory ligands of G protein-coupled receptors in neutrophil activation and 




Gradus-Pizlo, I., Bigelow, B., Mahomed, Y., Sawada, S. G., Rieger, K., & Feigenbaum, H. (2003). 
Left anterior descending coronary artery wall thickness measured by high-frequency 
transthoracic and epicardial echocardiography includes adventitia. Am J Cardiol, 91(1), 
27-32.  
Grewe, P. H., Deneke, T., Machraoui, A., Barmeyer, J., & Muller, K. M. (2000). Acute and 
chronic tissue response to coronary stent implantation: pathologic findings in human 
specimen. J Am Coll Cardiol, 35(1), 157-163.  
Grudzinska, M. K., Kurzejamska, E., Bojakowski, K., Soin, J., Lehmann, M. H., Reinecke, H., . . . 
Religa, P. (2013). Monocyte chemoattractant protein 1-mediated migration of 
mesenchymal stem cells is a source of intimal hyperplasia. Arterioscler Thromb Vasc 
Biol, 33(6), 1271-1279. doi: 10.1161/ATVBAHA.112.300773 
Gu, L., Tseng, S., Horner, R. M., Tam, C., Loda, M., & Rollins, B. J. (2000). Control of TH2 
polarization by the chemokine monocyte chemoattractant protein-1. Nature, 
404(6776), 407-411. doi: 10.1038/35006097 
Gudi, S., Huvar, I., White, C. R., McKnight, N. L., Dusserre, N., Boss, G. R., & Frangos, J. A. (2003). 
Rapid activation of Ras by fluid flow is mediated by Galpha(q) and Gbetagamma 
subunits of heterotrimeric G proteins in human endothelial cells. Arterioscler Thromb 
Vasc Biol, 23(6), 994-1000. doi: 10.1161/01.ATV.0000073314.51987.84 
Guo, X., Stice, S. L., Boyd, N. L., & Chen, S. Y. (2013). A novel in vitro model system for smooth 
muscle differentiation from human embryonic stem cell-derived mesenchymal cells. 
Am J Physiol Cell Physiol, 304(4), C289-298. doi: 10.1152/ajpcell.00298.2012 
Gutterman, D. D. (1999). Adventitia-dependent influences on vascular function. Am J Physiol, 
277(4 Pt 2), H1265-1272.  
Haghnegahdar, H., Du, J., Wang, D., Strieter, R. M., Burdick, M. D., Nanney, L. B., . . . Richmond, 
A. (2000). The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. 
J Leukoc Biol, 67(1), 53-62.  
Hahn, C., & Schwartz, M. A. (2009). Mechanotransduction in vascular physiology and 
atherogenesis. Nat Rev Mol Cell Biol, 10(1), 53-62. doi: 10.1038/nrm2596 
Han, K. H., Chang, M. K., Boullier, A., Green, S. R., Li, A., Glass, C. K., & Quehenberger, O. (2000). 
Oxidized LDL reduces monocyte CCR2 expression through pathways involving 
peroxisome proliferator-activated receptor gamma. J Clin Invest, 106(6), 793-802. doi: 
10.1172/JCI10052 
Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C., Wernig, M., . . . Jaenisch, R. 
(2008). Direct reprogramming of terminally differentiated mature B lymphocytes to 
pluripotency. Cell, 133(2), 250-264. doi: 10.1016/j.cell.2008.03.028 
Hao, H., Ropraz, P., Verin, V., Camenzind, E., Geinoz, A., Pepper, M. S., . . . Bochaton-Piallat, M. 
L. (2002). Heterogeneity of smooth muscle cell populations cultured from pig coronary 
artery. Arterioscler Thromb Vasc Biol, 22(7), 1093-1099.  
Hastings, N. E., Feaver, R. E., Lee, M. Y., Wamhoff, B. R., & Blackman, B. R. (2009). Human IL-8 
regulates smooth muscle cell VCAM-1 expression in response to endothelial cells 
exposed to atheroprone flow. Arterioscler Thromb Vasc Biol, 29(5), 725-731. doi: 
10.1161/ATVBAHA.109.184382 
Haurani, M. J., & Pagano, P. J. (2007). Adventitial fibroblast reactive oxygen species as 
autacrine and paracrine mediators of remodeling: bellwether for vascular disease? 
Cardiovasc Res, 75(4), 679-689. doi: 10.1016/j.cardiores.2007.06.016 
Heasman, S. J., & Ridley, A. J. (2008). Mammalian Rho GTPases: new insights into their 
functions from in vivo studies. Nat Rev Mol Cell Biol, 9(9), 690-701. doi: 
10.1038/nrm2476 
Hedges, J. C., Dechert, M. A., Yamboliev, I. A., Martin, J. L., Hickey, E., Weber, L. A., & 
Gerthoffer, W. T. (1999). A role for p38(MAPK)/HSP27 pathway in smooth muscle cell 
migration. J Biol Chem, 274(34), 24211-24219.  
Heidemann, J., Ogawa, H., Dwinell, M. B., Rafiee, P., Maaser, C., Gockel, H. R., . . . Binion, D. G. 




endothelial cells are mediated by CXCR2. J Biol Chem, 278(10), 8508-8515. doi: 
10.1074/jbc.M208231200 
Heinrich, J., Schulte, H., Schonfeld, R., Kohler, E., & Assmann, G. (1995). Association of 
variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary 
and peripheral arteries and those arteries supplying the brain. Thromb Haemost, 73(3), 
374-379.  
Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., & Betsholtz, C. (1999). Role of PDGF-B and 
PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during 
embryonic blood vessel formation in the mouse. Development, 126(14), 3047-3055.  
Hoffmann, R., Mintz, G. S., Dussaillant, G. R., Popma, J. J., Pichard, A. D., Satler, L. F., . . . Leon, 
M. B. (1996). Patterns and mechanisms of in-stent restenosis. A serial intravascular 
ultrasound study. Circulation, 94(6), 1247-1254.  
Holifield, B., Helgason, T., Jemelka, S., Taylor, A., Navran, S., Allen, J., & Seidel, C. (1996). 
Differentiated vascular myocytes: are they involved in neointimal formation? J Clin 
Invest, 97(3), 814-825. doi: 10.1172/JCI118481 
Holmes, D. R., Jr., Vlietstra, R. E., Smith, H. C., Vetrovec, G. W., Kent, K. M., Cowley, M. J., . . . et 
al. (1984). Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a 
report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J 
Cardiol, 53(12), 77C-81C.  
Hong, M.-K., Mintz, G. S., Lee, C. W., Song, J.-M., Han, K.-H., Kang, D.-H., . . . Fearnot, N. E. 
(2003). Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary 
arteries a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-
Eluting Stent Clinical Trial (ASPECT). Circulation, 107(4), 517-520.  
Hopkins, P. N. (2013). Molecular biology of atherosclerosis. Physiol Rev, 93(3), 1317-1542. doi: 
10.1152/physrev.00004.2012 
Hordijk, P. L., Anthony, E., Mul, F. P., Rientsma, R., Oomen, L. C., & Roos, D. (1999). Vascular-
endothelial-cadherin modulates endothelial monolayer permeability. J Cell Sci, 112 ( Pt 
12), 1915-1923.  
Hou, G., Mulholland, D., Gronska, M. A., & Bendeck, M. P. (2000). Type VIII collagen stimulates 
smooth muscle cell migration and matrix metalloproteinase synthesis after arterial 
injury. Am J Pathol, 156(2), 467-476. doi: 10.1016/S0002-9440(10)64751-7 
Hristov, M., Zernecke, A., Bidzhekov, K., Liehn, E. A., Shagdarsuren, E., Ludwig, A., & Weber, C. 
(2007). Importance of CXC chemokine receptor 2 in the homing of human peripheral 
blood endothelial progenitor cells to sites of arterial injury. Circ Res, 100(4), 590-597. 
doi: 10.1161/01.RES.0000259043.42571.68 
Hu, Y., Davison, F., Ludewig, B., Erdel, M., Mayr, M., Url, M., . . . Xu, Q. (2002). Smooth muscle 
cells in transplant atherosclerotic lesions are originated from recipients, but not bone 
marrow progenitor cells. Circulation, 106(14), 1834-1839.  
Hu, Y., Mayr, M., Metzler, B., Erdel, M., Davison, F., & Xu, Q. (2002). Both donor and recipient 
origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res, 91(7), e13-
20.  
Hu, Y., & Xu, Q. (2011). Adventitial biology: differentiation and function. Arterioscler Thromb 
Vasc Biol, 31(7), 1523-1529. doi: 10.1161/ATVBAHA.110.221176 
Hu, Y., Zhang, Z., Torsney, E., Afzal, A. R., Davison, F., Metzler, B., & Xu, Q. (2004). Abundant 
progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-
deficient mice. J Clin Invest, 113(9), 1258-1265. doi: 10.1172/JCI19628 
Huo, Y., Weber, C., Forlow, S. B., Sperandio, M., Thatte, J., Mack, M., . . . Ley, K. (2001). The 
chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest 
on early atherosclerotic endothelium. J Clin Invest, 108(9), 1307-1314. doi: 
10.1172/JCI12877 
Iakovou, I., Schmidt, T., Bonizzoni, E., Ge, L., Sangiorgi, G. M., Stankovic, G., . . . Colombo, A. 
(2005). Incidence, predictors, and outcome of thrombosis after successful implantation 




Jabs, A., Gobel, S., Wenzel, P., Kleschyov, A. L., Hortmann, M., Oelze, M., . . . Munzel, T. (2008). 
Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide 
adenosine dinucleotide phosphate oxidase-dependent superoxide production and 
decreased vascular nitric oxide formation. J Am Coll Cardiol, 51(22), 2130-2138. doi: 
10.1016/j.jacc.2008.01.058 
Jimenez, J. M., & Davies, P. F. (2009). Hemodynamically driven stent strut design. Ann Biomed 
Eng, 37(8), 1483-1494. doi: 10.1007/s10439-009-9719-9 
Johnson, R. C., Leopold, J. A., & Loscalzo, J. (2006). Vascular calcification: pathobiological 
mechanisms and clinical implications. Circ Res, 99(10), 1044-1059. doi: 
10.1161/01.RES.0000249379.55535.21 
Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., . . . Virmani, R. (2006). 
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J 
Am Coll Cardiol, 48(1), 193-202. doi: 10.1016/j.jacc.2006.03.042 
Juchem, G., Weiss, D. R., Gansera, B., Kemkes, B. M., Mueller-Hoecker, J., & Nees, S. (2010). 
Pericytes in the macrovascular intima: possible physiological and pathogenetic impact. 
Am J Physiol Heart Circ Physiol, 298(3), H754-770. doi: 10.1152/ajpheart.00343.2009 
Jude, E. B., Oyibo, S. O., Chalmers, N., & Boulton, A. J. (2001). Peripheral arterial disease in 
diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes 
Care, 24(8), 1433-1437.  
Jung, H., Mithal, D. S., Park, J. E., & Miller, R. J. (2015). Localized CCR2 Activation in the Bone 
Marrow Niche Mobilizes Monocytes by Desensitizing CXCR4. PLoS One, 10(6), 
e0128387. doi: 10.1371/journal.pone.0128387 
Kane, N. M., Meloni, M., Spencer, H. L., Craig, M. A., Strehl, R., Milligan, G., . . . Baker, A. H. 
(2010). Derivation of endothelial cells from human embryonic stem cells by directed 
differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler 
Thromb Vasc Biol, 30(7), 1389-1397. doi: 10.1161/ATVBAHA.110.204800 
Katare, R., Riu, F., Mitchell, K., Gubernator, M., Campagnolo, P., Cui, Y., . . . Madeddu, P. (2011). 
Transplantation of human pericyte progenitor cells improves the repair of infarcted 
heart through activation of an angiogenic program involving micro-RNA-132. Circ Res, 
109(8), 894-906. doi: 10.1161/CIRCRESAHA.111.251546 
Keeley, E. C., Boura, J. A., & Grines, C. L. (2003). Primary angioplasty versus intravenous 
thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 
randomised trials. Lancet, 361(9351), 13-20. doi: 10.1016/S0140-6736(03)12113-7 
Kepner, E. M., Yoder, S. M., Oh, E., Kalwat, M. A., Wang, Z., Quilliam, L. A., & Thurmond, D. C. 
(2011). Cool-1/betaPIX functions as a guanine nucleotide exchange factor in the cycling 
of Cdc42 to regulate insulin secretion. Am J Physiol Endocrinol Metab, 301(6), E1072-
1080. doi: 10.1152/ajpendo.00312.2011 
Kim, S., & Iwao, H. (2003). Stress and vascular responses: mitogen-activated protein kinases 
and activator protein-1 as promising therapeutic targets of vascular remodeling. J 
Pharmacol Sci, 91(3), 177-181.  
Kingston, P. A., Sinha, S., David, A., Castro, M. G., Lowenstein, P. R., & Heagerty, A. M. (2001). 
Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta 
type II receptor inhibits luminal loss and constrictive remodeling after coronary 
angioplasty and enhances adventitial collagen deposition. Circulation, 104(21), 2595-
2601.  
Kinnaird, T., Stabile, E., Burnett, M. S., Lee, C. W., Barr, S., Fuchs, S., & Epstein, S. E. (2004). 
Marrow-derived stromal cells express genes encoding a broad spectrum of 
arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through 
paracrine mechanisms. Circ Res, 94(5), 678-685. doi: 
10.1161/01.RES.0000118601.37875.AC 
Klein, D., Hohn, H. P., Kleff, V., Tilki, D., & Ergun, S. (2010). Vascular wall-resident stem cells. 




Klein, D., Weisshardt, P., Kleff, V., Jastrow, H., Jakob, H. G., & Ergun, S. (2011). Vascular wall-
resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells 
and contribute to new vessel maturation. PLoS One, 6(5), e20540. doi: 
10.1371/journal.pone.0020540 
Klein, K. R., Karpinich, N. O., Espenschied, S. T., Willcockson, H. H., Dunworth, W. P., Hoopes, S. 
L., . . . Caron, K. M. (2014). Decoy receptor CXCR7 modulates adrenomedullin-
mediated cardiac and lymphatic vascular development. Dev Cell, 30(5), 528-540. doi: 
10.1016/j.devcel.2014.07.012 
Komatsu, R., Ueda, M., Naruko, T., Kojima, A., & Becker, A. E. (1998). Neointimal tissue 
response at sites of coronary stenting in humans: macroscopic, histological, and 
immunohistochemical analyses. Circulation, 98(3), 224-233.  
Koppara, T., Cheng, Q., Yahagi, K., Mori, H., Sanchez, O. D., Feygin, J., . . . Joner, M. (2015). 
Thrombogenicity and early vascular healing response in metallic biodegradable 
polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv, 8(6), 
e002427. doi: 10.1161/CIRCINTERVENTIONS.115.002427 
Kornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998). In-stent 
restenosis: contributions of inflammatory responses and arterial injury to neointimal 
hyperplasia. J Am Coll Cardiol, 31(1), 224-230.  
Kovacic, J. C., Gupta, R., Lee, A. C., Ma, M., Fang, F., Tolbert, C. N., . . . Boehm, M. (2010). Stat3-
dependent acute Rantes production in vascular smooth muscle cells modulates 
inflammation following arterial injury in mice. J Clin Invest, 120(1), 303-314. doi: 
10.1172/JCI40364 
Krause, M., & Gautreau, A. (2014). Steering cell migration: lamellipodium dynamics and the 
regulation of directional persistence. Nat Rev Mol Cell Biol, 15(9), 577-590. doi: 
10.1038/nrm3861 
Krohn, R., Raffetseder, U., Bot, I., Zernecke, A., Shagdarsuren, E., Liehn, E. A., . . . Weber, C. 
(2007). Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in 
smooth muscle cells and contributes to neointima formation in atherosclerosis-prone 
mice. Circulation, 116(16), 1812-1820. doi: 10.1161/CIRCULATIONAHA.107.708016 
Ku, D. N., Giddens, D. P., Zarins, C. K., & Glagov, S. (1985). Pulsatile flow and atherosclerosis in 
the human carotid bifurcation. Positive correlation between plaque location and low 
oscillating shear stress. Arteriosclerosis, 5(3), 293-302.  
Kurihara, T., & Bravo, R. (1996). Cloning and functional expression of mCCR2, a murine 
receptor for the C-C chemokines JE and FIC. J Biol Chem, 271(20), 11603-11607.  
Lagarkova, M. A., Volchkov, P. Y., Lyakisheva, A. V., Philonenko, E. S., & Kiselev, S. L. (2006). 
Diverse epigenetic profile of novel human embryonic stem cell lines. Cell Cycle, 5(4), 
416-420.  
Lammermann, T., Renkawitz, J., Wu, X., Hirsch, K., Brakebusch, C., & Sixt, M. (2009). Cdc42-
dependent leading edge coordination is essential for interstitial dendritic cell migration. 
Blood, 113(23), 5703-5710. doi: 10.1182/blood-2008-11-191882 
Landry, D. B., Couper, L. L., Bryant, S. R., & Lindner, V. (1997). Activation of the NF-kappa B and 
I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular 
cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol, 
151(4), 1085-1095.  
Le, Y., Honczarenko, M., Glodek, A. M., Ho, D. K., & Silberstein, L. E. (2005). CXC chemokine 
ligand 12-induced focal adhesion kinase activation and segregation into membrane 
domains is modulated by regulator of G protein signaling 1 in pro-B cells. J Immunol, 
174(5), 2582-2590.  
Le, Y., Zhu, B. M., Harley, B., Park, S. Y., Kobayashi, T., Manis, J. P., . . . Silberstein, L. E. (2007). 
SOCS3 protein developmentally regulates the chemokine receptor CXCR4-FAK 





Lee, M. Y., San Martin, A., Mehta, P. K., Dikalova, A. E., Garrido, A. M., Datla, S. R., . . . 
Griendling, K. K. (2009). Mechanisms of vascular smooth muscle NADPH oxidase 1 
(Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc 
Biol, 29(4), 480-487. doi: 10.1161/ATVBAHA.108.181925 
Leeuwen, F. N., Kain, H. E., Kammen, R. A., Michiels, F., Kranenburg, O. W., & Collard, J. G. 
(1997). The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; 
opposing roles for the small GTPases Rac and Rho. J Cell Biol, 139(3), 797-807.  
Lei, Z. B., Zhang, Z., Jing, Q., Qin, Y. W., Pei, G., Cao, B. Z., & Li, X. Y. (2002). OxLDL upregulates 
CXCR2 expression in monocytes via scavenger receptors and activation of p38 
mitogen-activated protein kinase. Cardiovasc Res, 53(2), 524-532.  
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003). IL-8 directly enhanced 
endothelial cell survival, proliferation, and matrix metalloproteinases production and 
regulated angiogenesis. J Immunol, 170(6), 3369-3376.  
Li, A., Dubey, S., Varney, M. L., & Singh, R. K. (2002). Interleukin-8-induced proliferation, 
survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein 
endothelial cells. Microvasc Res, 64(3), 476-481.  
Li, Y., Zheng, Y., Li, T., Wang, Q., Qian, J., Lu, Y., . . . Cai, Z. (2015). Chemokines CCL2, 3, 14 
stimulate macrophage bone marrow homing, proliferation, and polarization in 
multiple myeloma. Oncotarget, 6(27), 24218-24229. doi: 10.18632/oncotarget.4523 
Libby, P., Schwartz, D., Brogi, E., Tanaka, H., & Clinton, S. K. (1992). A cascade model for 
restenosis. A special case of atherosclerosis progression. Circulation, 86(6 Suppl), III47-
52.  
Libby, P., & Simon, D. I. (2001). Inflammation and thrombosis: the clot thickens. Circulation, 
103(13), 1718-1720.  
Liehn, E. A., Schober, A., & Weber, C. (2004). Blockade of keratinocyte-derived chemokine 
inhibits endothelial recovery and enhances plaque formation after arterial injury in 
ApoE-deficient mice. Arterioscler Thromb Vasc Biol, 24(10), 1891-1896. doi: 
10.1161/01.ATV.0000143135.71440.75 
Lin, C. S., Ning, H., Lin, G., & Lue, T. F. (2012). Is CD34 truly a negative marker for mesenchymal 
stromal cells? Cytotherapy, 14(10), 1159-1163. doi: 10.3109/14653249.2012.729817 
Lindner, V., & Collins, T. (1996). Expression of NF-kappa B and I kappa B-alpha by aortic 
endothelium in an arterial injury model. Am J Pathol, 148(2), 427-438.  
Lippert, U., Zachmann, K., Henz, B. M., & Neumann, C. (2004). Human T lymphocytes and mast 
cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2. Exp 
Dermatol, 13(8), 520-525. doi: 10.1111/j.0906-6705.2004.00182.x 
Liu, F. Y., Safdar, J., Li, Z. N., Fang, Q. G., Zhang, X., Xu, Z. F., & Sun, C. F. (2014). CCR7 regulates 
cell migration and invasion through MAPKs in metastatic squamous cell carcinoma of 
head and neck. Int J Oncol, 45(6), 2502-2510. doi: 10.3892/ijo.2014.2674 
Lo, H. M., Lai, T. H., Li, C. H., & Wu, W. B. (2014). TNF-alpha induces CXCL1 chemokine 
expression and release in human vascular endothelial cells in vitro via two distinct 
signaling pathways. Acta Pharmacol Sin, 35(3), 339-350. doi: 10.1038/aps.2013.182 
Lock, F. E., Ryan, K. R., Poulter, N. S., Parsons, M., & Hotchin, N. A. (2012). Differential 
regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One, 7(2), 
e31423. doi: 10.1371/journal.pone.0031423 
Lotzer, K., Dopping, S., Connert, S., Grabner, R., Spanbroek, R., Lemser, B., . . . Habenicht, A. J. 
(2010). Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-
like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor 
NF-kappaB signaling. Arterioscler Thromb Vasc Biol, 30(3), 395-402. doi: 
10.1161/ATVBAHA.109.191395 
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., . . . Plath, K. (2008). 
Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl 




Loyer, X., Potteaux, S., Vion, A. C., Guerin, C. L., Boulkroun, S., Rautou, P. E., . . . Tedgui, A. 
(2014). Inhibition of microRNA-92a prevents endothelial dysfunction and 
atherosclerosis in mice. Circ Res, 114(3), 434-443. doi: 
10.1161/CIRCRESAHA.114.302213 
Lozito, T. P., & Tuan, R. S. (2014). Endothelial and cancer cells interact with mesenchymal stem 
cells via both microparticles and secreted factors. J Cell Mol Med, 18(12), 2372-2384. 
doi: 10.1111/jcmm.12391 
Ludwig, T. E., Levenstein, M. E., Jones, J. M., Berggren, W. T., Mitchen, E. R., Frane, J. L., . . . 
Thomson, J. A. (2006). Derivation of human embryonic stem cells in defined conditions. 
Nat Biotechnol, 24(2), 185-187. doi: 10.1038/nbt1177 
Lukacs, N. W. (2001). Role of chemokines in the pathogenesis of asthma. Nat Rev Immunol, 
1(2), 108-116. doi: 10.1038/35100503 
Lukacs, N. W., Strieter, R. M., Elner, V., Evanoff, H. L., Burdick, M. D., & Kunkel, S. L. (1995). 
Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, 
during monocyte: endothelial cell interactions. Blood, 86(7), 2767-2773.  
Lusis, A. J., Mar, R., & Pajukanta, P. (2004). Genetics of atherosclerosis. Annu Rev Genomics 
Hum Genet, 5, 189-218. doi: 10.1146/annurev.genom.5.061903.175930 
Ma, J., Xue, Y., Liu, W., Yue, C., Bi, F., Xu, J., . . . Chen, Y. (2013). Role of activated Rac1/Cdc42 in 
mediating endothelial cell proliferation and tumor angiogenesis in breast cancer. PLoS 
One, 8(6), e66275. doi: 10.1371/journal.pone.0066275 
Ma, Q., Zhou, Y., Nie, X., Yu, M., Gao, F., Wang, Z., . . . Xu, X. (2012). Rapamycin affects tissue 
plasminogen activator and plasminogen activator inhibitor I expression: a potential 
prothrombotic mechanism of drug-eluting stents. Angiology, 63(5), 330-335. doi: 
10.1177/0003319711418219 
Madi, H. A., Riches, K., Warburton, P., O'Regan, D. J., Turner, N. A., & Porter, K. E. (2009). 
Inherent differences in morphology, proliferation, and migration in saphenous vein 
smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am J 
Physiol Cell Physiol, 297(5), C1307-1317. doi: 10.1152/ajpcell.00608.2008 
Majesky, M. W., Dong, X. R., Hoglund, V., Mahoney, W. M., Jr., & Daum, G. (2011). The 
adventitia: a dynamic interface containing resident progenitor cells. Arterioscler 
Thromb Vasc Biol, 31(7), 1530-1539. doi: 10.1161/ATVBAHA.110.221549 
Majumdar, R., Sixt, M., & Parent, C. A. (2014). New paradigms in the establishment and 
maintenance of gradients during directed cell migration. Curr Opin Cell Biol, 30, 33-40. 
doi: 10.1016/j.ceb.2014.05.010 
Malchinkhuu, E., Sato, K., Horiuchi, Y., Mogi, C., Ohwada, S., Ishiuchi, S., . . . Okajima, F. (2005). 
Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response 
to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene, 
24(44), 6676-6688. doi: 10.1038/sj.onc.1208805 
Manka, D., Chatterjee, T. K., Stoll, L. L., Basford, J. E., Konaniah, E. S., Srinivasan, R., . . . 
Weintraub, N. L. (2014). Transplanted perivascular adipose tissue accelerates injury-
induced neointimal hyperplasia: role of monocyte chemoattractant protein-1. 
Arterioscler Thromb Vasc Biol, 34(8), 1723-1730. doi: 10.1161/ATVBAHA.114.303983 
Mantovani, A. (1999). The chemokine system: redundancy for robust outputs. Immunol Today, 
20(6), 254-257.  
Marfaing-Koka, A., Devergne, O., Gorgone, G., Portier, A., Schall, T. J., Galanaud, P., & Emilie, D. 
(1995). Regulation of the production of the RANTES chemokine by endothelial cells. 
Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J 
Immunol, 154(4), 1870-1878.  
Margariti, A., Winkler, B., Karamariti, E., Zampetaki, A., Tsai, T. N., Baban, D., . . . Xu, Q. (2012). 
Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and 
reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A, 109(34), 




Marx, S. O., Jayaraman, T., Go, L. O., & Marks, A. R. (1995). Rapamycin-FKBP inhibits cell cycle 
regulators of proliferation in vascular smooth muscle cells. Circ Res, 76(3), 412-417.  
Mason, D. P., Kenagy, R. D., Hasenstab, D., Bowen-Pope, D. F., Seifert, R. A., Coats, S., . . . 
Clowes, A. W. (1999). Matrix metalloproteinase-9 overexpression enhances vascular 
smooth muscle cell migration and alters remodeling in the injured rat carotid artery. 
Circ Res, 85(12), 1179-1185.  
Masszi, A., Di Ciano, C., Sirokmany, G., Arthur, W. T., Rotstein, O. D., Wang, J., . . . Kapus, A. 
(2003). Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin 
expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol, 
284(5), F911-924. doi: 10.1152/ajprenal.00183.2002 
Matozaki, T., Nakanishi, H., & Takai, Y. (2000). Small G-protein networks: their crosstalk and 
signal cascades. Cell Signal, 12(8), 515-524.  
Mazighi, M., Pelle, A., Gonzalez, W., Mtairag el, M., Philippe, M., Henin, D., . . . Feldman, L. J. 
(2004). IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J 
Physiol Heart Circ Physiol, 287(2), H866-871. doi: 10.1152/ajpheart.00918.2003 
McFadden, E. P., Stabile, E., Regar, E., Cheneau, E., Ong, A. T., Kinnaird, T., . . . Serruys, P. W. 
(2004). Late thrombosis in drug-eluting coronary stents after discontinuation of 
antiplatelet therapy. Lancet, 364(9444), 1519-1521. doi: 10.1016/S0140-
6736(04)17275-9 
Medoff, B. D., Wain, J. C., Seung, E., Jackobek, R., Means, T. K., Ginns, L. C., . . . Luster, A. D. 
(2006). CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation 
and function. J Immunol, 176(11), 7087-7095.  
Mellado, M., Rodriguez-Frade, J. M., Vila-Coro, A. J., Fernandez, S., Martin de Ana, A., Jones, D. 
R., . . . Martinez, A. C. (2001). Chemokine receptor homo- or heterodimerization 
activates distinct signaling pathways. EMBO J, 20(10), 2497-2507. doi: 
10.1093/emboj/20.10.2497 
Meng, Z., Yan, C., Deng, Q., Gao, D. F., & Niu, X. L. (2013). Curcumin inhibits LPS-induced 
inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-
MAPK/NF-kappaB pathways. Acta Pharmacol Sin, 34(7), 901-911. doi: 
10.1038/aps.2013.24 
Michael, K. E., Dumbauld, D. W., Burns, K. L., Hanks, S. K., & Garcia, A. J. (2009). Focal adhesion 
kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell, 
20(9), 2508-2519. doi: 10.1091/mbc.E08-01-0076 
Michel, J. B., Thaunat, O., Houard, X., Meilhac, O., Caligiuri, G., & Nicoletti, A. (2007). 
Topological determinants and consequences of adventitial responses to arterial wall 
injury. Arterioscler Thromb Vasc Biol, 27(6), 1259-1268. doi: 
10.1161/ATVBAHA.106.137851 
Mickelson, J. K., Lakkis, N. M., Villarreal-Levy, G., Hughes, B. J., & Smith, C. W. (1996). 
Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism 
for recurrent disease? J Am Coll Cardiol, 28(2), 345-353. doi: 10.1016/0735-
1097(96)00164-7 
Missouris, C. G., Buckenham, T., Cappuccio, F. P., & MacGregor, G. A. (1994). Renal artery 
stenosis: a common and important problem in patients with peripheral vascular 
disease. Am J Med, 96(1), 10-14.  
Mitchell, R. N., & Libby, P. (2007). Vascular remodeling in transplant vasculopathy. Circ Res, 
100(7), 967-978. doi: 10.1161/01.RES.0000261982.76892.09 
Mitra, A. K., & Agrawal, D. K. (2006). In stent restenosis: bane of the stent era. J Clin Pathol, 
59(3), 232-239. doi: 10.1136/jcp.2005.025742 
Mitra, S. K., Hanson, D. A., & Schlaepfer, D. D. (2005). Focal adhesion kinase: in command and 
control of cell motility. Nat Rev Mol Cell Biol, 6(1), 56-68. doi: 10.1038/nrm1549 
Mittelstadt, P. R., Salvador, J. M., Fornace, A. J., Jr., & Ashwell, J. D. (2005). Activating p38 




Miyake, M., Goodison, S., Urquidi, V., Gomes Giacoia, E., & Rosser, C. J. (2013). Expression of 
CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor 
and the ERK1/2 and EGF pathways. Lab Invest, 93(7), 768-778. doi: 
10.1038/labinvest.2013.71 
Moreno, P. R., Bernardi, V. H., Lopez-Cuellar, J., Newell, J. B., McMellon, C., Gold, H. K., . . . 
Fallon, J. T. (1996). Macrophage infiltration predicts restenosis after coronary 
intervention in patients with unstable angina. Circulation, 94(12), 3098-3102.  
Mori, E., Komori, K., Yamaoka, T., Tanii, M., Kataoka, C., Takeshita, A., . . . Sugimachi, K. (2002). 
Essential role of monocyte chemoattractant protein-1 in development of restenotic 
changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty 
in hypercholesterolemic rabbits. Circulation, 105(24), 2905-2910.  
Moser, B., & Loetscher, P. (2001). Lymphocyte traffic control by chemokines. Nat Immunol, 
2(2), 123-128. doi: 10.1038/84219 
Mudgett, J. S., Ding, J., Guh-Siesel, L., Chartrain, N. A., Yang, L., Gopal, S., & Shen, M. M. (2000). 
Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. 
Proc Natl Acad Sci U S A, 97(19), 10454-10459. doi: 10.1073/pnas.180316397 
Muldowney, J. A., 3rd, Stringham, J. R., Levy, S. E., Gleaves, L. A., Eren, M., Piana, R. N., & 
Vaughan, D. E. (2007). Antiproliferative agents alter vascular plasminogen activator 
inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. 
Arterioscler Thromb Vasc Biol, 27(2), 400-406. doi: 
10.1161/01.ATV.0000254677.12861.b8 
Mullaly, S. C., Moyse, R. J., Nelson, R. C., & Murray, A. G. (2002). Stable lymphocyte contact 
induces remodeling of endothelial cell matrix receptor complexes. Eur J Immunol, 
32(5), 1493-1501. doi: 10.1002/1521-4141(200205)32:5&lt;1493::AID-
IMMU1493&gt;3.0.CO;2-G 
Nagase, M., & Fujita, T. (2013). Role of Rac1-mineralocorticoid-receptor signalling in renal and 
cardiac disease. Nat Rev Nephrol, 9(2), 86-98. doi: 10.1038/nrneph.2012.282 
Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., . . . et al. (1991). 
Monocyte transmigration induced by modification of low density lipoprotein in 
cocultures of human aortic wall cells is due to induction of monocyte chemotactic 
protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest, 88(6), 
2039-2046. doi: 10.1172/JCI115532 
Navarro-Lopez, F., Francino, A., Serra, A., Enjuto, M., Reverter, J. C., Jimenez de Anta, T., & 
Betriu, A. (2003). [Late T-lymphocyte and monocyte activation in coronary restenosis. 
Evidence for a persistent inflammatory/immune mechanism?]. Rev Esp Cardiol, 56(5), 
465-472.  
Nelken, N. A., Coughlin, S. R., Gordon, D., & Wilcox, J. N. (1991). Monocyte chemoattractant 
protein-1 in human atheromatous plaques. J Clin Invest, 88(4), 1121-1127. doi: 
10.1172/JCI115411 
Nikkari, S. T., Geary, R. L., Hatsukami, T., Ferguson, M., Forough, R., Alpers, C. E., & Clowes, A. 
W. (1996). Expression of collagen, interstitial collagenase, and tissue inhibitor of 
metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol, 148(3), 
777-783.  
Niu, J., Profirovic, J., Pan, H., Vaiskunaite, R., & Voyno-Yasenetskaya, T. (2003). G Protein 
betagamma subunits stimulate p114RhoGEF, a guanine nucleotide exchange factor for 
RhoA and Rac1: regulation of cell shape and reactive oxygen species production. Circ 
Res, 93(9), 848-856. doi: 10.1161/01.RES.0000097607.14733.0C 
Nobes, C. D., & Hall, A. (1995). Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, lamellipodia, and 
filopodia. Cell, 81(1), 53-62.  
Nobes, C. D., & Hall, A. (1999). Rho GTPases control polarity, protrusion, and adhesion during 




Nobuyoshi, M., Kimura, T., Nosaka, H., Mioka, S., Ueno, K., Yokoi, H., . . . Ohishi, H. (1988). 
Restenosis after successful percutaneous transluminal coronary angioplasty: serial 
angiographic follow-up of 229 patients. J Am Coll Cardiol, 12(3), 616-623.  
Nobuyoshi, M., Kimura, T., Ohishi, H., Horiuchi, H., Nosaka, H., Hamasaki, N., . . . Kim, K. (1991). 
Restenosis after percutaneous transluminal coronary angioplasty: pathologic 
observations in 20 patients. J Am Coll Cardiol, 17(2), 433-439.  
Noels, H., Zhou, B., Tilstam, P. V., Theelen, W., Li, X., Pawig, L., . . . Weber, C. (2014). Deficiency 
of endothelial CXCR4 reduces reendothelialization and enhances neointimal 
hyperplasia after vascular injury in atherosclerosis-prone mice. Arterioscler Thromb 
Vasc Biol, 34(6), 1209-1220. doi: 10.1161/ATVBAHA.113.302878 
Nunez, J., Minana, G., Bodi, V., Nunez, E., Sanchis, J., Husser, O., & Llacer, A. (2011). Low 
lymphocyte count and cardiovascular diseases. Curr Med Chem, 18(21), 3226-3233.  
Ohashi, N., Matsumori, A., Furukawa, Y., Ono, K., Okada, M., Iwasaki, A., . . . Sasayama, S. 
(2000). Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after 
vascular injury. Arterioscler Thromb Vasc Biol, 20(12), 2521-2526.  
Okada, T., Ngo, V. N., Ekland, E. H., Forster, R., Lipp, M., Littman, D. R., & Cyster, J. G. (2002). 
Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J Exp 
Med, 196(1), 65-75.  
Oparil, S., Chen, S. J., Chen, Y. F., Durand, J. N., Allen, L., & Thompson, J. A. (1999). Estrogen 
attenuates the adventitial contribution to neointima formation in injured rat carotid 
arteries. Cardiovasc Res, 44(3), 608-614.  
Orr, A. W., Hahn, C., Blackman, B. R., & Schwartz, M. A. (2008). p21-activated kinase signaling 
regulates oxidant-dependent NF-kappa B activation by flow. Circ Res, 103(6), 671-679. 
doi: 10.1161/CIRCRESAHA.108.182097 
Ott, I., Neumann, F. J., Gawaz, M., Schmitt, M., & Schomig, A. (1996). Increased neutrophil-
platelet adhesion in patients with unstable angina. Circulation, 94(6), 1239-1246.  
Owens, G. K., Kumar, M. S., & Wamhoff, B. R. (2004). Molecular regulation of vascular smooth 
muscle cell differentiation in development and disease. Physiol Rev, 84(3), 767-801. 
doi: 10.1152/physrev.00041.2003 
Panoulas, V. F., & Colombo, A. (2014). Interventional cardiology: Outcomes in coronary stent 
trials--1 year is not enough. Nat Rev Cardiol, 11(6), 318-320. doi: 
10.1038/nrcardio.2014.63 
Park, D. W., Park, S. W., Park, K. H., Lee, B. K., Kim, Y. H., Lee, C. W., . . . Park, S. J. (2006). 
Frequency of and risk factors for stent thrombosis after drug-eluting stent 
implantation during long-term follow-up. Am J Cardiol, 98(3), 352-356. doi: 
10.1016/j.amjcard.2006.02.039 
Park, I. H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., . . . Daley, G. Q. (2008). 
Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 
451(7175), 141-146. doi: 10.1038/nature06534 
Pasquinelli, G., Pacilli, A., Alviano, F., Foroni, L., Ricci, F., Valente, S., . . . Paolo Bagnara, G. 
(2010). Multidistrict human mesenchymal vascular cells: pluripotency and stemness 
characteristics. Cytotherapy, 12(3), 275-287. doi: 10.3109/14653241003596679 
Pasquinelli, G., Tazzari, P. L., Vaselli, C., Foroni, L., Buzzi, M., Storci, G., . . . Conte, R. (2007). 
Thoracic aortas from multiorgan donors are suitable for obtaining resident angiogenic 
mesenchymal stromal cells. Stem Cells, 25(7), 1627-1634. doi: 10.1634/stemcells.2006-
0731 
Passman, J. N., Dong, X. R., Wu, S. P., Maguire, C. T., Hogan, K. A., Bautch, V. L., & Majesky, M. 
W. (2008). A sonic hedgehog signaling domain in the arterial adventitia supports 
resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci U S A, 105(27), 
9349-9354. doi: 10.1073/pnas.0711382105 
Pattison, J. M., Nelson, P. J., Huie, P., Sibley, R. K., & Krensky, A. M. (1996). RANTES chemokine 
expression in transplant-associated accelerated atherosclerosis. J Heart Lung 




Peault, B., Rudnicki, M., Torrente, Y., Cossu, G., Tremblay, J. P., Partridge, T., . . . Huard, J. 
(2007). Stem and progenitor cells in skeletal muscle development, maintenance, and 
therapy. Mol Ther, 15(5), 867-877. doi: 10.1038/mt.sj.6300145 
Peeters, W., Hellings, W. E., de Kleijn, D. P., de Vries, J. P., Moll, F. L., Vink, A., & Pasterkamp, G. 
(2009). Carotid atherosclerotic plaques stabilize after stroke: insights into the natural 
process of atherosclerotic plaque stabilization. Arterioscler Thromb Vasc Biol, 29(1), 
128-133. doi: 10.1161/ATVBAHA.108.173658 
Pescatore, L. A., Bonatto, D., Forti, F. L., Sadok, A., Kovacic, H., & Laurindo, F. R. (2012). Protein 
disulfide isomerase is required for platelet-derived growth factor-induced vascular 
smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase 
activation. J Biol Chem, 287(35), 29290-29300. doi: 10.1074/jbc.M112.394551 
Petitclerc, E., Boutaud, A., Prestayko, A., Xu, J., Sado, Y., Ninomiya, Y., . . . Brooks, P. C. (2000). 
New functions for non-collagenous domains of human collagen type IV. Novel integrin 
ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem, 275(11), 8051-
8061.  
Piek, J. J., van der Wal, A. C., Meuwissen, M., Koch, K. T., Chamuleau, S. A., Teeling, P., . . . 
Becker, A. E. (2000). Plaque inflammation in restenotic coronary lesions of patients 
with stable or unstable angina. J Am Coll Cardiol, 35(4), 963-967.  
Piotrowicz, R. S., Hickey, E., & Levin, E. G. (1998). Heat shock protein 27 kDa expression and 
phosphorylation regulates endothelial cell migration. FASEB J, 12(14), 1481-1490.  
Pober, J. S., & Sessa, W. C. (2007). Evolving functions of endothelial cells in inflammation. Nat 
Rev Immunol, 7(10), 803-815. doi: 10.1038/nri2171 
Poddar, R., Sivasubramanian, N., DiBello, P. M., Robinson, K., & Jacobsen, D. W. (2001). 
Homocysteine induces expression and secretion of monocyte chemoattractant 
protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular 
disease. Circulation, 103(22), 2717-2723.  
Potteaux, S., Combadiere, C., Esposito, B., Lecureuil, C., Ait-Oufella, H., Merval, R., . . . Mallat, Z. 
(2006). Role of bone marrow-derived CC-chemokine receptor 5 in the development of 
atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb 
Vasc Biol, 26(8), 1858-1863. doi: 10.1161/01.ATV.0000231527.22762.71 
Proctor, B. M., Jin, X., Lupu, T. S., Muglia, L. J., Semenkovich, C. F., & Muslin, A. J. (2008). 
Requirement for p38 mitogen-activated protein kinase activity in neointima formation 
after vascular injury. Circulation, 118(6), 658-666. doi: 
10.1161/CIRCULATIONAHA.107.734848 
Proudfoot, A. E., Power, C. A., Hoogewerf, A. J., Montjovent, M. O., Borlat, F., Offord, R. E., & 
Wells, T. N. (1996). Extension of recombinant human RANTES by the retention of the 
initiating methionine produces a potent antagonist. J Biol Chem, 271(5), 2599-2603.  
Psaltis, P. J., Puranik, A. S., Spoon, D. B., Chue, C. D., Hoffman, S. J., Witt, T. A., . . . Simari, R. D. 
(2014). Characterization of a resident population of adventitial macrophage progenitor 
cells in postnatal vasculature. Circ Res, 115(3), 364-375. doi: 
10.1161/CIRCRESAHA.115.303299 
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002). Vascular and haematopoietic 
stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer, 2(11), 826-835. 
doi: 10.1038/nrc925 
Raftopoulou, M., & Hall, A. (2004). Cell migration: Rho GTPases lead the way. Dev Biol, 265(1), 
23-32.  
Rakesh, K., & Agrawal, D. K. (2005). Cytokines and growth factors involved in apoptosis and 
proliferation of vascular smooth muscle cells. Int Immunopharmacol, 5(10), 1487-1506. 
doi: 10.1016/j.intimp.2005.05.003 
Reddy, K. B., & Howe, P. H. (1993). Transforming growth factor beta 1-mediated inhibition of 
smooth muscle cell proliferation is associated with a late G1 cell cycle arrest. J Cell 




Regelmann, A. G., Danzl, N. M., Wanjalla, C., & Alexandropoulos, K. (2006). The hematopoietic 
isoform of Cas-Hef1-associated signal transducer regulates chemokine-induced inside-
out signaling and T cell trafficking. Immunity, 25(6), 907-918. doi: 
10.1016/j.immuni.2006.09.014 
Rehman, J., Li, J., Orschell, C. M., & March, K. L. (2003). Peripheral blood "endothelial 
progenitor cells" are derived from monocyte/macrophages and secrete angiogenic 
growth factors. Circulation, 107(8), 1164-1169.  
Reidy, M. A., Fingerle, J., & Lindner, V. (1992). Factors controlling the development of arterial 
lesions after injury. Circulation, 86(6 Suppl), III43-46.  
Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A., & Bongso, A. (2000). Embryonic stem cell 
lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol, 18(4), 
399-404. doi: 10.1038/74447 
Reutershan, J., Morris, M. A., Burcin, T. L., Smith, D. F., Chang, D., Saprito, M. S., & Ley, K. 
(2006). Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the 
lung. J Clin Invest, 116(3), 695-702. doi: 10.1172/JCI27009 
Richards, M., Fong, C. Y., Chan, W. K., Wong, P. C., & Bongso, A. (2002). Human feeders 
support prolonged undifferentiated growth of human inner cell masses and embryonic 
stem cells. Nat Biotechnol, 20(9), 933-936. doi: 10.1038/nbt726 
Richardson, R. M., Marjoram, R. J., Barak, L. S., & Snyderman, R. (2003). Role of the 
cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and 
regulation. J Immunol, 170(6), 2904-2911.  
Ritzman, A. M., Hughes-Hanks, J. M., Blaho, V. A., Wax, L. E., Mitchell, W. J., & Brown, C. R. 
(2010). The chemokine receptor CXCR2 ligand KC (CXCL1) mediates neutrophil 
recruitment and is critical for development of experimental Lyme arthritis and carditis. 
Infect Immun, 78(11), 4593-4600. doi: 10.1128/IAI.00798-10 
Rollins, B. J. (1997). Chemokines. Blood, 90(3), 909-928.  
Rollins, B. J., Yoshimura, T., Leonard, E. J., & Pober, J. S. (1990). Cytokine-activated human 
endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J 
Pathol, 136(6), 1229-1233.  
Rose, J. J., Foley, J. F., Murphy, P. M., & Venkatesan, S. (2004). On the mechanism and 
significance of ligand-induced internalization of human neutrophil chemokine 
receptors CXCR1 and CXCR2. J Biol Chem, 279(23), 24372-24386. doi: 
10.1074/jbc.M401364200 
Ross, R., Glomset, J., & Harker, L. (1977). Response to injury and atherogenesis. Am J Pathol, 
86(3), 675-684.  
Rot, A. (1992). Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol 
Today, 13(8), 291-294. doi: 10.1016/0167-5699(92)90039-A 
Rougerie, P., Largeteau, Q., Megrelis, L., Carrette, F., Lejeune, T., Toffali, L., . . . Delon, J. (2013). 
Fam65b is a new transcriptional target of FOXO1 that regulates RhoA signaling for T 
lymphocyte migration. J Immunol, 190(2), 748-755. doi: 10.4049/jimmunol.1201174 
Rousseau, S., Dolado, I., Beardmore, V., Shpiro, N., Marquez, R., Nebreda, A. R., . . . Cohen, P. 
(2006). CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-
K2-HSP27 pathway. Cell Signal, 18(11), 1897-1905. doi: 10.1016/j.cellsig.2006.02.006 
Rousseau, S., Houle, F., Landry, J., & Huot, J. (1997). p38 MAP kinase activation by vascular 
endothelial growth factor mediates actin reorganization and cell migration in human 
endothelial cells. Oncogene, 15(18), 2169-2177. doi: 10.1038/sj.onc.1201380 
Rudijanto, A. (2007). The role of vascular smooth muscle cells on the pathogenesis of 
atherosclerosis. Acta Med Indones, 39(2), 86-93.  
Rus, H. G., Vlaicu, R., & Niculescu, F. (1996). Interleukin-6 and interleukin-8 protein and gene 
expression in human arterial atherosclerotic wall. Atherosclerosis, 127(2), 263-271.  
Rzucidlo, E. M., Martin, K. A., & Powell, R. J. (2007). Regulation of vascular smooth muscle cell 




Sacco, R. L., Kargman, D. E., Gu, Q., & Zamanillo, M. C. (1995). Race-ethnicity and determinants 
of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke 
Study. Stroke, 26(1), 14-20.  
Saederup, N., Chan, L., Lira, S. A., & Charo, I. F. (2008). Fractalkine deficiency markedly reduces 
macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: 
evidence for independent chemokine functions in atherogenesis. Circulation, 117(13), 
1642-1648. doi: 10.1161/CIRCULATIONAHA.107.743872 
Saiura, A., Sata, M., Hirata, Y., Nagai, R., & Makuuchi, M. (2001). Circulating smooth muscle 
progenitor cells contribute to atherosclerosis. Nat Med, 7(4), 382-383. doi: 
10.1038/86394 
Salcedo, R., Ponce, M. L., Young, H. A., Wasserman, K., Ward, J. M., Kleinman, H. K., . . . 
Murphy, W. J. (2000). Human endothelial cells express CCR2 and respond to MCP-1: 
direct role of MCP-1 in angiogenesis and tumor progression. Blood, 96(1), 34-40.  
Sarafi, M. N., Garcia-Zepeda, E. A., MacLean, J. A., Charo, I. F., & Luster, A. D. (1997). Murine 
monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural 
and functional homologue of human MCP-1. J Exp Med, 185(1), 99-109.  
Sartore, S., Chiavegato, A., Faggin, E., Franch, R., Puato, M., Ausoni, S., & Pauletto, P. (2001). 
Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: 
from innocent bystander to active participant. Circ Res, 89(12), 1111-1121.  
Sata, M. (2003). Circulating vascular progenitor cells contribute to vascular repair, remodeling, 
and lesion formation. Trends Cardiovasc Med, 13(6), 249-253.  
Schall, T. J., Bacon, K., Toy, K. J., & Goeddel, D. V. (1990). Selective attraction of monocytes and 
T lymphocytes of the memory phenotype by cytokine RANTES. Nature, 347(6294), 669-
671. doi: 10.1038/347669a0 
Schall, T. J., & Bacon, K. B. (1994). Chemokines, leukocyte trafficking, and inflammation. Curr 
Opin Immunol, 6(6), 865-873.  
Schepers, A., Eefting, D., Bonta, P. I., Grimbergen, J. M., de Vries, M. R., van Weel, V., . . . Quax, 
P. H. (2006). Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells 
proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler 
Thromb Vasc Biol, 26(9), 2063-2069. doi: 10.1161/01.ATV.0000235694.69719.e2 
Schmidt, A., Ulrich, M., Winkler, B., Klaeffling, C., Bausback, Y., Braunlich, S., . . . Scheinert, D. 
(2010). Angiographic patency and clinical outcome after balloon-angioplasty for 
extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv, 76(7), 1047-1054. 
doi: 10.1002/ccd.22658 
Schober, A., Manka, D., von Hundelshausen, P., Huo, Y., Hanrath, P., Sarembock, I. J., . . . 
Weber, C. (2002). Deposition of platelet RANTES triggering monocyte recruitment 
requires P-selectin and is involved in neointima formation after arterial injury. 
Circulation, 106(12), 1523-1529.  
Schober, A., Zernecke, A., Liehn, E. A., von Hundelshausen, P., Knarren, S., Kuziel, W. A., & 
Weber, C. (2004). Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after 
arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 
presentation on platelets. Circ Res, 95(11), 1125-1133. doi: 
10.1161/01.RES.0000149518.86865.3e 
Scotland, R. S., Vallance, P. J., & Ahluwalia, A. (2000). Endogenous factors involved in 
regulation of tone of arterial vasa vasorum: implications for conduit vessel physiology. 
Cardiovasc Res, 46(3), 403-411.  
Scott, N. A., Cipolla, G. D., Ross, C. E., Dunn, B., Martin, F. H., Simonet, L., & Wilcox, J. N. (1996). 
Identification of a potential role for the adventitia in vascular lesion formation after 
balloon overstretch injury of porcine coronary arteries. Circulation, 93(12), 2178-2187.  
Seay, U., Sedding, D., Krick, S., Hecker, M., Seeger, W., & Eickelberg, O. (2005). Transforming 
growth factor-beta-dependent growth inhibition in primary vascular smooth muscle 





Sebastiani, S., Allavena, P., Albanesi, C., Nasorri, F., Bianchi, G., Traidl, C., . . . Cavani, A. (2001). 
Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory 
activity. J Immunol, 166(2), 996-1002.  
Sechler, J. L., Corbett, S. A., Wenk, M. B., & Schwarzbauer, J. E. (1998). Modulation of cell-
extracellular matrix interactions. Ann N Y Acad Sci, 857, 143-154.  
Serruys, P. W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., . . . et al. 
(1994). A comparison of balloon-expandable-stent implantation with balloon 
angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J 
Med, 331(8), 489-495. doi: 10.1056/NEJM199408253310801 
Serruys, P. W., Luijten, H. E., Beatt, K. J., Geuskens, R., de Feyter, P. J., van den Brand, M., . . . 
Hugenholtz, P. G. (1988). Incidence of restenosis after successful coronary angioplasty: 
a time-related phenomenon. A quantitative angiographic study in 342 consecutive 
patients at 1, 2, 3, and 4 months. Circulation, 77(2), 361-371.  
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010). The final steps of integrin activation: the end 
game. Nat Rev Mol Cell Biol, 11(4), 288-300. doi: 10.1038/nrm2871 
Shea-Donohue, T., Thomas, K., Cody, M. J., Aiping, Z., Detolla, L. J., Kopydlowski, K. M., . . . 
Vogel, S. N. (2008). Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit 
increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun, 
14(2), 117-124. doi: 10.1177/1753425908088724 
Shi, Y., O'Brien, J. E., Fard, A., Mannion, J. D., Wang, D., & Zalewski, A. (1996). Adventitial 
myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. 
Circulation, 94(7), 1655-1664.  
Shyy, Y. J., Hsieh, H. J., Usami, S., & Chien, S. (1994). Fluid shear stress induces a biphasic 
response of human monocyte chemotactic protein 1 gene expression in vascular 
endothelium. Proc Natl Acad Sci U S A, 91(11), 4678-4682.  
Simpson, J. E., Newcombe, J., Cuzner, M. L., & Woodroofe, M. N. (1998). Expression of 
monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and 
inflammatory cells in multiple sclerosis lesions. J Neuroimmunol, 84(2), 238-249.  
Sinha, S., Hoofnagle, M. H., Kingston, P. A., McCanna, M. E., & Owens, G. K. (2004). 
Transforming growth factor-beta1 signaling contributes to development of smooth 
muscle cells from embryonic stem cells. Am J Physiol Cell Physiol, 287(6), C1560-1568. 
doi: 10.1152/ajpcell.00221.2004 
Sitnik, K. M., Wendland, K., Weishaupt, H., Uronen-Hansson, H., White, A. J., Anderson, G., . . . 
Agace, W. W. (2016). Context-Dependent Development of Lymphoid Stroma from 
Adult CD34(+) Adventitial Progenitors. Cell Rep, 14(10), 2375-2388. doi: 
10.1016/j.celrep.2016.02.033 
Skoff, R. P., & Knapp, P. E. (1991). Division of astroblasts and oligodendroblasts in postnatal 
rodent brain: evidence for separate astrocyte and oligodendrocyte lineages. Glia, 4(2), 
165-174. doi: 10.1002/glia.440040208 
Smith, A. G. (2001). Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol, 17, 
435-462. doi: 10.1146/annurev.cellbio.17.1.435 
Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G., Moreau, J., Stahl, M., & Rogers, D. 
(1988). Inhibition of pluripotential embryonic stem cell differentiation by purified 
polypeptides. Nature, 336(6200), 688-690. doi: 10.1038/336688a0 
Smith, J. D., Bryant, S. R., Couper, L. L., Vary, C. P., Gotwals, P. J., Koteliansky, V. E., & Lindner, V. 
(1999). Soluble transforming growth factor-beta type II receptor inhibits negative 
remodeling, fibroblast transdifferentiation, and intimal lesion formation but not 
endothelial growth. Circ Res, 84(10), 1212-1222.  
Sousa, J. E., Serruys, P. W., & Costa, M. A. (2003). New frontiers in cardiology drug-eluting 
stents: part I. Circulation, 107(17), 2274-2279.  
Spinetti, G., Wang, M., Monticone, R., Zhang, J., Zhao, D., & Lakatta, E. G. (2004). Rat aortic 




function. Arterioscler Thromb Vasc Biol, 24(8), 1397-1402. doi: 
10.1161/01.ATV.0000134529.65173.08 
Sprague, A. H., & Khalil, R. A. (2009). Inflammatory cytokines in vascular dysfunction and 
vascular disease. Biochem Pharmacol, 78(6), 539-552. doi: 10.1016/j.bcp.2009.04.029 
Spring, H., Schuler, T., Arnold, B., Hammerling, G. J., & Ganss, R. (2005). Chemokines direct 
endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A, 102(50), 
18111-18116. doi: 10.1073/pnas.0507158102 
Stamatovic, S. M., Keep, R. F., Kunkel, S. L., & Andjelkovic, A. V. (2003). Potential role of MCP-1 
in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci, 
116(Pt 22), 4615-4628. doi: 10.1242/jcs.00755 
Stanford, M. M., & Issekutz, T. B. (2003). The relative activity of CXCR3 and CCR5 ligands in T 
lymphocyte migration: concordant and disparate activities in vitro and in vivo. J Leukoc 
Biol, 74(5), 791-799. doi: 10.1189/jlb.1102547 
Stegemann, J. P., Hong, H., & Nerem, R. M. (2005). Mechanical, biochemical, and extracellular 
matrix effects on vascular smooth muscle cell phenotype. J Appl Physiol (1985), 98(6), 
2321-2327. doi: 10.1152/japplphysiol.01114.2004 
Stenmark, K. R., Yeager, M. E., El Kasmi, K. C., Nozik-Grayck, E., Gerasimovskaya, E. V., Li, M., . . . 
Frid, M. G. (2013). The adventitia: essential regulator of vascular wall structure and 
function. Annu Rev Physiol, 75, 23-47. doi: 10.1146/annurev-physiol-030212-183802 
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., . . . et al. 
(1995). The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. 
J Biol Chem, 270(45), 27348-27357.  
Suga, H., Matsumoto, D., Eto, H., Inoue, K., Aoi, N., Kato, H., . . . Yoshimura, K. (2009). 
Functional implications of CD34 expression in human adipose-derived stem/progenitor 
cells. Stem Cells Dev, 18(8), 1201-1210. doi: 10.1089/scd.2009.0003 
Sun, W., Wang, G., Zhang, Z. M., Zeng, X. K., & Wang, X. (2005). Chemokine RANTES is 
upregulated in monocytes from patients with hyperhomocysteinemia. Acta Pharmacol 
Sin, 26(11), 1317-1321. doi: 10.1111/j.1745-7254.2005.00178.x 
Takahara, N., Kashiwagi, A., Maegawa, H., & Shigeta, Y. (1996). Lysophosphatidylcholine 
stimulates the expression and production of MCP-1 by human vascular endothelial 
cells. Metabolism, 45(5), 559-564.  
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. 
(2007). Induction of pluripotent stem cells from adult human fibroblasts by defined 
factors. Cell, 131(5), 861-872. doi: 10.1016/j.cell.2007.11.019 
Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676. doi: 
10.1016/j.cell.2006.07.024 
Tanaka, K., Sata, M., Hirata, Y., & Nagai, R. (2003). Diverse contribution of bone marrow cells to 
neointimal hyperplasia after mechanical vascular injuries. Circ Res, 93(8), 783-790. doi: 
10.1161/01.RES.0000096651.13001.B4 
Tang, Y., Urs, S., Boucher, J., Bernaiche, T., Venkatesh, D., Spicer, D. B., . . . Liaw, L. (2010). 
Notch and transforming growth factor-beta (TGFbeta) signaling pathways 
cooperatively regulate vascular smooth muscle cell differentiation. J Biol Chem, 
285(23), 17556-17563. doi: 10.1074/jbc.M109.076414 
Taubman, M. B., Rollins, B. J., Poon, M., Marmur, J., Green, R. S., Berk, B. C., & Nadal-Ginard, B. 
(1992). JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth 
factor-stimulated vascular smooth muscle cells. Circ Res, 70(2), 314-325.  
Taylor, J. M., Mack, C. P., Nolan, K., Regan, C. P., Owens, G. K., & Parsons, J. T. (2001). Selective 
expression of an endogenous inhibitor of FAK regulates proliferation and migration of 





Taylor, J. M., Macklem, M. M., & Parsons, J. T. (1999). Cytoskeletal changes induced by GRAF, 
the GTPase regulator associated with focal adhesion kinase, are mediated by Rho. J 
Cell Sci, 112 ( Pt 2), 231-242.  
ten Klooster, J. P., Jaffer, Z. M., Chernoff, J., & Hordijk, P. L. (2006). Targeting and activation of 
Rac1 are mediated by the exchange factor beta-Pix. J Cell Biol, 172(5), 759-769. doi: 
10.1083/jcb.200509096 
Tesfamariam, B. (2008). Platelet function in intravascular device implant-induced intimal injury. 
Cardiovasc Revasc Med, 9(2), 78-87. doi: 10.1016/j.carrev.2007.12.001 
Thelen, M. (2001). Dancing to the tune of chemokines. Nat Immunol, 2(2), 129-134. doi: 
10.1038/84224 
Thomas, E. D., Lochte, H. L., Jr., Lu, W. C., & Ferrebee, J. W. (1957). Intravenous infusion of 
bone marrow in patients receiving radiation and chemotherapy. N Engl J Med, 257(11), 
491-496. doi: 10.1056/NEJM195709122571102 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., 
& Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. 
Science, 282(5391), 1145-1147.  
Tigges, U., Komatsu, M., & Stallcup, W. B. (2013). Adventitial pericyte progenitor/mesenchymal 
stem cells participate in the restenotic response to arterial injury. J Vasc Res, 50(2), 
134-144. doi: 10.1159/000345524 
000345524 
Tomar, A., & Schlaepfer, D. D. (2009). Focal adhesion kinase: switching between GAPs and 
GEFs in the regulation of cell motility. Curr Opin Cell Biol, 21(5), 676-683. doi: 
10.1016/j.ceb.2009.05.006 
Turner, C. E., & Miller, J. T. (1994). Primary sequence of paxillin contains putative SH2 and SH3 
domain binding motifs and multiple LIM domains: identification of a vinculin and 
pp125Fak-binding region. J Cell Sci, 107 ( Pt 6), 1583-1591.  
Uchida, Y., Uchida, Y., Matsuyama, A., Koga, A., Kanai, M., & Sakurai, T. (2010). Formation of 
web- and membrane-like structures on the edges of bare-metal coronary stents. Circ J, 
74(9), 1830-1836.  
Usui, M., Egashira, K., Ohtani, K., Kataoka, C., Ishibashi, M., Hiasa, K., . . . Takeshita, A. (2002). 
Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes 
(neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J, 16(13), 
1838-1840. doi: 10.1096/fj.02-0094fje 
Van Aelst, L., & D'Souza-Schorey, C. (1997). Rho GTPases and signaling networks. Genes Dev, 
11(18), 2295-2322.  
van Royen, N., Hoefer, I., Bottinger, M., Hua, J., Grundmann, S., Voskuil, M., . . . Piek, J. J. 
(2003). Local monocyte chemoattractant protein-1 therapy increases collateral artery 
formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b 
expression, neointimal formation, and plaque progression. Circ Res, 92(2), 218-225.  
van Wetering, S., van Buul, J. D., Quik, S., Mul, F. P., Anthony, E. C., ten Klooster, J. P., . . . 
Hordijk, P. L. (2002). Reactive oxygen species mediate Rac-induced loss of cell-cell 
adhesion in primary human endothelial cells. J Cell Sci, 115(Pt 9), 1837-1846.  
Vande Broek, I., Asosingh, K., Vanderkerken, K., Straetmans, N., Van Camp, B., & Van Riet, I. 
(2003). Chemokine receptor CCR2 is expressed by human multiple myeloma cells and 
mediates migration to bone marrow stromal cell-produced monocyte chemotactic 
proteins MCP-1, -2 and -3. Br J Cancer, 88(6), 855-862. doi: 10.1038/sj.bjc.6600833 
Varon, C., Rottiers, P., Ezan, J., Reuzeau, E., Basoni, C., Kramer, I., & Genot, E. (2008). TGFbeta1 
regulates endothelial cell spreading and hypertrophy through a Rac-p38-mediated 
pathway. Biol Cell, 100(9), 537-550. doi: 10.1042/BC20080021 
Veillard, N. R., Kwak, B., Pelli, G., Mulhaupt, F., James, R. W., Proudfoot, A. E., & Mach, F. 
(2004). Antagonism of RANTES receptors reduces atherosclerotic plaque formation in 




Veillard, N. R., Steffens, S., Burger, F., Pelli, G., & Mach, F. (2004). Differential expression 
patterns of proinflammatory and antiinflammatory mediators during atherogenesis in 
mice. Arterioscler Thromb Vasc Biol, 24(12), 2339-2344. doi: 
10.1161/01.ATV.0000146532.98235.e6 
Veillard, N. R., Steffens, S., Pelli, G., Lu, B., Kwak, B. R., Gerard, C., . . . Mach, F. (2005). 
Differential influence of chemokine receptors CCR2 and CXCR3 in development of 
atherosclerosis in vivo. Circulation, 112(6), 870-878. doi: 
10.1161/CIRCULATIONAHA.104.520718 
Vestweber, D. (2015). How leukocytes cross the vascular endothelium. Nat Rev Immunol, 
15(11), 692-704. doi: 10.1038/nri3908 
Virmani, R., Kolodgie, F. D., Farb, A., & Lafont, A. (2003). Drug eluting stents: are human and 
animal studies comparable? Heart, 89(2), 133-138.  
von Hundelshausen, P., Koenen, R. R., Sack, M., Mause, S. F., Adriaens, W., Proudfoot, A. E., . . . 
Weber, C. (2005). Heterophilic interactions of platelet factor 4 and RANTES promote 
monocyte arrest on endothelium. Blood, 105(3), 924-930. doi: 10.1182/blood-2004-
06-2475 
von Hundelshausen, P., Weber, K. S., Huo, Y., Proudfoot, A. E., Nelson, P. J., Ley, K., & Weber, C. 
(2001). RANTES deposition by platelets triggers monocyte arrest on inflamed and 
atherosclerotic endothelium. Circulation, 103(13), 1772-1777.  
Wagner, E. F., & Nebreda, A. R. (2009). Signal integration by JNK and p38 MAPK pathways in 
cancer development. Nat Rev Cancer, 9(8), 537-549. doi: 10.1038/nrc2694 
Wang, D., Wang, H., Brown, J., Daikoku, T., Ning, W., Shi, Q., . . . DuBois, R. N. (2006). CXCL1 
induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med, 
203(4), 941-951. doi: 10.1084/jem.20052124 
Wang, Z., & Newman, W. H. (2003). Smooth muscle cell migration stimulated by interleukin 6 
is associated with cytoskeletal reorganization. J Surg Res, 111(2), 261-266.  
Weber, C. (2003). Novel mechanistic concepts for the control of leukocyte transmigration: 
specialization of integrins, chemokines, and junctional molecules. J Mol Med (Berl), 
81(1), 4-19. doi: 10.1007/s00109-002-0391-x 
Weber, C., Draude, G., Weber, K. S., Wubert, J., Lorenz, R. L., & Weber, P. C. (1999). 
Downregulation by tumor necrosis factor-alpha of monocyte CCR2 expression and 
monocyte chemotactic protein-1-induced transendothelial migration is antagonized by 
oxidized low-density lipoprotein: a potential mechanism of monocyte retention in 
atherosclerotic lesions. Atherosclerosis, 145(1), 115-123.  
Weber, C., Fraemohs, L., & Dejana, E. (2007). The role of junctional adhesion molecules in 
vascular inflammation. Nature Reviews Immunology, 7(6), 467-477.  
Weber, K. S., Nelson, P. J., Grone, H. J., & Weber, C. (1999). Expression of CCR2 by endothelial 
cells : implications for MCP-1 mediated wound injury repair and In vivo inflammatory 
activation of endothelium. Arterioscler Thromb Vasc Biol, 19(9), 2085-2093.  
Weber, K. S., von Hundelshausen, P., Clark-Lewis, I., Weber, P. C., & Weber, C. (1999). 
Differential immobilization and hierarchical involvement of chemokines in monocyte 
arrest and transmigration on inflamed endothelium in shear flow. Eur J Immunol, 29(2), 
700-712. doi: 10.1002/(SICI)1521-4141(199902)29:02&#60;700::AID-
IMMU700&#62;3.0.CO;2-1 
Welt, F. G., Edelman, E. R., Simon, D. I., & Rogers, C. (2000). Neutrophil, not macrophage, 
infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler 
Thromb Vasc Biol, 20(12), 2553-2558.  
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., . . . Jaenisch, R. 
(2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. 
Nature, 448(7151), 318-324. doi: 10.1038/nature05944 
Wery-Zennaro, S., Zugaza, J. L., Letourneur, M., Bertoglio, J., & Pierre, J. (2000). IL-4 regulation 
of IL-6 production involves Rac/Cdc42- and p38 MAPK-dependent pathways in 




Wessely, R., Schomig, A., & Kastrati, A. (2006). Sirolimus and Paclitaxel on polymer-based drug-
eluting stents: similar but different. J Am Coll Cardiol, 47(4), 708-714. doi: 
10.1016/j.jacc.2005.09.047 
White, J. R., Lee, J. M., Young, P. R., Hertzberg, R. P., Jurewicz, A. J., Chaikin, M. A., . . . Sarau, H. 
M. (1998). Identification of a potent, selective non-peptide CXCR2 antagonist that 
inhibits interleukin-8-induced neutrophil migration. J Biol Chem, 273(17), 10095-10098.  
Wight, T. N., Kinsella, M. G., & Qwarnstrom, E. E. (1992). The role of proteoglycans in cell 
adhesion, migration and proliferation. Curr Opin Cell Biol, 4(5), 793-801.  
Wight, T. N., & Potter-Perigo, S. (2011). The extracellular matrix: an active or passive player in 
fibrosis? Am J Physiol Gastrointest Liver Physiol, 301(6), G950-955. doi: 
10.1152/ajpgi.00132.2011 
Wilcox, J. N., Okamoto, E. I., Nakahara, K. I., & Vinten-Johansen, J. (2001). Perivascular 
responses after angioplasty which may contribute to postangioplasty restenosis: a role 
for circulating myofibroblast precursors? Ann N Y Acad Sci, 947, 68-90; dicussion 90-62.  
Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., . . . Gough, N. 
M. (1988). Myeloid leukaemia inhibitory factor maintains the developmental potential 
of embryonic stem cells. Nature, 336(6200), 684-687. doi: 10.1038/336684a0 
Wong, M. M., Winkler, B., Karamariti, E., Wang, X., Yu, B., Simpson, R., . . . Xu, Q. (2013). 
Sirolimus stimulates vascular stem/progenitor cell migration and differentiation into 
smooth muscle cells via epidermal growth factor receptor/extracellular signal-
regulated kinase/beta-catenin signaling pathway. Arterioscler Thromb Vasc Biol, 33(10), 
2397-2406. doi: 10.1161/ATVBAHA.113.301595 
Wong, M. M., Yin, X., Potter, C., Yu, B., Cai, H., Di Bernardini, E., & Xu, Q. (2014). Over-
expression of HSP47 augments mouse embryonic stem cell smooth muscle 
differentiation and chemotaxis. PLoS One, 9(1), e86118. doi: 
10.1371/journal.pone.0086118 
Wood, N. B., Zhao, S. Z., Zambanini, A., Jackson, M., Gedroyc, W., Thom, S. A., . . . Xu, X. Y. 
(2006). Curvature and tortuosity of the superficial femoral artery: a possible risk factor 
for peripheral arterial disease. J Appl Physiol (1985), 101(5), 1412-1418. doi: 
10.1152/japplphysiol.00051.2006 
Wu, J. H., Fanaroff, A. C., Sharma, K. C., Smith, L. S., Brian, L., Eipper, B. A., . . . Zhang, L. (2013). 
Kalirin promotes neointimal hyperplasia by activating Rac in smooth muscle cells. 
Arterioscler Thromb Vasc Biol, 33(4), 702-708. doi: 10.1161/ATVBAHA.112.300234 
Xiao, Q., Zeng, L., Zhang, Z., Hu, Y., & Xu, Q. (2007). Stem cell-derived Sca-1+ progenitors 
differentiate into smooth muscle cells, which is mediated by collagen IV-integrin 
alpha1/beta1/alphav and PDGF receptor pathways. Am J Physiol Cell Physiol, 292(1), 
C342-352. doi: 10.1152/ajpcell.00341.2006 
Xiao, Q., Zeng, L., Zhang, Z., Margariti, A., Ali, Z. A., Channon, K. M., . . . Hu, Y. (2006). Sca-1+ 
progenitors derived from embryonic stem cells differentiate into endothelial cells 
capable of vascular repair after arterial injury. Arterioscler Thromb Vasc Biol, 26(10), 
2244-2251. doi: 10.1161/01.ATV.0000240251.50215.50 
Xiao, Q., Zhang, F., Grassia, G., Hu, Y., Zhang, Z., Xing, Q., . . . Ye, S. (2014). Matrix 
metalloproteinase-8 promotes vascular smooth muscle cell proliferation and 
neointima formation. Arterioscler Thromb Vasc Biol, 34(1), 90-98. doi: 
10.1161/ATVBAHA.113.301418 
Xiao, Q., Zhang, F., Lin, L., Fang, C., Wen, G., Tsai, T. N., . . . Ye, S. (2013). Functional role of 
matrix metalloproteinase-8 in stem/progenitor cell migration and their recruitment 
into atherosclerotic lesions. Circ Res, 112(1), 35-47. doi: 
10.1161/CIRCRESAHA.112.274019 
Xu, Q. (2004). Mouse models of arteriosclerosis: from arterial injuries to vascular grafts. Am J 
Pathol, 165(1), 1-10. doi: 10.1016/S0002-9440(10)63270-1 
Yamamoto, T., Shibata, R., Ishii, M., Kanemura, N., Kito, T., Suzuki, H., . . . Murohara, T. (2013). 




injury--brief report. Arterioscler Thromb Vasc Biol, 33(9), 2218-2221. doi: 
10.1161/ATVBAHA.113.301313 
Yamasaki, K., Asai, T., Shimizu, M., Aoki, M., Hashiya, N., Sakonjo, H., . . . Morishita, R. (2003). 
Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site 
reduces neointimal formation in porcine balloon-injured coronary artery model. Gene 
Ther, 10(4), 356-364. doi: 10.1038/sj.gt.3301875 
Yang, S., Eto, H., Kato, H., Doi, K., Kuno, S., Kinoshita, K., . . . Yoshimura, K. (2013). Comparative 
characterization of stromal vascular cells derived from three types of vascular wall and 
adipose tissue. Tissue Eng Part A, 19(23-24), 2724-2734. doi: 
10.1089/ten.TEA.2013.0057 
Yang, X., Thomas, D. P., Zhang, X., Culver, B. W., Alexander, B. M., Murdoch, W. J., . . . 
Sreejayan, N. (2006). Curcumin Inhibits Platelet-Derived Growth Factor–Stimulated 
Vascular Smooth Muscle Cell Function and Injury-Induced Neointima Formation. 
Arterioscler Thromb Vasc Biol, 26(1), 85-90.  
Yla-Herttuala, S., Lipton, B. A., Rosenfeld, M. E., Sarkioja, T., Yoshimura, T., Leonard, E. J., . . . 
Steinberg, D. (1991). Expression of monocyte chemoattractant protein 1 in 
macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci 
U S A, 88(12), 5252-5256.  
Yoshida, T., Kaestner, K. H., & Owens, G. K. (2008). Conditional deletion of Kruppel-like factor 4 
delays downregulation of smooth muscle cell differentiation markers but accelerates 
neointimal formation following vascular injury. Circ Res, 102(12), 1548-1557. doi: 
10.1161/CIRCRESAHA.108.176974 
Yoshimura, S., Morishita, R., Hayashi, K., Yamamoto, K., Nakagami, H., Kaneda, Y., . . . Ogihara, 
T. (2001). Inhibition of intimal hyperplasia after balloon injury in rat carotid artery 
model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel 
molecular strategy. Gene Ther, 8(21), 1635-1642. doi: 10.1038/sj.gt.3301566 
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., . . . 
Thomson, J. A. (2007). Induced pluripotent stem cell lines derived from human somatic 
cells. Science, 318(5858), 1917-1920. doi: 10.1126/science.1151526 
Yu, X., Dluz, S., Graves, D. T., Zhang, L., Antoniades, H. N., Hollander, W., . . . Sonenshein, G. E. 
(1992). Elevated expression of monocyte chemoattractant protein 1 by vascular 
smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A, 89(15), 
6953-6957.  
Yuan, L., Sakamoto, N., Song, G., & Sato, M. (2013). Low-level shear stress induces human 
mesenchymal stem cell migration through the SDF-1/CXCR4 axis via MAPK signaling 
pathways. Stem Cells Dev, 22(17), 2384-2393. doi: 10.1089/scd.2012.0717 
Zampetaki, A., Zhang, Z., Hu, Y., & Xu, Q. (2005). Biomechanical stress induces IL-6 expression 
in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-kappaB signaling pathways. Am J 
Physiol Heart Circ Physiol, 288(6), H2946-2954. doi: 10.1152/ajpheart.00919.2004 
Zeiffer, U., Schober, A., Lietz, M., Liehn, E. A., Erl, W., Emans, N., . . . Weber, C. (2004). 
Neointimal smooth muscle cells display a proinflammatory phenotype resulting in 
increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res, 
94(6), 776-784. doi: 10.1161/01.RES.0000121105.72718.5C 
Zengin, E., Chalajour, F., Gehling, U. M., Ito, W. D., Treede, H., Lauke, H., . . . Ergun, S. (2006). 
Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. 
Development, 133(8), 1543-1551. doi: 10.1242/dev.02315 
Zernecke, A., Schober, A., Bot, I., von Hundelshausen, P., Liehn, E. A., Mopps, B., . . . Weber, C. 
(2005). SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and 
recruitment of smooth muscle progenitor cells. Circ Res, 96(7), 784-791. doi: 
10.1161/01.RES.0000162100.52009.38 
Zerwes, H. G., & Risau, W. (1987). Polarized secretion of a platelet-derived growth factor-like 




Zhang, L., Peppel, K., Brian, L., Chien, L., & Freedman, N. J. (2004). Vein graft neointimal 
hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-
intrinsic cells. Arterioscler Thromb Vasc Biol, 24(12), 2277-2283. doi: 
10.1161/01.ATV.0000147766.68987.0d 
Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., & Bokoch, G. M. (1995). 
Rho family GTPases regulate p38 mitogen-activated protein kinase through the 
downstream mediator Pak1. J Biol Chem, 270(41), 23934-23936.  
Zhang, S. J., Zhang, H., Hou, M., Zheng, Z., Zhou, J., Su, W., . . . Hu, S. (2007). Is it possible to 
obtain "true endothelial progenitor cells" by in vitro culture of bone marrow 
mononuclear cells? Stem Cells Dev, 16(4), 683-690. doi: 10.1089/scd.2006.0062 
Zhao, Z. J., Liu, F. Y., Li, P., Ding, X., Zong, Z. H., & Sun, C. F. (2011). CCL19-induced chemokine 
receptor 7 activates the phosphoinositide-3 kinase-mediated invasive pathway 
through Cdc42 in metastatic squamous cell carcinoma of the head and neck. Oncol Rep, 
25(3), 729-737. doi: 10.3892/or.2010.1109 
Zhou, Z., Subramanian, P., Sevilmis, G., Globke, B., Soehnlein, O., Karshovska, E., . . . Schober, A. 
(2011). Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by 
releasing CXCL1 from the endothelium. Cell Metab, 13(5), 592-600. doi: 
10.1016/j.cmet.2011.02.016 
Zimmerlin, L., Donnenberg, V. S., Pfeifer, M. E., Meyer, E. M., Peault, B., Rubin, J. P., & 
Donnenberg, A. D. (2010). Stromal vascular progenitors in adult human adipose tissue. 
Cytometry A, 77(1), 22-30. doi: 10.1002/cyto.a.20813 
Zimmerlin, L., Donnenberg, V. S., Rubin, J. P., & Donnenberg, A. D. (2013). Mesenchymal 
markers on human adipose stem/progenitor cells. Cytometry A, 83(1), 134-140. doi: 
10.1002/cyto.a.22227 
 
